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Abstract 
 
The main goal of this project was to develop an efficient methodology allowing 
rapid access to structurally diverse scaffolds decorated with various functional groups.  
Initially, we discovered and subsequently developed an experimentally 
straightforward, high-yielding photoinduced conversion of readily accessible diverse 
starting materials into polycyclic aldehydes and their (hemi)acetals decorated by various 
pendants. The two step sequence, involving the Diels-Alder addition of heterocyclic 
chalcones and other benzoyl ethylenes to a variety of dienes, followed by the Paternò-
Büchi reaction, was described as an alkene-carbonyl oxametathesis. This methodology 
offers a rapid increase in molecular complexity and diversity of the target scaffolds [30]. 
To develop this novel methodology further and explore its generality, we directed 
our attention to the Diels-Alder adducts based on various chromones. We discovered that 
the Diels-Alder adducts of chromones are capable of photoinduced alkene-arene [2+2] 
cycloaddition producing different dienes, which can either dimerize or be introduced into 
a double-tandem [4π+2π]◦[2π+2π]◦[4π+2π]◦[2π+2π] synthetic sequence, followed by an 
acid-catalyzed oxametathesis, leading to a rapid expansion of molecular complexity over 
a few experimentally simple steps [35]. 
In view of the fact that oxametathesis previously was primarily observed in 
aromatic oxetanes, we decided to prepare model aliphatic oxetanes with a 
conformationally unconstrained or “flexible” methyl group based on the Diels-Alder 
 iii 
adducts of cyclohexadiene or cyclopentadiene with methyl vinyl ketone. Upon addition 
of an acid, the expected oxametathesis occurred with results similar to those observed in 
the aromatic series [30, 35] proving the generality of this approach. Also we synthesized 
polycyclic oxetanes resulting from the Diels-Alder adducts of cyclic ketones. This not 
only gave us access to remarkably strained oxetane systems, but also the mechanism for 
their protolytic ring opening provided a great deal of insight to how the strain affects the 
reactivity. 
Additionally, we discovered that although the model Hetero-Diels-Alder adducts 
did not undergo [2+2] cycloaddition, both exo- and endo-Sulfa-Diels-Alder products, 
nonetheless, were photochemically active and various products with defined 
stereochemistry could be produced upon photolysis.  
In conclusion, we have developed an approach to the encoding and screening of 
solution phase libraries based on the photorelease of externally sensitized photolabile 
tags. The encoding tags can be released into solution only when a binding event occurs 
between the ligand and the receptor, equipped with an electron transfer sensitizer. The 
released tags are analyzed in solution revealing the identity of the lead ligand or 
narrowing the range of potential leads [50]. 
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Chapter One: Literature review 
A. Drug discovery. 
A large portion of research in chemistry these days is driven by big pharma and 
research institutes, which are trying to find either new biologically active compounds or 
improve pharmacokinetic and pharmacodynamic properties of recently discovered and 
well-known drugs. Drug discovery, design and development are long processes which 
take decades. A lead compound – a compound with desired pharmaceutical activity [1] – 
may be discovered in various ways: (1) screening of natural products; (2) screening of 
synthetic combinatorial libraries; (3) improving existing drugs; (4) starting from a natural 
ligand or modulator; (5) combinatorial synthesis; (6) computer-aided design; (7) 
serendipity, etc.  
From a basic knowledge of medicinal chemistry we know what is necessary for a 
potential lead compound to gain a higher “drug score” or be more “drug-like”. Lipinski’s 
rule of five [1] is a well-known criterion, which is, however, more often violated by new 
discovered drugs. The approach based on branched or “spider-like” molecules increases 
the chances of finding a lead compound (Scheme 1). The “arms” contain various 
functional groups, which are used to probe a binding side for binding regions. The 
chances of success in finding a lead compound are much greater if the “arms” are evenly 
spread around the scaffold. Even though a “drug score” can be estimated for any 
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molecule, it does not evaluate the actual specific effect that the drug exerts (biological 
activity) [1]. 
 
Scheme 1. “Spider-like” molecule probing for an interaction [1]. 
Although many companies are still relying on rational drug design, generally we 
have a vague idea of what a good drug must look like. The creation and screening of 
synthetic combinatorial libraries is an elegant method to find a lead compound. Such a 
library can be prepared through combinatorial synthesis – a technology for creating 
structurally related molecules in large quantity and testing them rapidly for desirable 
properties – or by using diversity oriented synthesis approach – a strategy used to create a 
massively diverse set of molecules with an emphasis on structural diversity (structurally 
unrelated compounds). 
B. Diversity oriented synthesis. 
Diversity Oriented Synthesis (DOS) represents the synthesis of moderately small 
libraries of organic molecules (compared to combinatorial libraries) that have a greater 
variety of core structures, are structurally more complex, and possess richer 
stereochemical variations than those produced by traditional combinatorial chemistry [2]. 
DOS includes two alternative strategies: convergent and divergent syntheses.  
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1. Convergent synthesis. 
Convergent synthesis is an approach which is designed to improve the efficiency 
of multi-step chemical synthesis. In a very simple “linear” synthesis the overall yield 
quickly drops with each reaction step [3a-c]: 
 
Suppose the yields are 90%, 50% and 20% respectively for each consecutive step, 
then the overall yield of Product is only 9% from A. In convergent synthesis the overall 
yield of Product is dramatically improved and now equals 18%: 
 
Convergent synthesis is mostly utilized in the synthesis of complex molecules, 
biologically active compounds and natural products; it is also known as total synthesis – a 
broad area of modern organic chemistry designed to produce complex, biologically 
important structures from simple building blocks (starting materials) usually without 
assistance from biological processes.  
1.1 First total synthesis of natural compounds. 
The beginning of total synthesis occurred in the nineteenth century. In 1828 
Wöhler reported the very first “total” synthesis of urea – a natural product [4a]. This 
event can be considered the beginning of organic synthesis and the first example, where 
an organic compound was synthesized from inorganic substances. Kolbe’s synthesis of 
acetic acid is the second major achievement in the history of synthetic organic chemistry. 
4 
But the most profound total synthesis at that time was performed by E. Fischer, when he 
obtained (+)-glucose (Figure 1): 
 
Figure 1. Selected 19th century total syntheses of natural products [4a]. 
With the help of technological progress and tremendous scientific advancement, 
the twentieth century changed the entire look on synthetic organic chemistry. 
Woodward’s achievements in total synthesis between 1944 and 1981 were the most 
prominent at that time. E. J. Corey introduced retrosynthetic analysis into organic 
chemistry – the logic of chemical synthesis, helping to analyze complex target molecules 
and come up with possible synthetic pathways for their construction [4a]. He received the 
Nobel Prize in chemistry in 1990, having synthesized hundreds of natural and designed 
products between 1960 and 1991 (Figure 2): 
 
Woodward (1973)
Corey (1888)
Fischer (1929) vitamin B12
(+)-biotin
 
Figure 2. Selected 20th century total syntheses of natural products [4a]. 
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1.2 Examples of modern total syntheses. 
The chemical literature of the twentieth century abounds with hundreds of 
examples of total syntheses of natural products. Every new published structure is even 
more complicated and challenging than the previous one. Each reported synthetic 
pathway is more daring and revolutionary than the other. I will focus mostly on 
methodological breakthroughs relevant to this dissertation because it is absolutely not 
possible to even select the most important and striking examples. However, it is still 
worth mentioning a few molecules that have “changed the world”. 
Taxol is one of such compounds. It was isolated from the Pacific yew tree, Taxus 
brevifolia. Its structure was reported in 1971 and only twenty years later it was approved 
by FDA for the treatment of ovarian, breast and lung cancers. It is also used in the 
treatment of Kaposi's sarcoma. Its first total synthesis was reported in 1994 [4b-c].  
Brevetoxin B is another “amazing” molecule. Its architecture includes eleven 
rings and twenty three stereogenic centers. Brevetoxins are neurotoxins that bind to 
voltage-gated sodium channels in nerve cells, leading to disruption of normal 
neurological processes. After several attempts it was finally synthesized in 1995 [4d-e]. 
 
taxol
brevetoxin B
 
Figure 3. “Molecules that changed the world” [4a]. 
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Vancomycin is a glycopeptide antibiotic used in the prophylaxis and treatment of 
infections caused by Gram-positive bacteria. It was isolated in the 1950s, the structure 
was revealed in 1982 and the first total synthesis was reported in 1999 (Figure 3) [4a, 4f].  
1.3 Cascade reactions. 
While more and more exotic chemical structures were required to be synthesized, 
chemists continued discovering and developing more sophisticated methodologies. A 
typical total synthesis may include more than thirty steps. If each step is at least 90%, 
total yield of the synthesis can be as low as (0.9)30 *100% = 4%. One way to overcome 
this complication and inefficiency is to develop a method where several transformations 
are carried out in one reaction vessel in tandem. Such transformations are called cascade 
reactions (or tandem or domino reactions).  
1.3.1 Robinson’ synthesis. 
Perhaps the first example of a cascade reaction, which was utilized in total 
synthesis, was a tandem sequence reported in 1917 by Robert Robinson [5]. His 
biomimetic synthesis, which aimed to obtain tropinone – a natural alkaloid, includes two 
consecutive Mannich reactions (Scheme 2): 
 
Scheme 2. Total synthesis of tropinone (Robinson, 1917) [5].  
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The first one is an inter-molecular and the second is an intra-molecular reaction. 
Tropinone was eventually obtained in a simple one-pot procedure.  
1.3.2 Palladium catalyzed tandem sequences. 
Another striking example of a cascade reaction is the cycloisomerization of 
polyenynes with a catalyst derived from Pd(0), acetic acid and a ligand to polycycles. The 
process involves the stages of initiation (by addition of Pd-H to an acetylene), 
propagation (by intramolecular carbopalladation) and termination (by β-hydrogen 
elimination). Increasing the number of double bonds is directly related to the number of 
rings formed [6] (Scheme 3): 
 
Scheme 3. A Palladium zipper [6].  
This approach for construction of polycycles can be considered equivalent to a 
palladium zipper, in which the π orbitals are the “teeth” and the palladium complex in the 
“tab”. Closing the zipper stitches the π bonds into σ bonds with creation of the 
polycycles.  
1.3.3 Ladder Polyether Synthesis. 
The ladder polyether natural products (Figure 4) are an amazing family of 
molecules that have very complex structures, demonstrate exceptionally potent and 
dramatic biological effects, and are the toxic constituents of marine phenomena known 
collectively as Red Tide. All of the junctions between the fused rings are trans, and 
consecutive ring junctions are syn to one another. This trans-syn combination is 
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responsible for the “ladder” topography of these molecules. Twenty years ago Nakanishi 
hypothesized that a polyepoxide may transform into a ladder polyether via a cascade of 
epoxide-opening events [7].  
 
Figure 4. A ladder polyether – gymnocin B.  
Many attempts to form ladder polyethers have been reported, but in multiple cases 
exo regioselectivity tends to dominate. Recently a method based on removable 
trimethylsilyl (SiMe3) was published (Scheme 4). This functional group dictates the 
regioselectivity of epoxide opening and leaves no trace of itself by the time the cascade 
has come to an end [7].  
 
Scheme 4. Cascade cyclization of polyepoxysilanes under basic conditions [7]. 
A cascade reaction is sometimes called a living reaction because it shares some 
characteristics with a living polymerization. 
2. Divergent synthesis. 
In chemistry a divergent synthesis is an alternative approach with intent to 
improve the efficiency of chemical synthesis. It is often an alternative to convergent 
synthesis [8a-b]. Divergent synthesis aims to generate a library of structurally unrelated 
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chemical compounds. Each successive generation of compounds is generated by further 
reactions with each compound in the previous generation. This methodology quickly 
diverges to large numbers of new compounds (Scheme 5): 
 
Scheme 5. Divergent synthesis produces a large number of new compounds.  
In another strategy, divergent synthesis begins from a molecule as a central core 
from which consecutive generations of building blocks are added. A good example is the 
divergent synthesis of dendrimers, where in each generation a new monomer reacts to the 
growing surface of the sphere [8a-b]. 
One of the most striking examples of diversity oriented synthesis was reported by 
Schreiber in 2006 [9]. A short and efficient pathway was found that uses intramolecular 
cyclization reactions of readily synthesized and functionalized amino alcohols. They used 
the Petasis three-component, boronic acid Mannich reaction followed by an amine 
propargylation to yield β-amino alcohol (2.6) (compound 2, Scheme 6). Then a series of 
skeletal diversification reactions with (2.6) was explored. Cycloisomerization catalyzed 
by [Pd(PPh3)2(OAc)2] ended up in opening of the cyclopropyl ring to afford triene (3.6) 
by β-hydrogen elimination/reductive elimination sequence. Enyne metathesis of (2.6) 
using Hoveyda-Grubbs catalyst gave diene (4.6). Cycloisomerization catalyzed by 
[CpRu(MeCN)3PF6] resulted in a [5+2] reaction to afford cyclic diene (5.6) by a 
cyclopropyl ring-opening/reductive elimination sequence. Electrophilic activation of the 
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alkyne in (2.6) with NaAuCl4 in MeOH led to the intramolecular cyclization of the 
hydroxyl group followed by incorporation of MeOH to give a morpholine skeleton (6.6).  
 
Scheme 6. Skeletal diversification of β-amino alcohol (2.6). 
The Pauson-Khand reaction of (2.6) with [Co2(CO)8] in the presence of trimethylamine 
N-oxide produced azabicyclo[3.3.0] (7.6). Treatment of (2.6) with NaH at room 
temperature gave lactone (8.6). Finally, reaction of (2.6) with MCPBA yielded product 
(9.6) (Scheme 6).  
2.1 Multicomponent reactions. 
Divergent synthesis is heavily dependent on densely functionalized compounds. 
Such compounds often require time and money consuming multistep syntheses. A desired 
product, however, can be also obtained in a one-pot reaction of three or more starting 
materials – a multicomponent reaction (MCR). Even though MCRs are convergent 
(Figure 5), they lead to complex molecules decorated by a variety of pendants. Such 
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structures can be further converted in a diversity oriented fashion to produce various 
products with unique topology [10].  
 
Figure 5. Multi-component reactions.  
MCRs have been known for more than 150 years. It should be mentioned that in 
MCRs the starting materials do not react simultaneously in one step, but rather in a 
sequence of elementary steps according to a prescribed program. The first three-
component reaction was discovered in 1838 by Strecker [10] during his attempt to 
synthesize α-amino acids via α-amino cyanides. But the most important reaction was 
described by Mario Passerini in 1921 [10]. 
2.1.1 Three-component reactions (Passerini reaction – 3CR). 
The Passerini reaction involves an isocyanide, a carbonyl and a carboxylic acid to 
form an α-acyloxy amide (3.7) (compound 3, Scheme 7): 
 
Scheme 7. Suggested mechanism of the Passerini reaction [10].  
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The mechanism involves the formation of a loosely H-bonded adduct (1.7) from a 
carbonyl and a carboxylic acid, followed by the α-addition of the electrophilic carbonyl 
carbon and the nucleophilic oxygen atom of the carboxylic acid to the isocyanide carbon 
leading to the formation of a cyclic transition state with all three compounds. 
Intermediate (2.7), which cannot be isolated, rearranges in an intramolecular 
transacylation to the stable α-acyloxy carboxamide (3.7) [10].  
2.1.2 Four-component reactions (Ugi reaction – 4CR). 
In 1959, Ugi described the most important variants of the four-component 
condensation, the Ugi reaction. Carboxylic acids, hydrazoic acids, cyanates, thiocyanates, 
carbonic acid monoesters, salts of secondary amines, water, hydrogen sulfide as Na2S2O3 
and hydrogen selenide as the acid components in the Ugi reaction react with ketones or 
aldehydes, primary and secondary amines, hydrazines and hydroxylamines as the amine 
components, and C-isocyanides [10].  
For instance, an interesting tandem Ugi – Intramolecular Diels-Alder (IMDA) 
reaction was discovered in 2006 [11]. Tricyclic adducts (1.8) resulting from the Ugi four-
component condensation of a furfural, a monoderivatized maleic acid, a primary amine, 
and an isonitrile followed by IMDA further rearranged in 85% H3PO4 providing (2.8) 
(Scheme 8): 
 
Scheme 8. Ugi/IMDA reaction product and its acid-promoted transformation.  
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Due to the technical simplicity and high yield, the process can be viewed as a promising 
chemotype-differential tool in DOS of novel compound libraries for biological screening.  
There are not many “original” or named four-component reactions. Another 
example is the Asinger reaction. An α-halogenated carbonyl-component reacts with 
NaSH and forms in situ a thiole. The thiole reacts directly with another carbonyl-
component and ammonia to form thiazolines [12].  
2.1.3 Five-component reactions (5CR). 
Cases of 5CR are less common. In 2008 Shaabani and co-workers [13] described 
a one-pot pseudo-five-component synthesis of 4,5,6,7-tetrahydro-1H-1,4-diazepine-5-
carboxamide derivatives starting from simple and readily available inputs including 2,3-
diaminomaleonitrile (DAMN), ketones, an isocyanide, and water in the presence of a 
catalytic amount of p-toluenesulfonic acid (Scheme 9): 
 
Scheme 9. Pseudo-five-component synthesis of 4,5,6,7-tetrahydro-1H-1,4-
diazepine-5-carboxamide derivatives [13].  
It is likely that the initial event is the formation of diimine from condensation 
between DAMN and the ketones. Then an intramolecular imine-enamine cyclization 
produces a seven-membered ring. After a nucleophilic attack of isocyanide to iminium 
followed by a nucleophilic attack of a H2O molecule on the nitrilium moiety and 
subsequent tautomerization of a new intermediate, the final product is formed. 
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Another example of a one-pot, two-step, five-component synthesis [14] is based 
on an Ugi four-component condensation of 3-formylchromones with amines, isocyanides, 
and glyoxylic acids followed by a nucleophilic Michael addition and intramolecular 
cyclization. The experimental minimalism and tolerance to a large variety of substituents 
makes this method utilizable for combinatorial synthesis (Scheme 10): 
 
Scheme 10. Five-component synthesis of spiropyrrolidinochromanones [14]. 
2.1.4 Six-component reactions (6CR). 
The exact nature of this sort of reactions is rather complicated to assess; a 
simultaneous interaction of three or more different molecules is less likely, resulting in a 
low reaction rate. These reactions are more likely to involve a series of bimolecular 
reactions.  
Functionalized depsipeptides (2.11) based on a dihydropyridin-2-one core were 
synthesized by the combination of a 4CR and a 5CR [15]. The synthesis combines a one-
pot Horner-Wadsworth-Emmons cyclocondensation sequence leading to isonitrile 
functionalized 3,4-dihydropyridine-2-ones (1.11) with an isonitrile-based Passerini 
MCR. The two MCRs could also be performed as a one-pot procedure, simplifying the 
protocol and leading to a new and highly variable 6CR (Scheme 11): 
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Scheme 11. MCR leading to depsipeptides [15]. 
2.1.5 Seven-component reactions (7CR). 
Although reports on novel MCRs appear regularly in recent literature, MCRs 
using more than five components are extremely rare. A milestone in this context is the 
seven-component reaction (7CR) reported by Dömling and Ugi [10, 16], which was 
essentially a one-pot combination of a modified Asinger and Ugi reactions. In this 7CR, 
two different aldehydes, NaSH, NH3, an isocyanide, CO2, and a primary alcohol are 
combined to produce triazoline (1.12) first and then thiazolidine (2.12) efficiently. 
However, NaSH, NH3, and CO2 are invariable components in this reaction (Scheme 12): 
 
Scheme 12. Seven-component Asinger-Ugi reaction [16].  
2.2 Photochemical reactions. 
Organic photochemistry is a sub-discipline of organic chemistry concerned with 
structures and dynamic processes that result from the interaction of electromagnetic 
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radiation with organic molecules [17]. The most important classes of organic compounds, 
which may be photo-reactive, can be narrowed down to: carbonyl compounds; olefins; 
enones and dienones; aromatic molecules and some supramolecular structures [17]. 
Although organic photochemistry is still underappreciated and underutilized by 
the synthetic community, it can be an excellent tool to fashion topologically unique 
scaffolds in an elegant manner. It is a different approach, allowing the preparation of 
scaffolds which cannot be made easily through “ground state” chemistry.  
One of the striking features of photochemical reactions is the fact that singlets can 
react differently from triplets.  
2.2.1 Triplet (sensitized) versus Singlet (direct) irradiation. 
The photochemical behavior of myrcene showed the contrast between direct and 
sensitized reactions [18]. Direct irradiation of myrcene gives at least seven products. 
Three major compounds were identified (Scheme 13). However, when it is irradiated in 
the presence of a variety of photosensitizers (acetophenone, benzophenone, triphenylene, 
benzil, 9-fluorenone, etc), the formation of a single product was observed (Scheme 13): 
CH3H3C
H3C CH3
H3C CH3
CH3H3C
CH3
CH3
T1
S1
3sens
h
myrcene
52 %
22 % 12 %
85 %
 
Scheme 13. Photoaddition of myrcene upon direct and sensitized irradiations [18].  
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This case illustrates not only the differences between the chemical properties of 
excited singlets (S) and triplets (T), but also shows that intersystem crossing from S1 of 
dienes to the T1 must be inefficient. In addition, it is an example of the “rule of five” – 
the general preference of 5- over 4- and 6-membered rings in a radical cyclization [17].  
2.2.2 Phase-selective photochemical reactions. 
Phase-selective photoreactions provide another opportunity to alter the outcome 
of a photochemical process. For instance, irradiation of 2-pyridones (1.14) in benzene 
produced rearranged products (2.14) with 30-40% yield through a photo-[1,3] migration 
of pyridine methylene group [19]. However, intermolecular [4 + 4] photocycloaddition 
occurred quantitatively in the solid state, yielding photodimers (3.14) (Scheme 14): 
 
Scheme 14. Photochemical reaction of 2-pyridone derivatives [19].  
An effective π-π stacking and dipole-dipole interaction between two pyridone 
moieties might play central roles in an efficient configuration of precursors (1.14) 
(compound 1, Scheme 14) for photo-dimerization in their crystal structures. 
2.2.3 Synthetic application of photochemistry. 
Photochemistry more frequently finds its relevance in synthetic organic 
chemistry. In some cases it can significantly shorten a total synthesis and quite often 
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complex, polycyclic or highly functionalized structures can be obtained from simple steps 
[20].  
A remarkable cascade reaction was observed, when a terpene-derivative was 
irradiated in the presence of an electron acceptor 1,4-dicyanobenzene (1,4-DCB) and 
sodium dodecyl sulfate (micellar medium) as shown in Scheme 15:  
 
Scheme 15. Sensitized intramolecular cascade cyclization of a polyene [21]. 
Despite the low yields (20 - 25%), these results are outstanding since the regio- and 
stereo-selective incorporation of water together with the formation of trans-ring fusions 
mimics characteristics of bio-derivation of terpenes. From a mechanistic point of view, 
the products could be derived from free-radical-type or ionic cyclizations [21]. 
A range of complex polycyclic alkaloids can be synthesized through oxa-di-π-
methane rearrangement (ODPM) [22]. Magellanine is one of the alkaloids which has 
been isolated from club mosses. Its polycyclic framework became accessible by a method 
which included the Diels-Alder reaction of a masked o-benzoquinone followed by ODPM 
rearrangement (Scheme 16): 
 
Scheme 16. Synthesis of Magellanine through ODPM rearrangement [22]. 
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Irradiation of the Diels-Alder adduct in acetone with fluorescent lamps (RUL-
3000 Å) through Pyrex filters in a Rayonet reactor afforded the tetracyclic diketone 
through the ODPM rearrangement in excellent yield. 
An extraordinary example of the application of [2+2] photocycloaddition as a key 
step in the total synthesis of Ginkgolide B was reported by Crimmins and co-workers in 
2000 [23]. Ginkgolides (Figure 6) were first isolated in 1932 from Ginkgo biloba. It is 
one of the oldest surviving plants with ancestors dating to 230 million B.C. This unique 
tree, which flourished in the Jurassic Period, is also known as a “living fossil”. 
 
Figure 6. Ginkgolide B 1 (X = OH, Y = H, Z = OH), first isolated from the root 
bark by Furukawa in 1932 [23]. 
Because of the complex molecular architecture of ginkgolide B, it is an 
intimidating challenge for chemical synthesis. The molecule contains six rings, eleven 
stereogenic centers, ten oxygenated carbons, an unusual tert-butyl group and four tertiary 
carbon atoms. The congested core of the molecule was constructed through a 
stereoselective intramolecular photocycloaddition on enone (1.17). Based on the analysis 
of substituent effects in numerous model systems it was predicted that irradiation of 
cyclopentenone (1.17) in hexanes at >350 nm would furnish a single diastereomeric 
photocycloadduct (2.17) in quantitative yield (compound 2, Scheme 17): 
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Scheme 17. Stereoselective intramolecular photocycloaddition of enone (1.17) [23]. 
It should be noticed that the next required step was the installation of the D ring 
bridged lactone (3.17). Then a series of structural diversification reactions with (3.17) 
was investigated (Scheme 17). Even though the compounds obtained from (3.17) were 
just intermediates, this example is a good illustration to how a photochemical reaction 
can be utilized as a key step in the construction of structurally unique scaffolds.  
C. Combinatorial synthesis. 
Combinatorial synthesis (along with DOS) has been one of the most rapidly 
developing fields in the pharmaceutical industry. Now it is an important tool in the 
discovery and development of new drugs. Unlike DOS, combinatorial synthesis is 
conditioned to create structurally related compounds with high yields. Usually this is 
done on a very small scale. Combinatorial synthesis can be performed either in a parallel 
fashion – a single product is obtained in each different reaction flask, or the process can 
be planned in such a way that mixtures of different molecules are produced in each 
reaction vessel [1].  
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1. Methods of parallel synthesis. 
1.1 Houghten’s teabag procedure. 
A general method for rapid solid-phase synthesis of large numbers of peptides, 
known today as the “teabag procedure”, was first described by Richard Houghten in 
1985 [24]. Standard polymeric support resin (50-100 mg) is enclosed in polypropylene 74 
µm mesh packets with estimated dimensions of 15 x 20 mm (Figure 7). Then a number is 
placed at the top of the unsealed bag, the packet is closed and the number is permanently 
sealed into the polypropylene to give a clear label for each bag. After that the teabags are 
placed in different containers and various amino acids are added to each bottle. 
Deprotection and washing can be carried out in one vessel and the teabags are then 
redistributed between the bottles for the addition of a second amino acid, etc. 
 
Figure 7. An example of a mesh packet containing resin [24].  
By using this method, 10-20 mg of 248 different 13-residue peptides representing 
single amino acid variants of a segment of the hemagglutinin protein (HA1) have been 
prepared and characterized in less than 4 weeks. 
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The advantage of this approach is that it is cost-effective and does not require 
expensive equipment. The major weakness is the fact that it is manual and this limits the 
quantity and efficiency with which new compounds can be synthesized. Therefore, 
automatic or semi-automatic methods are more preferred for parallel synthesis [1].  
1.2 Automated parallel synthesis.  
Automated and semi-automated synthesizers can cope with parallel synthesis [1]. 
The addition of solvents and reagents can be performed automatically using syringes. 
Automated work-up procedures are also possible. Reactions can be carried out under 
inert atmosphere, heated or cooled as required.  
 
Figure 8. Titan-357 peptide synthesizer.  
Automated synthesizers are designed to be multifunctional. For example, the 
Titan-357 peptide synthesizer (Figure 8) can not only prepare up to 36 separate peptides 
simultaneously in 36 reaction wells of the reactor assembly, but also produce hundreds of 
thousands to millions of peptides via the "mix-and-split" method. 
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2. Mixed combinatorial synthesis. 
Combinatorial synthesis is often designed to produce a mixture of products. All 
the mixtures resulting from a combinatorial synthesis can be stored and referred to as 
combinatorial (compound) libraries [1]. To produce large quantities of various 
structures, it is important to minimize the effort involved.  
The “split-and-mix” method, first described by Furka in 1991, is a clever way of 
achieving this goal. Using this approach, a library of 81 tetrapeptides can be efficiently 
synthesized from just three different amino acids (A1, A2 and A3). First, each amino acid 
needs to be linked to a solid support (see Scheme 18 - each sphere represents a resin bead 
with an appropriate linker). Then the beads are mixed together and separated into three 
equal portions. Each portion is exposed to another set of the three amino acids. After 
isolation of all the beads, mixing them together and splitting into three equal portions 
each portion contains all nine possible dipeptides (not shown on Scheme 18). Next, each 
set of dipeptides can react with one of the three amino acids to produce 27 different 
tripeptides. After another split-and-mix cycle a library of 81 tetrapeptides can be 
synthesized in just four experiments (Scheme 18).  
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Scheme 18. An illustration of the split-and-mix (split-and-pool) method.  
Combinatorial libraries containing millions of compounds can be stored and later 
analyzed by the high-throughput screening technique to find an active compound, 
antibody or a gene. This methodology is especially popular in drug discovery and 
development.  
D. Dynamic combinatorial chemistry. 
Dynamic combinatorial chemistry (DCC) is another discipline of combinatorial 
chemistry. Even though it is an alternative to the classic “mixed” combinatorial synthesis, 
this development occupies its own important niche. In a dynamic combinatorial library 
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(DCL) all constituents are in equilibrium, which requires the interconversion of library 
members into one another through reversible chemical processes involving (a) covalent 
bonds or (b) non-covalent interactions (hydrogen and coordinative bonding) [25].  
1.  General concept.  
DCC relies on the selection of the most thermodynamically stable product from 
an equilibrating mixture. This concept was first utilized in the 19th century in the studies 
of Emil Fischer on carbohydrates and of Werner on coordination complexes.  
The key element of DCC is the reversible reaction that mediates the exchange of 
the building blocks between the library members. Reversible reactions have to meet a 
number of requirements: (a) it needs to be reversible on a reasonable time scale; (b) the 
reversible reaction needs to be compatible with the experimental conditions of the 
selection process, the functional groups, the solvent, and the pH; (c) reaction conditions 
should be mild, so as to not interfere with the fragile non-covalent interactions; (d) it 
needs to guarantee the solubility of all the library members at equilibrium; (e) it should 
be possible to “turn off” the reaction in order to isolate and characterize several selected 
library members; (f) ideally all library members need to be isoenergetic in order to 
prevent the production of reaction mixtures that are strongly predisposed toward certain 
products [25].  
One important application is the recognition or selection of the most stable 
structure in mixtures of structures with different conformational properties or foldamers 
(Figure 9a). The structures with the most favorable internal non-covalent interactions will 
be stabilized and assembled in preference over those members that do not have such 
stabilization. 
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Figure 9. Different ways of selecting specific members of a DCL [25]. 
The stabilization of particular library members can occur through intermolecular non-
covalent interactions between other members; the library composition is biased toward 
those members that create stable assemblies or aggregates (Figure 9b). Templating can be 
used to select structures that act as hosts or receptors (Figure 9c), as well as for the 
discovery of new guests or ligands (Figure 9d). Although there are different approaches 
to select a specific member of a DCL, in all cases one general principle is applied - the 
compound that is most stabilized through non-covalent interactions tends to be amplified 
in preference over other library members [25]. 
2. Synthetic application.  
A remarkable example of a DCL was reported in 2005 by Sanders and co-workers 
[26]. They discovered that acetylcholine (a neurotransmitter) acts as a template to 
amplify [2]-catenanes from small peptide-hydrazone building blocks (1.19) (structure 1, 
Scheme 19).  Library development was initiated by the addition of trifluoroacetic acid to 
a solution of the building block (1.19) in 95:5 chloroform/DMSO. HPLC analysis 
revealed that linear intermediates were formed in several minutes, transforming over the 
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next 60 min into a series of simple cyclic oligomers up to the cyclic hexamer (6.19). The 
library reached equilibrium in 3 days. 
 
 
Scheme 19. Acetylcholine acting as a template amplifying [2]-catenanes (7.19). 
Next, acetylcholine chloride was added to the solution to serve as a template. Initially the 
cyclic dimer (2.19) was amplified, becoming the major product of the library and within 
an hour a new product (7.19) was formed at the expense of all the other members in the 
library. This compound was not observed in the absence of acetylcholine. Compound 
(7.19) continued to build up over a period of 45 days, eventually reaching 70% of the 
total material in the library [26]. 
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Chapter Two: Oxametathesis in the aromatic series 
Photo-cyclization reactions can lead to prohibitively strained polycyclic scaffolds. 
Further transformations offer rapid access to challenging synthetic targets by utilizing the 
strain created previously in the photochemical step.  
A. Introduction. 
An excellent example is the Paternò–Büchi reaction in acylnorbornenes, studied 
by Rawal, where a radical fragmentation of strained polycyclic oxetanes yielded di- and 
triquinanes [27]. Guilford Jones in 1973 first observed that oxetanes can also be 
converted pyrolytically to an alternative pair of an alkene and an aldehyde. This 
conversion represents a carbonyl-olefin metathesis (proposed by Jones [28]): 
  
Much later, in 2006, Griesbeck observed a similar reaction, which occurred via an 
electron transfer-induced mechanism [29]. The majority of pyrolytic transformations 
occur under harsh conditions with low yields, that is why they are not applicable for 
labile polyfunctional compounds. Only one example of milder TsOH-catalyzed reaction 
was reported by Jones [28]. Although such oxametathesis showed a synthetic potential, it 
was neglected for four decades.  
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B. Results and discussion. 
We hypothesized that if the oxetane motif was a part of a strained polycycle, the 
fragmentation could occur under exceptionally mild conditions. We discovered a high-
yielding two-step sequence, where the oxametathesis is induced by a very mild acid-
catalyzed reaction in strained oxetanes 2, affording novel polycyclic aldehydes 3 or their 
(hemi)acetals 4 (Scheme 20) [30]: 
 
Scheme 20. Photoprotolytic oxametathesis in polycyclic systems [30]. 
Many kinds of (het)aroyl polycycloalkenes are available via the Diels-Alder (D.-
A.) addition of heterocyclic chalcones [31] and other benzoyl ethylenes to a variety of 
dienes. The Paternò-Büchi step is the most critical part of the synthesis. This is where the 
strain in the polycyclic oxetane is captured. The Paternò-Büchi [2+2] cycloaddition is 
forbidden in the ground state and can only occur in the excited state. Thus it requires a 
UV source of irradiation which is capable of exciting the aroyl group into its n→π* 
excited state and eventually produce an oxetane, decorated by a variety of heterocyclic 
pendants. With such abundance of oxetane precursors, this oxametathesis sequence 
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allows for fast access to structures 4 having diverse polycyclic cores decorated by a 
variety of heterocyclic pendants (Scheme 20). 
In general, irradiation of ketones 1 in benzene with a UV source, is conditioned to 
excite the aromatic carbonyl groups into their singlet (S1) n→π* excited state. In many 
cases the reaction is not concerted but stepwise occurring via a triplet (T1) n→π* excited 
state [17]. Since the transition from S1 (n→π*) to T1 (n→π*) is forbidden, intersystem 
crossing (ISC) must occur first to T2 (π→π*) and then via internal conversion (IC) a 
reactive and more stable T1 (n→π*) is formed. The formation of a 1,4-diradical and 
another ISC leads to oxetanes with > 97% yield in most of the cases (Scheme 21):  
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Scheme 21. A mechanism of the Paternò–Büchi reaction [17]. 
 Both the Paternò–Büchi step 1→2 and the cycloreversion 2→3→4 are 
remarkably clean reactions [30]. 
The mechanism of the protolytic metathesis 2→3 (oxetane → aldehyde) involves 
protonation of the polycylic oxetane. There are two possibilities for fragmentation 
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(Scheme 22): either pathway (a) the retro-Paternò-Büchi reaction involving the formation 
of a secondary carbocation and further reaction producing started materials or pathway 
(b) the oxametathesis involving formation of a tertiary carbocation and further Grob-like 
fragmentation. In order for the Grob-like fragmentation to occur (pathway b), the aryl 
substituent (R1) in the oxetane must not destabilize the benzylic carbocation. This 
mechanism imposes only one constraint on the nature of the endo-aroyl group R1, which 
had to be an Electron Releasing (Donating) Group (ERG). In cases where R1 was an 
Electron Withdrawing Group (EWG), either the reaction was not observed or a retro- 
Paternò-Büchi opening took place (pathway a): 
 
Scheme 22. A plausible mechanism of the 2 → 3 step: (a) the retro-Paternò-
Büchi reaction or (b) oxametathesis. 
This two-step 1→3 conversion can also be implemented as a one-pot 
transformation, with the fragmentation being effected by a trace amount of HCl present in 
solvents such as chloroform or DCM. In most cases, aldehydes 3 form when the 
precursors 1 are irradiated in reagent grade CH2Cl2. With more HCl added, a secondary 
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electrophilic addition to the newly formed styrene double bond of 3 takes place, yielding 
hemiacetals 4 as a result of the formyl participation. Lewis acids, such as boron 
trifluoride, promote oxetane transformation into aldehydes 3 but do not allow for the 
hemiacetal formation. Protic acids in the presence of water furnish hemiacetals in most 
cases.  
Variations in the carbocyclic framework slightly modulate the reactivity. D.-A. 
adducts 1rs of cycloheptatriene, with a tricyclo[3.2.2.02,4]nonane core, form oxetanes 2rs, 
which are stable at room temperature in the presence of HCl. However, they are 
converted into aldehydes 3rs via a BF3-catalyzed reaction as shown in Figure 10: 
 
Figure 10. Transformation of 2r to 3r as followed by NMR [30].  
The starting oxetane 2r (top spectrum) is cleanly converted into the aldehyde 3r 
upon addition of BF3·OEt2. The bottom spectrum is a snapshot of the reaction mixture 
without purification. 
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Oxametathesis of oxetane 2t derived from the 1:1 adduct of dibenzoyl ethylene 
and cyclooctatetraene (COT) 1t yields aldehyde 3t (Scheme 23). However, upon further 
acidolysis, 3t did not cyclize into a hemiacetal but rather produced formylcyclopropane 
5t. A plausible mechanism for the formation of 5t involves the enol moiety in 3t-enol 
acting as an internal nucleophile. The conversion of 3t into 5t was approximately 90% 
with 10% of residual 3t remaining in the reaction mixture.  
 
Scheme 23. Oxametathesis of 2t derived from dibenzoyl ethylene and COT [30].  
As expected, pyridyl oxetanes 2c,d,m-q (Scheme 24A) rearrange into aldehydes 3 
only with modest yields (< 30%). Protic acids (HCl, TsOH, TfOH), even upon heating, 
do not effect the transformation in this series due to protonation of the pyridine moiety 
and further destabilization of the carbocation. However, the introduction of an electron-
donating methoxy group in the para-position, as in 2k, suppresses the destabilizing effect 
of the pyridyl and restores the reactivity: 2k undergoes BF3-catalyzed rearrangement 
yielding aldehyde 3k (95% yield over two steps, Scheme 24B). 
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Scheme 24. Oxametathesis of endo-pyridyl oxetanes (A) 2c,d,m-q; (B) 2k [30]. 
To summarize, we have developed a new, experimentally simple, high-yielding 
photoinduced transformation of readily available diverse starting materials into 
polycyclic aldehydes and their (hemi)acetals decorated with various pendants. This 
methodology offers an expeditious increase of molecular complexity and diversity of the 
target scaffolds. 
C. Experimental section. 
Common solvents were purchased from Pharmco and used as is, except for THF, 
which was refluxed over and distilled from potassium benzophenone ketyl prior to use. 
Common reagents were purchased from Aldrich or TCI America and used without 
additional purification, unless indicated otherwise. NMR spectra were recorded at 25oC 
on a Bruker Avance III 500 MHz or Varian Mercury 400 MHz instrument in CDCl3 with 
TMS as an internal standard (unless noted otherwise). X-Ray structures were obtained 
with a Bruker APEX II instrument (see Appendix A). High resolution mass spectra were 
obtained on the MDS SCIEX/Applied Biosystems API QSTARTM Pulsar i Hybrid 
LC/MS/MS System mass spectrometer by Dr. Shuji Kato from the University of Colorado 
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at Boulder. For the synthetic details, 1H, 13C, COSY NMR spectra see supporting 
information [30]. 
1. Preparation of the Paternò–Büchi adducts (2): 
Approximately 0.1 M solution of an endo-precursor 1 in benzene (or other 
specified solvent) was irradiated in Pyrex vials in a Rayonet reactor equipped with RPR-
3500 UV lamps (broadband 300-400 nm UV source with peak emission at 350 nm) or a 
UVLED-based illuminator with five 250 mW @ 365 nm Nichia chips. Irradiation 
resulted in a quantitative conversion to oxetanes 2, which were used without further 
purification. Crystalline oxetanes were recrystallized and their X-Ray structures obtained. 
NOTE: We attempted to further purify reaction mixtures by chromatography. The 
strained polycyclic oxetanes are not stable on silica gel, producing various amounts of 
aldehydes 3 via oxametathesis.   
 4-Phenyl-7-(3-pyridyl)-3-oxatetracyclo[4.2.1.02,5.04,8]nonane (2b): A 
solution of 40 mg of trans-endo-2-benzoyl-3-(3-pyridyl)bicyclo[2.2.1]hept-5-ene in 40 
mL of DCM (10 mL per one glass vial) was irradiated with UV LED-365 for 24 hours. 
1H NMR (400 MHz, CDCl3) δ = 8.60 (m, 1H), 8.48 (m, 1H), 7.90 (m, 1H), 7.50-7.36 (m, 
6H), 4.48 (dd, J = 3.7, 2.2 Hz, 1H), 3.64 (dddd, J = 3.8, 3.8, 1.8, 1.8 Hz, 1H), 3.34 (m, 
1H), 3.19 (ddd, J = 4.3, 2.1, 2.1 Hz, 1H), 3.00 (m, J = 4.1, 2.1 Hz, 1H), 2.34 (m, 1H), 
1.62 (dd, J = 11.3, 2.4 Hz, 1H), 1.53 (dd, J = 11.3, 2.4 Hz, 1H).  
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 4-(2-Pyridyl)-7-(3-pyridyl)-3-oxatetracyclo[4.2.1.02,5.04,8]nonane (2c): 
A solution of 100 mg of trans-endo-2-(2-pyridoyl)-3-(3-pyridyl)bicyclo[2.2.1]hept-5-ene 
in 40 mL of DCM (10 mL per one glass vial) was irradiated with UV LED-365 for 24 
hours. 1H NMR (400 MHz, CDCl3) δ = 8.60 (d, J = 4.8 Hz, 1H), 8.48 (d, J = 2.3 Hz, 
1H), 8.45 (dd, J = 4.8, 1.6 Hz, 1H), 7.72 (ddd, J = 7.7, 7.7, 1.8 Hz, 1H), 7.51 (t, J = 8.2 
Hz, 2H), 7.23 (m, 2H), 4.86 (dd, J = 3.7, 2.3 Hz, 1H), 3.90 (m, 1H), 3.70 (dddd, J = 3.7, 
3.7, 1.8, 1.8 Hz, 1H), 3.22 (ddd, J = 4.1, 2.0, 2.0 Hz, 1H), 3.01 (dddd, J = 4.0, 4.0, 2.1, 
2.1 Hz, 1H), 2.41 (m, 1H), 1.64 (dd, J = 11.4, 2.7 Hz, 1H), 1.55 (dd, J = 11.4, 2.6 Hz, 
1H).  
 4,7-Bis(4-pyridyl)-3-oxatetracyclo[4.2.1.02,5.04,8]nonane (2d): A 
solution of 100 mg of trans-endo-2-(4-pyridoyl)-3-(4-pyridyl)bicyclo[2.2.1]hept-5-ene in 
40 mL of DCM (10 mL per one glass vial) was irradiated with UV LED-365 for 24 
hours. 1H NMR (400 MHz, CDCl3) δ = 8.65 (d, J = 5.9 Hz, 2H), 8.52 (d, J = 5.8 Hz, 
2H), 7.35 (d, J = 5.9 Hz, 2H), 7.09 (d, J = 5.8 Hz, 2H), 4.86 (dd, J = 3.8, 2.2 Hz, 1H), 
3.62 (dddd, J = 3.8, 3.8, 1.9, 1.9 Hz, 1H), 3.30 (m, 1H), 3.16 (ddd, J = 4.0, 1.8, 1.8 Hz, 
1H), 3.02 (m, 1H), 2.40 (m, 1H), 1.59 (m, 2H).  
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 4,7-Diphenyl-3-oxatetracyclo[4.2.2.02,5.04,8]decane (2e): A solution of 
0.29 g of trans-endo-2-benzoyl-3-phenylbicyclo[2.2.2]oct-5-ene in 50 mL of benzene or 
DCM (the presence of HCl in DCM induces metathesis)  (10 mL per one glass vial) was 
irradiated with UV LED-365 for 24 hours. 1H NMR (400 MHz, CDCl3) δ = 7.49 (dd, J = 
8.2, 1.4 Hz, 2H), 7.37 (m, J = 7.9, 1.4 Hz, 2H), 7.34-7.30 (m, 1H), 7.30-7.27 (m, 4H), 
7.19 (m, 1H), 4.53 (dd, J = 3.8, 1.7 Hz, 1H), 3.62 (dddd, J = 5.5, 3.5, 1.6, 1.6 Hz, 1H), 
3.30 (d, J = 6.7 Hz, 1H), 3.20-3.15 (d, J = 6.6 Hz, 1H), 2.70 (m, 1H), 2.46-2.38 (m, J = 
6.2, 3.9, 1.9, Hz, 1H), 1.64 (dtd, J = 14.2, 10.1, 1.9 Hz, 1H), 1.55-1.39 (m, J = 17.4, 13.5, 
10.2, 4.1 Hz, 2H), 1.14 (m, 1H). 1H NMR (400 MHz, benzene-d6) δ = 7.49 (dd, J = 7.5, 
1.6 Hz, 2H), 7.15-6.96 (m, 8H), 4.28 (dd, J = 3.6, 1.9 Hz, 1H), 3.34 (dddd, J = 5.5, 3.4, 
1.5, 1.5 Hz, 1H), 3.29-3.22 (d, J = 6.7 Hz, 1H), 3.05 (m, 1H), 2.56 (m, 1H), 2.01-1.92 
(m, 1H), 1.62-1.46 (dddd, J = 13.8, 9.7, 9.7, 2.1 Hz, 1H), 1.33 (ddd, J = 13.4, 9.8, 4.2 
Hz, 1H), 1.17-1.04 (ddd, J = 13.9, 10.2, 3.8 Hz, 1H), 0.79 (m, 1H). 13C NMR (400 MHz, 
CDCl3) δ = 141.65, 137.53, 128.70, 128.56, 128.19, 127.97, 127.48, 125.84, 97.85, 
82.77, 57.84, 48.09, 45.68, 39.51, 32.81, 20.64, 18.01. 
O Ph
 4-Phenyl-3-oxatetracyclo[4.2.2.02,5.04,8]decane (2f): A solution of 0.21 g of 
endo-2-benzoylbicyclo[2.2.2]oct-5-ene in 50 mL of DCM (10 mL per one glass vial) was 
irradiated with UV LED-365 for 24 hours. 1H NMR (400 MHz, CDCl3) δ = 7.49-7.28 (m, 
5H), 4.56-4.44 (dt, J = 3.7, 1.3 Hz, 1H), 3.36 (dddd, J = 5.5, 3.5, 1.7, 1.7 Hz, 1H), 2.55 
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(m, 2H), 2.04-1.86 (m, 2H), 1.74 (m, 2H), 1.60 (dddd, J = 12.8, 9.65, 4.6, 1.0 Hz, 2H), 
1.21 (m, 1H). 
 4-Phenyl-7-(3-pyridyl)-3-oxatetracyclo[4.2.2.02,5.04,8]decane (2g): A 
solution of 100 mg of trans-endo-2-benzoyl-3-(3-pyridyl)bicyclo[2.2.2]oct-5-ene in 40 
mL of DCM (10 mL per one glass vial) was irradiated with UV LED-365 for 24 hours. 
(The product also could be purified on a silica gel column using hexane/EtOH 5:1). 1H 
NMR (400 MHz, CDCl3) δ = 8.58 (d, J = 1.7 Hz, 1H), 8.46 (d, J = 4.9 Hz, 1H), 7.68 (d, 
J = 7.8 Hz, 1H), 7.49-7.29 (m, 6H), 4.55 (dd, J = 3.6, 2.0 Hz, 1H), 3.64 (dddd, J = 5.6, 
3.5, 1.7, 1.7 Hz, 1H), 3.27 (d, J = 6.5 Hz, 1H), 3.19 (d, J = 6.5 Hz, 1H), 2.73 (m, 1H), 
2.47 (m, J = 6.0, 6.0, 3.8, 2.0, 2.0 Hz, 1H), 1.54-1.40 (m, 3H), 1.23 (m, 1H). 
O
N
O
 4-(2-Furanyl)-7-(4-pyridyl)-3-oxatetracyclo[4.2.2.02,5.04,8]decane 
(2h): A solution of 0.12 g of trans-endo-2-(2-furoyl)-3-(4-pyridyl)bicyclo[2.2.2]oct-5-ene 
in 50 mL of DCM (10 mL per one glass vial) was irradiated with UV LED-365 for 24 
hours. 1H NMR (400 MHz, CDCl3) δ = 8.54 (m, 2H), 7.45 (dd, J = 1.8, 0.8 Hz, 1H), 7.24 
(ddd, J = 5.0, 1.1, 1.1 Hz, 2H), 6.49 (dd, J = 3.3, 0.8 Hz, 1H), 6.39 (dd, J = 3.3, 1.8 Hz, 
1H), 4.48 (dd, J = 3.5, 1.8 Hz, 1H), 3.76 (dddd, J = 5.6, 3.4, 1.6, 1.6 Hz, 1H), 3.31-3.27 
(m, 2H), 2.65 (m, 1H), 2.41 (m, 1H), 1.53-1.42 (m 3H), 1.15 (m, 1H). 
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 7-(3-Pyridyl)-4-(2-thienyl)-3-oxatetracyclo[4.2.2.02,5.04,8]decane (2i): 
A solution of 0.35 g of trans-endo-2-(2-thienoyl)-3-(3-pyridyl)bicyclo[2.2.2]oct-5-ene in 
50 mL of benzene (10 mL per one glass vial) was irradiated with UV LED-365 for 24 
hours. 1H NMR (400 MHz, CDCl3) δ = 8.57 (m, 1H), 8.46 (m, 1H), 7.60 (m, 1H), 7.36 
(m, 1H), 7.24 (m, J = 7.9, 4.9 Hz, 1H), 7.17 (dd, J = 3.6, 1.2 Hz, 1H), 7.02 (dd, J = 5.0, 
3.6 Hz, 1H), 4.50 (dd, J = 3.5, 1.8 Hz, 1H), 3.65 (dddd, J = 5.7, 3.6, 1.9, 1.9 Hz, 1H), 
3.40 (d, J = 6.7 Hz, 1H), 3.23 (d, J = 6.7 Hz, 1H), 2.71 (m, 1H), 2.45 (m, J = 6.1, 4.2, 2.0 
Hz, 1H), 1.55-1.40 (m, 3H), 1.18 (m, 1H). 13C NMR (400 MHz, CDCl3) δ = 149.46, 
147.43, 140.33, 136.83, 135.38, 127.25, 127.18, 127.15, 123.19, 93.31, 82.30, 60.33, 
46.67, 46.46, 39.32, 32.46, 20.28, 17.80. 
 4-(4-Methoxyphenyl)-7-(4-pyridyl)-3-
oxatetracyclo[4.2.2.02,5.04,8]decane (2j): A solution of 0.28 g of trans-endo-2-(4-
methoxybenzoyl)-3-(4-pyridyl)bicyclo[2.2.2]oct-5-ene in 50 mL of benzene (10 mL per 
one glass vial) was irradiated with UV LED-365 for 72 hours. 1H NMR (400 MHz, 
CDCl3) δ = 8.51 (m, 2H), 7.42 (m, 2H), 7.20 (m, 2H), 6.91 (m, 2H), 4.50 (dd, J = 3.7, 1.8 
Hz, 1H), 3.80 (s, 3H), 3.61 (dddd, J = 5.6, 3.5, 1.7, 1.7 Hz, 1H), 3.20 (d, J = 6.6 Hz, 1H), 
3.16 (d, J = 6.6 Hz, 1H), 2.69 (m, 1H), 2.43 (m, 1H), 1.54-1.44 (m, 3H), 1.17 (m, 1H). 
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13C NMR (400 MHz, CDCl3) δ = 160.13, 151.08, 149.64, 129.06, 128.96, 123.43, 114.08, 
97.46, 82.26, 57.31, 55.53, 47.79, 45.07, 39.35, 32.28, 20.55, 17.94.  HRMS (ESI) calcd 
for C21H21NNaO2+ (MNa+) 342.1465, found 342.1461. 
O
N
N O
 4-(4-Methoxy-3-pyridyl)-7-(3-pyridyl)-3-
oxatetracyclo[4.2.2.02,5.04,8]decane (2k): A solution of 0.17 g of trans-endo-2-(4-
methoxy-3-pyridoyl)-3-(3-pyridyl)bicyclo[2.2.2]oct-5-ene in 50 mL of benzene (10 mL 
per one glass vial) was irradiated with UV LED-365 for 72 hours. 1H NMR (400 MHz, 
CDCl3) δ = 8.56 (m, 1H), 8.45 (d, J = 4.7 Hz, 1H), 8.27 (d, J = 2.4 Hz, 1H), 7.72 (dd, J 
= 8.6, 2.5 Hz, 1H),  7.56 (d, J = 7.7 Hz, 1H), 7.24 (dd, J = 7.9, 4.8 Hz, 1H),  6.78 (d, J = 
8.6 Hz, 1H), 4.53 (dd, J = 3.7, 1.8 Hz, 1H), 3.93 (s, 3H), 3.65 (dddd, J = 5.9, 3.9, 2.0, 2.0 
Hz, 1H), 3.20 (d, J = 7.0 Hz, 2H), 2.71 (m, 1H), 2.44 (m, J = 6.1, 4.2, 2.0 Hz, 1H), 1.57-
1.41 (m, 3H), 1.19 (m, 1H). 13C NMR (400 MHz, CDCl3) δ = 164.55, 149.35, 147.39, 
146.32, 138.05, 136.67, 135.38, 128.50, 125.43, 123.17, 111.13, 95.78, 82.74, 57.43, 
53.75, 46.04, 44.79, 39.25, 32.43, 20.32, 17.77. 
 4-Phenyl-7-(2-pyridyl)-3-oxatetracyclo[4.2.2.02,5.04,8]decane (2l): A 
solution of 130 mg of trans-endo-2-benzoyl-3-(2-pyridyl)bicyclo[2.2.2]oct-5-ene in 50 
mL of DCM (10 mL per one glass vial) was irradiated with UV LED-365 for 24 hours. 
1H NMR (400 MHz, CDCl3) δ = 8.60 (d, J = 4.5 Hz, 1H), 7.75 (m, 1H), 7.49 (m, J = 6.8 
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Hz, 2H), 7.41-7.24 (m, 5H), 4.55 (dd, J = 3.6, 1.8 Hz, 1H), 3.64 (dddd, J = 5.5, 3.5, 1.6, 
1.6 Hz, 1H), 3.42 (d, J = 6.6 Hz, 1 H), 3.30 (d, J = 6.6 Hz, 1 H), 2.76 (m, 2H), 1.51 (m, 
3H), 1.24 (m, 1H). 
O N
N
 4,7-Bis(4-pyridyl)-3-oxatetracyclo[4.2.2.02,5.04,8]decane (2m): A 
solution of 60 mg of trans-endo-2-(4-pyridoyl)-3-(4-pyridyl)bicyclo[2.2.2]oct-5-ene in 
20 mL of DCM (10 mL per one glass vial) was irradiated with UV LED-365 for 24 
hours. 1H NMR (400 MHz, CDCl3) δ = 8.64 (m, 2H), 8.54 (m, 2H), 8.36 (m, 2H), 8.25 
(m, 2H), 4.59 (dd, J = 3.7, 1.9 Hz, 1H), 3.63 (dddd, J = 5.7, 3.6, 1.8, 1.8 Hz, 1H), 3.24 
(d, J = 6.7 Hz, 1H), 3.14 (d, J = 6.7 Hz, 1H), 2.75 (m, 1H), 2.51 (m, 1H), 1.55-1.48 (m, 
3H), 1.23 (m, 1H). 13C NMR (400 MHz, CDCl3) δ = 150.95, 150.20, 149.26, 145.97, 
123.48, 121.84, 96.02, 83.19, 57.90, 47.71, 45.97, 39.47, 32.35, 20.44, 17.65. 
 4,7-Bis(2-pyridyl)-3-oxatetracyclo[4.2.2.02,5.04,8]decane (2n): A 
solution of 70 mg of trans-endo-2-(2-pyridoyl)-3-(2-pyridyl)bicyclo[2.2.2]oct-5-ene in 
30 mL of DCM (10 mL per one glass vial) was irradiated with UV LED-365 for 24 
hours. 1H NMR (400 MHz, CDCl3) δ = 8.49 (m, 1H), 7.62 (ddd, J = 7.8, 7.8, 1.8 Hz, 
1H), 7.53 (ddd, J = 7.7, 7.7, 1.8 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.23 (d, J = 7.9 Hz, 
1H), 7.13 (dd, J = 7.5, 5.0 Hz, 1H), 7.03 (dd, J =  7.4, 4.9 Hz, 1H), 4.50 (dd, J = 3.6, 1.8 
Hz, 1H), 3.80 (d, J = 6.6 Hz, 1H), 3.60 (dddd, J = 5.6, 3.5, 1.8, 1.8 Hz, 1H), 3.32 (J = 
 42 
6.6 Hz, 1H), 2.68 (m, 1H), 2.55 (m ,1H), 1.52-1.40 (m, 3H), 1.12 (m, 1H). 13C NMR (400 
MHz, CDCl3) δ = 162.10, 157.95, 149.26, 149.07, 136.52, 135.90, 123.02, 122.70, 
121.75, 120.92, 97.47, 83.09, 58.81, 50.64, 46.79, 39.79, 32.77, 20.93, 18.03. 
 4-(2-Pyridyl)-7-phenyl-3-oxatetracyclo[4.2.2.02,5.04,8]decane (2o): A 
solution of 90 mg trans-endo-2-(2-pyridoyl)-3-phenylbicyclo[2.2.2]oct-5-ene in 30 mL of 
DCM (10 mL per one glass vial) was irradiated with UV LED-365 for 24 hours. 1H NMR 
(400 MHz, CDCl3) δ = 8.59 (d, J = 4.9 Hz, 1H), 7.70 (ddd, J = 7.8, 7.8, 1.8 Hz, 1H), 
7.53(d, J = 7.8 Hz, 1H), 7.31-7.20 (m, 6H), 4.57  (dd, J = 6.6, 1.9 Hz, 1H), 3.75 (d, J = 
6.8 Hz, 1H), 3.68 (dddd, J = 5.6, 3.6, 1.8, 1.8 Hz, 1H), 3.23 (d, J = 6.7 Hz, 1H), 2.71 (m, 
1H), 2.51 (m, J = 6.3, 4.0, 2.0, Hz, 1H), 1.70-1.49 (m, 3H), 1.16 (m, 1H). 
O
N
N
 4,7-Bis(3-pyridyl)-3-oxatetracyclo[4.2.2.02,5.04,8]decane (2p): A 
solution of 0.12 g of trans-endo-2-(3-pyridoyl)-3-(3-pyridyl)bicyclo[2.2.2]oct-5-ene in 50 
mL of DCM (10 mL per one glass vial) was irradiated with UV LED-365 for 24 hours. 
1H NMR (400 MHz, CDCl3) δ = 8.73 (dd, J = 2.3, 0.8 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 
1H), 8.57 (d, J = 2.3 Hz, 1H), 7.81 (ddd, J = 7.9, 2.3, 1.7 Hz, 1H), 7.59 (d, J = 7.8 Hz, 
1H), 7.33 (ddd, J = 7.9, 4.8, 0.9 Hz, 1H), 7.24 (ddd, J = 7.8, 4.8, 0.9 Hz, 1H), 4.58 (dd, J 
= 3.6, 1.9 Hz, 1H), 3.69 (m, 1H), 3.23 (d, J = 6.9 Hz, 2H), 2.76 (m, 1H), 2.49 (m, 1H), 
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1.57-1.43 (m, 3H), 1.21 (m, 1H). 13C NMR (400 MHz, CDCl3) δ = 150.22, 149.44, 
148.93, 147.59, 136.44, 135.37, 134.99, 132.79, 123.60, 123.22, 95.87, 83.21, 57.67, 
46.02, 45.31, 39.39, 32.52, 20.33, 17.72. HRMS (ESI) calcd for C19H19N2O+ (MH+) 
291.1492, found 291.1488. 
Ph
O
N
 4-(3-Pyridyl)-7-phenyl-3-oxatetracyclo[4.2.2.02,5.04,8]decane (2q): A 
solution of 90 mg of trans-endo-2-(3-pyridoyl)-3-phenylbicyclo[2.2.2]oct-5-ene in 30 mL 
of DCM (10 mL per one glass vial) was irradiated with UV LED-365 for 24 hours. 1H 
NMR (400 MHz, CDCl3) δ = 8.74 (m, 1H), 8.57 (m, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.34-
7.23 (m, 6H), 4.57 (s, 1H), 3.67 (m, 1H), 3.25 (d, J = 6.7 Hz, 1H), 3.21 (d, J = 6.7 Hz, 
1H), 2.72 (m, 1H), 2.44 (m, 1H), 1.65 (m, 1H), 1.49 (m, 2H), 1.15 (m, 1H).  
 11-benzoyl-4-phenyl-3-oxapentacyclo[4.3.2.02,5. 04,10.07,9]undecane 
(2r): A solution of 0.32 g of trans-8,9-dibenzoyltricyclo[3.2.2.02,4]non-6-ene in 50 mL of 
DCM (10 mL per one glass vial) was irradiated with UV LED-365 for 24 hours. The 
product was purified on a silica gel column using hexane/EtOAc gradient (20:1 to 15:1). 
The product was obtained with 75% yield (0.24 g). 1H NMR (400 MHz, CDCl3) 
δ = 7.87 (dd, J = 7.9, 1.6 Hz, 2H),  7.53 (t, J = 7.3 Hz, 1H), 7.48-7.34 (m, 7H), 4.47 (dd, 
J = 2.7, 2.7 Hz, 1 H), 3.63 (dd, J = 6.4, 1.2 Hz, 1H), 3.37 (dddd, J = 5.5, 3.7, 2.2, 2.2 Hz, 
1H), 3.18 (dd, J = 6.3, 1.4 Hz, 1H), 3.05 (dddd, J = 6.1, 6.1, 2.2, 2.2 Hz, 1H), 2.87 (q, J 
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= 5.5 Hz, 1H), 1.27 (m, 1H), 0.82 (tt, J = 8.4, 4.2 Hz, 1H), 0.27 (ddd, J = 6.4, 3.9, 3.9 
Hz, 1H), 0.20 (dt, J = 7.9, 7.9, 6.3 Hz, 1H). 1H NMR (400 MHz, CD2Cl2) δ = 7.87 (d, J = 
7.6 Hz, 2H), 7.56 (t, J = 7.2 Hz, 1H), 7.49-7.39 (m, 7H), 4.44 (dd, J = 2.7 Hz, 1H), 3.63 
(dd, J = 6.5, 1.4 Hz, 1H), 3.36 (dddd, J = 5.5, 3.4, 2.1, 2.1 Hz, 1H), 3.12 (dd, J = 6.3, 1.5 
Hz, 1H), 2.98 (dddd, J = 6.1, 6.1, 2.2, 2.2 Hz, 1H), 2.88 (q, J = 5.5 Hz, 1H), 1.22 (dddd, 
J = 8.0, 8.0, 6.0, 3.8 Hz, 1H), 0.80 (tt, J = 8.4, 4.3 Hz, 1H), 0.28 (dt, J = 6.2, 3.9, 3.9 Hz, 
1H), 0.19 (dt, J = 7.9, 7.9, 6.4 Hz, 1H). 13C NMR (400 MHz, CDCl3) δ = 200.10, 136.98, 
136.88, 133.15, 129.05, 128.90, 128.86, 128.06, 127.45, 96.29, 83.29, 56.99, 56.56, 
46.55, 37.82, 35.96, 14.41, 7.82, 4.03. 13C NMR (400 MHz, CD2Cl2) δ = 200.20, 137.55, 
137.41, 133.35, 129.18, 129.05, 128.87, 128.30, 127.77, 96.42, 83.44, 57.33, 56.86, 
47.00, 38.27, 36.16, 14.66, 8.07, 4.06. 
PhO
 4-Phenyl-3-oxapentacyclo[4.3.2.02,5.04,10.07,9]undecane (2s): A solution of 
0.17 g of endo-8-benzoyltricyclo[3.2.2.02,4]non-6-ene in 50 mL of benzene (10 mL per 
one glass vial) was irradiated with UV LED-365 for 24 hours. 1H NMR (400 MHz, 
CDCl3) δ = 7.92 (m, 2H), 7.52−7.27 (m, 3Η), 4.44 (dd, J = 2.81 Hz, 1H), 3.15 (dddd, J = 
5.42, 3.55, 1.90, 1.90 Hz, 1H), 2.79 (dddd, J = 6.02, 6.02, 2.11, 2.11 Hz, 1H), 2.60 (m, J 
= 6.23 Hz, 1H), 2.24 (m, J = 5.51 Hz, 1H), 1.85 (ddd, J = 11.44, 6.34, 1.56 Hz, 1H), 
1.65 (dd, J = 11.50, 2.02 Hz, 1H), 1.30 (m, 1H), 1.19 (m, 1H), 0.29 (m, 2H). 
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 12-Benzoyl-4-phenyl-3-oxapentacyclo[4.4.2.02,5.04,11.07,10]dodec-8-ene 
(2t): A solution of 1.41 g of trans-7,8-dibenzoyltricyclo[4.2.2.02,5]deca-3,9-diene (4.14 
mmol) in 10 mL of DCM (1 mL per one quartz or glass vial) was irradiated with RPR-
3000 or UV LED-365 (in case of RPR-3500 reaction occurs slower) for 48 hours. The 
eluent is ethyl acetate/hexane, 1:30 (initially), and then 1:20. The product was obtained 
with 34% yield (0.48 g). 1H NMR (400 MHz, CDCl3) δ = 7.82 (dd, J = 7.4, 1.5 Hz, 2H), 
7.55-7.48 (m, 3H), 7.44-7.35 (m, 5H), 6.14 (d, J = 2.6 Hz, 1H), 5.93 (ddd, J = 2.7, 1.3, 
1.3 Hz, 1H), 4.84 (dd, J = 3.2, 1.9 Hz, 1H), 3.67 (dd, J = 7.0, 1.5 Hz, 1H), 3.57 (dddd, J 
= 5.4, 3.6, 1.9, 1.9 Hz, 1H), 3.37 (ddd, J = 4.5, 4.5, 1.0 Hz, 1H), 3.25 (m, 1H), 3.03 
(dddd, J = 6.7, 4.8, 1.9, 1.9 Hz, 1H), 2.70 (m, 1H), 2.65 (m, 1H). 13C NMR (400 MHz, 
CDCl3) δ = 200.46, 142.12, 137.62, 136.88, 136.81, 133.23, 129.03, 128.91, 128.86, 
128.08, 127.51, 96.00, 82.62, 56.33, 55.61, 44.88, 43.50, 42.00, 41.31, 38.30. GCMS 
m/z: 77 (67), 105 (100), 235 (16), 262 (34), 340 (M+, 5). HRMS (ESI) calcd for 
C24H21O2+ (MH+) 341.1536, found 341.1531. 
2. Preparation of the oxametathesis products (3-7): 
(A) BF3-catalyzed formation of aldehydes 3: BF3-Et2O (small molar excess per 
heteroatom in 2) was added to a solution of oxetane 2 in dichloromethane (DCM) and 
stirred overnight at room temperature, washed twice with a saturated solution of Na2CO3 
and water. The crude aldehyde 3 was purified on a silica gel column using hexane–ethyl 
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acetate as an eluent.  For pyridine-containing aldehydes hexane–ethanol was used as the 
eluent. 
(B) HCl-catalyzed formation of aldehydes 3: To a solution of 2 in DCM, a 
catalytic amount of HCl (4.0 M solution in dioxane) was added. The resulting mixture 
was stirred at room temperature for 24 h, washed twice with a saturated solution of 
Na2CO3 and water, concentrated, and purified on a silica gel column using hexane–ethyl 
acetate (or hexane–ethanol for the pyridine-containing hemiacetals). 
(C) Oxametathesis yielding hemi-acetals 4: To a solution of 2 in DCM, a 
catalytic amount of HCl (4.0 M solution in dioxane) and 1-3 drops of water were added. 
The resulting mixture was stirred at room temperature for 24 h, washed twice with a 
saturated solution of Na2CO3 and water, concentrated, and purified on a silica gel column 
using hexane–ethyl acetate (or hexane–ethanol for the pyridine-containing hemiacetals). 
(D) Oxametathesis in alcohols yielding acetals 6: Oxetane 2 was dissolved in a 
5% HCl solution in methanol or benzyl alcohol and stirred for 24 h. The resulting mixture 
was evaporated, dissolved in DCM, washed twice with saturated Na2CO3 and water. The 
crude acetals 6 or 7 were purified on a silica gel column using hexane–ethanol as an 
eluent. 
 7-Phenyl-syn-8-(3-pyridyl)bicyclo[3.2.1]oct-6-ene-endo-2-
carboxaldehyde (3g): (method B) from 0.040 g (0.14 mmol) of 2g and 100 µL of HCl 
(4.0 M, 0.42 mmol) in DCM: 0.029 g (72%). 1H NMR (400 MHz, CDCl3) δ = 9.44 (d, J 
 47 
= 1.6 Hz, 1H), 8.64 (m, 1H), 8.52 (d, J = 4.6 Hz, 1H), 7.88 (d, J = 7.3 Hz, 1H), 7.66 (d, J 
= 7.7 Hz, 1H), 7.50 (d, J = 7.7 Hz, 2H), 7.35 (m, 2H), 7.27 (m, 1H), 6.61 (d, J = 3.4 Hz, 
1H), 4.01 (d, J = 4.3 Hz, 1H), 3.70 (m, 1H), 3.32 (m, 1H), 2.52 (m, 1H), 1.83-1.72 (m, 
2H), 1.55-1.43 (m, 2H). HRMS (ESI) calcd for C20H20NO+ (MH+) 290.1539, found 
290.1533. 
 syn-8-(3-pyridyl)-7-(2-thienyl)bicyclo[3.2.1]oct-6-ene-endo-2-
carboxaldehyde (3i): (method B) from 0.150 g (0.51 mmol) of 2i and 0.25 mL of HCl 
(4.0 M, 1.02 mmol) in DCM: 0.096 g (64%), as 1.9:1 mixture of epimers (after silica gel 
column using hexane/EtOH gradient 20:1 to 10:1). 1H NMR (400 MHz, CDCl3) δ = 9.55 
(d, J = 1.4 Hz, 1H), 8.93* (s, 1H, epimer), 8.61 (ddd, J = 2.3, 1.2, 1.2 Hz, 1H), 8.52 (m, 
1H), 7.64 (dddd, J = 7.9, 2.5, 1.5, 1.5 Hz, 1H), 7.35 (dd, J = 8.0, 4.8 Hz, 1H),  7.20 (m, 
1H), 6.98 (m, 1H), 6.95 (d, J = 3.3 Hz, 1H), 6.42 (d, J = 3.4 Hz, 1H), 3.90 (d, J = 4.7 Hz, 
1H), 3.69 (t, J = 4.5 Hz, 1H), 3.29 (m, 1H), 2.51 (m, 1H), 1.80-1.70 (m, 2H), 1.55 (m, 
1H), 1.45 (m, 1H). HRMS (ESI) calcd for C18H18NOS+ (MH+) 296.1104, found 
296.1106. Sodium ion-bound: HRMS (ESI) calcd for C18H17NNaOS+ (MNa+) 318.0923, 
found 318.0913. 
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 7-(4-Methoxyphenyl)-syn-8-(4-pyridyl)bicyclo[3.2.1]oct-6-ene-endo-2-
carboxaldehyde (3j): (method B) from 70 mg (0.22 mmol) of 2j and 28 µL of HCl (4.0 
M, 0.11 mmol) in DCM: 65 mg (93%). 1H NMR (400 MHz, CDCl3) δ = 9.42 (d, J = 1.65 
Hz, 1H), 8.63 (d, J = 5.9 Hz, 2H), 7.42 (d, J = 8.9 Hz, 2H), 7.27 (d, J = 4.8 Hz, 2H), 6.88 
(d, J = 8.9 Hz, 2H), 6.45 (d, J = 3.3 Hz, 1H), 3.93 (dd, J = 4.7, 1.7 Hz, 1H), 3.82 (s, 3H), 
3.61 (t, J = 4.5 Hz, 1H), 3.25 (m, 1H), 2.47 (dddd, J = 11.6, 5.4, 1.8, 1.8 Hz, 1H), 1.77 
(dddd, J = 12.5, 12.5, 12.5, 6.5 Hz, 1H), 1.70 (m, J = 12.0, 5.4, 2.1 Hz, 1H), 1.52-1.40 
(2H). 13C NMR (400 MHz, CDCl3) δ = 204.72, 159.55, 150.46, 148.95, 142.79, 127.48, 
127.27, 127.00, 123.73, 114.26, 55.48, 52.11, 43.25, 41.61, 39.97, 18.78, 17.77. 
 7-(4-Methoxy-3-pyridyl)-syn-8-(3-pyridyl)bicyclo[3.2.1]oct-6-ene-endo-
2-carboxaldehyde (3k): (method A) from 0.068 g (0.21 mmol) of 2k and 0.22 mL of 
BF3•Et2O (48%, 1.75 mmol) in DCM: 0.067 g (98%) (hexane/EtOH gradient 20:1 to 
15:1). 1H NMR (400 MHz, CDCl3) δ = 9.98 (d, J = 0.9 Hz, 1H), 8.62 (m, 1H), 8.52 (ddd, 
J = 4.7, 1.3, 1.3 Hz, 1H), 8.28 (d, J = 2.5 Hz, 1H), 7.73 (dd, J = 8.7, 2.5 Hz, 1H), 7.65 
(d, J = 7.9 Hz, 1H), 7.36 (dd, J = 7.9, 4.8 Hz, 1H), 6.74 (d, J = 8.7 Hz, 1H), 6.50 (d, J = 
3.4 Hz, 1H), 3.99 (d, J = 4.6 Hz, 1H), 3.95 (s, 3H), 3.69 (t, J = 4.6 Hz, 1H), 3.30 (q, J = 
3.7 Hz, 1H), 2.53 (m, 1H), 1.80-1.69 (m, 2H), 1.55 (m, 1H), 1.45 (m, 1H). 13C NMR (400 
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MHz, CDCl3) δ = 203.94, 163.87, 150.07, 147.67, 144.67, 140.44, 136.55, 136.05, 
134.96, 128.71, 123.99, 111.16, 53.78, 50.66, 42.98, 41.34, 40.15, 18.87, 17.65. HRMS 
(ESI) calcd for C20H20N2NaO2+ (MNa+) 343.1417, found 343.1401. 
 syn-8-(4-pyridyl)-7-(2-furanyl)bicyclo[3.2.1]oct-6-ene-endo-2-
carboxaldehyde (3h): (method C): from 40 mg (0.14 mmol) of 2h and 72 µL of HCl (4.0 
M, 0.28 mmol) in DCM: trace amount of aldehyde 3h was obtained after the column 
chromatography (hemiacetal 4h was the major product after the column). 1H NMR (400 
MHz, CDCl3) δ = 9.55 (s, 1H), 9.04* (s, 1H, epimer), 8.63 (d, J = 6.1 Hz, 2H), 7.38 (m, 
1H), 7.20 (d, J = 6.1 Hz, 2H), 6.44 (d, J = 3.4 Hz, 1H), 6.40 (dd, J = 3.4, 1.9 Hz, 1H), 
6.31 (d, J = 3.3 Hz, 1H), 3.78 (d, J = 4.8 Hz, 1H), 3.62 (m, 1H), 3.26 (m, 1H), 2.47 (m, 
1H), 1.76-1.63 (m, 2H), 1.54 (m, 1H), 1.44 (m, 1H). HRMS (ESI) calcd for C18H18NO2+ 
(MH+) 280.1332, found 280.1343. 
O
Ph
Ph
O
 syn-9-Benzoyl-8-phenyltricyclo[4.2.1.03,5]non-7-ene-endo-2-
carboxaldehyde (3r): (method A) from 0.17 g (0.52 mmol) of (2r) and 0.27 mL of 
BF3•Et2O (48%, 2.17 mmol) in DCM: 0.16 g (94%) (hexane/EtOAc gradient 20:1 to 
10:1). 1H NMR (400 MHz, CDCl3) δ = 9.92 (s, 1H), 8.00 (d, J = 7.1 Hz, 2H), 7.59 (t, J = 
7.4 Hz, 1H), 7.51 (m, 4H), 7.38 (t, J = 7.7 Hz, 2H), 7.29 (t, J = 7.3 Hz, 1H), 6.18 (d, J = 
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3.6 Hz, 1H), 3.93 (t, J = 4.2 Hz, 1H), 3.63 (d, J = 4.0 Hz, 1H) overlaps with 3.61 (ddd, J 
= 7.7, 4.1, 4.1 Hz, 1H), 2.26 (s, 1H), 1.33 (ddd, J = 9.0, 9.0, 5.6 Hz, 1H), 0.69 (dddd, J = 
8.3, 8.3, 7.2, 4.9 Hz, 1H), 0.57 (ddd, J = 8.8, 8.8, 5.0 Hz, 1H), 0.39 (q, J = 5.1 Hz, 1H). 
13C NMR (400 MHz, CDCl3) δ = 203.50, 201.17, 147.92, 137.18, 133.33, 133.28, 
129.09, 128.91, 128.33, 128.30, 126.93, 125.71, 55.66, 42.49, 42.05, 41.34, 11.48, 7.31, 
6.91. 
Ph
O
 8-Phenyltricyclo[4.2.1.03,5]non-7-ene-endo-2-carboxaldehyde (3s): 
(method B) from 0.17 g (0.76 mmol) of 2s and 0.27 mL of HCl (4.0 M, 1.10 mmol) in 
DCM.  NMR of reaction mixture showed >90% conversion. However, attempts to purify 
it on the column failed due to losses and complete epimerization. 
 1-Phenyl-7-(3-pyridyl)-2-oxatricyclo[4.2.1.04,8]nonan-3-ol (4b): (method 
C) from 0.045 g (0.16 mmol) of 2b and 0.16 mL of HCl (4.0 M, 0.65 mmol) in DCM: 
0.031 g (67%) (hexane/EtOH gradient 10:1 to 5:1). 1H NMR (400 MHz, CDCl3) δ = 8.58 
(m, 1H), 8.48 (d, J = 4.5 Hz, 1H), 7.61-7.57 (m, 3H), 7.38 (t, J = 7.3 Hz, 2H), 7.31-7.22 
(m, 2H), 5.39 (s, 1H), 3.42 (ddd, J = 4.3, 1.5, 1.5 Hz, 1H), 3.37 (m, 1H), 2.79 (t, J = 3.7 
Hz, 1H), 2.69 (exchanges, m, 1H), 2.57 (ddd, J = 10.8, 4.2, 2.6 Hz, 1H), 2.33 (ddd, J = 
13.0, 3.3, 3.3 Hz, 1H), 1.91 (d, J = 13.1 Hz, 1H), 1.76 (dddd, J = 13.3, 10.9, 4.2, 3.0 Hz, 
1H), 1.37 (d, J = 13.1 Hz, 1H). 13C NMR (400 MHz, CDCl3) δ = 149.35, 147.93, 144.51, 
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135.54, 135.23, 128.61, 127.46, 125.72, 123.46, 101.88, 91.14, 54.00, 51.50, 47.40, 
45.95, 40.33, 30.22. HRMS (ESI) calcd for C19H20NNO2+ (MH+) 294.1489, found 
294.1486. 
 1-(2-Furanyl)-8-(4-pyridyl)-2-oxatricyclo[4.2.1.04,9]decan-3-ol (4h): 
(method C) from 0.040 g (0.14 mmol) of 2h, 72 µL of HCl (4.0 M, 0.29 mmol) in 
dioxane and 72 µL of water (4.00 mmol) in DCM/dioxane mixture: 0.041 g (97%) w/o 
chromatography. 1H NMR (400 MHz, CDCl3) δ = 8.54 (d, J = 6.1 Hz, 2H), 7.41 (dd, J = 
1.7, 0.9 Hz, 1H), 7.30 (m, 2H), 6.33 (m, 2H), 5.30 (s, 1H), 3.59 (ddd, J = 7.8, 4.9, 1.5 Hz, 
1H), 3.24 (t, J = 4.3 Hz, 1H), 2.84 (m, 2H), 2.68 (ddd, J = 8.1, 8.1, 1.7 Hz, 1H ), 2.36 
(ddd, J = 13.6, 5.8, 1.1 Hz, 1H), 2.05 (d, J = 13.6 Hz, 1H), 1.95 (ddd, J = 14.2, 8.9, 8.9 
Hz, 1H), 1.63 (ddd, J = 14.0, 9.7, 9.7 Hz, 1H), 1.22 (m, 1H ), 1.11 (m, 1H ). 13C NMR 
(400 MHz, CDCl3) δ = 158.07, 151.26, 150.17, 142.43, 122.65, 110.51, 106.43, 105.92, 
90.62, 48.59, 46.46, 45.94, 45.11, 34.59, 24.57, 19.29. HRMS (ESI) calcd for 
C18H20NO3+ (MH+) 298.1438, found 298.1430. 
 8-(3-Pyridyl)-1-(2-thienyl)-2-oxatricyclo[4.2.1.04,9]decan-3-ol (4i): 
(method C) from 0.071 g (0.24 mmol) of 2i, 0.30 mL of HCl (4.0 M, 1.20 mmol) and 
0.30 mL of water (17 mmol) in benzene/dioxane: 0.07 g (93%) w/o chromatography. 1H 
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NMR (400 MHz, CDCl3) δ = 8.67 (m, 1H), 8.49 (d, J = 4.8 Hz, 1H), 7.69 (d, J = 7.8 Hz, 
1H), 7.27 (dd, J = 7.9, 4.8 Hz, 1H), 7.20 (dd, J = 5.1, 1.2 Hz, 1H), 7.04 (dd, J = 3.6, 1.2 
Hz, 1H), 6.97 (dd, J = 5.1, 3.6 Hz, 1H), 5.36 (s, 1H), 3.56 (ddd, J = 7.7, 4.9, 1.6 Hz, 1H), 
3.41 (t, J = 4.3 Hz, 1H), 2.91 (m, 1H), 2.80 (s, 1H), 2.69 (ddd, J = 8.1, 8.1, 1.9 Hz, 1H), 
2.37 (dd, J = 13.7, 5.7 Hz, 1H), 2.22 (d, J = 13.7 Hz, 1H), 1.95 (ddd, J = 14.1, 9.1, 9.1 
Hz, 1H), 1.64 (ddd, J = 14.7, 9.3, 9.3 Hz, 1H), 1.24 (m, 1H), 1.13 (m, 1H). 13C NMR 
(400 MHz, CDCl3) δ = 153.27, 148.85, 147.61, 137.44, 134.75, 127.13, 124.11, 123.70, 
122.37, 106.34, 93.29, 52.23, 51.30, 44.94, 44.50, 35.14, 24.39, 19.39. HRMS (ESI) 
calcd for C18H19NNaO2S+ (MNa+) 336.1029, found 336.1027. 
Ph
O
Ph
H
O
 syn-10-Benzoyl-9-phenyltertracyclo[5.2.1.0.2,903,6]dec-4-ene-2-
carboxaldehyde (5t): (method B) from 0.065 g (0.20 mmol) of 2t and 100 µL of HCl 
(4.0 M, 0.40 mmol) in DCM: 0.059 g (90%) (hexane/EtOAc gradient 20:1 to 10:1). 1H 
NMR (400 MHz, CDCl3) δ = 8.59 (s, 1H), 8.02 (d, J = 7.1 Hz, 2H), 7.61 (t, J = 7.3 Hz, 
1H), 7.51 (t, J = 7.6 Hz, 2H), 7.35-7.30 (m, 4H), 7.28-7.23 (m, 1H), 6.50 (d, J = 2.7 Hz, 
1H), 5.80 (d, J = 2.7 Hz, 1H), 4.41 (dd, J = 5.6, 3.0 Hz, 1H), 3.45 (d, J = 4.7 Hz, 1H), 
2.86 (d, J = 12.5 Hz, 1H), 2.76 (q, J = 5.1 Hz, 1H), 2.67 (m, 2H), 1.98 (m, 1H). 13C 
NMR (400 MHz, CDCl3) δ = 201.52, 199.89, 141.21, 138.97, 137.77, 136.97, 133.48, 
129.03, 128.35, 127.46, 52.56, 43.18, 41.34, 38.51, 37.97, 36.93, 36.87, 28.58.  HRMS 
(ESI) calcd for C24H20NaO2+ (MNa+) 363.1356, found 363.1363. 
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3-Methoxy-8-(3-Pyridyl)-1-(2-thienyl)-2-
oxatricyclo[4.2.1.04,9]decane (6i): (method D) from 0.160 g (0.54 mmol) of 2i and 0.80 
mL of HCl (4.0 M, 3.24 mmol) in methanol: 0.17 g (96%) (hexane/EtOH 15:1). 1H NMR 
(400 MHz, CDCl3) δ = 8.66 (ddd, J = 2.3, 1.1, 1.1 Hz, 1H), 8.48 (dd, J = 4.7, 1.3 Hz, 
1H),  7.67 (d, J = 7.8 Hz, 1H), 7.25 (dd, J = 8.0, 4.8 Hz, 1H), 7.21 (dd, J = 5.1, 1.2, Hz, 
1H), 7.01 (dd, J = 3.6, 1.2, Hz, 1H), 6.96 (dd, J = 5.1, 3.6, Hz, 1H), 4.81 (s, 1H), 3.50 
(ddd, J = 7.8, 4.8, 1.6 Hz, 1H), 3.39 (s, 3H), 3.36 (t, J = 4.1 Hz, 1H), 2.90 (m, 1H), 2.67 
(ddd, J = 8.1, 8.1, 1.8 Hz, 1H), 2.38 (dd, J = 13.7, 5.8 Hz, 1H), 2.22 (d, J = 13.7 Hz, 
1H), 1.95 (ddd, J = 14.2, 8.8, 8.8 Hz, 1H), 1.65 (dt, J = 14.4, 9.4 Hz, 1H), 1.24 (m, 1H), 
1.14 (m, 1H). 13C NMR (400 MHz, CDCl3) δ = 152.67, 148.83, 147.57, 137.43, 134.64, 
126.85, 124.30, 123.63, 122.44, 113.16, 92.89, 55.17, 52.38, 50.91, 44.42, 44.37, 35.04, 
24.48, 19.57. HRMS (ESI) calcd for C19H22NO2S+ (MH+) 328.1366, found 328.1360. 
3-Benzyloxy-8-(3-Pyridyl)-1-(2-thienyl)-2-
oxatricyclo[4.2.1.04,9]decane (7i): (method D) from 0.040 g (0.14 mmol) of 2i and 0.21 
mL of HCl (4.0 M, 0.84 mmol) in benzyl alcohol: 0.041 g, (72%) (hexane/EtOH 20:1). 
1H NMR (400 MHz, CDCl3) δ = 8.68 (dd, J = 2.3, 1.2 Hz, 1H), 8.48 (d, J = 4.8 Hz, 1H), 
7.69 (d, J = 7.9 Hz, 1H), 7.32-7.21 (m, 7H), 7.05 (dd, J = 3.6, 1.2 Hz, 1H), 6.97 (dd, J = 
 54 
5.1, 3.6 Hz, 1H), 5.01 (s, 1H), 4.80 (d, J = 11.8 Hz, 1H), 4.44 (d, J = 1.8 Hz, 1H), 3.63 
(ddd, J = 7.7, 4.9, 1.6 Hz, 1H), 3.38 (t, J = 4.2 Hz, 1H), 2.91 (m, 1H), 2.75 (ddd, J = 8.1, 
8.1, 1.8 Hz, 1H), 2.37 (dd, J = 13.6, 5.7 Hz, 1H), 2.25 (d, J = 13.6 Hz, 1H), 1.96 (ddd, J 
= 14.1, 9.1, 9.1 Hz, 1H), 1.67 (dt, J = 14.2, 9.5 Hz, 1H), 1.22 (m,1H), 1.13 (m, 1H). 13C 
NMR (400 MHz, CDCl3) δ = 152.70, 148.87, 147.59, 138.16, 137.49, 134.71, 128.56, 
128.28, 127.79, 126.87, 124.30, 123.64, 122.41, 110.97, 92.95, 69.15, 52.21, 51.10, 
44.58, 44.45, 35.13, 24.51, 19.56. HRMS (ESI) calcd for C25H25NNaO2S+ (MNa+) 
426.1498, found 426.1503. 
3. Preparation of aldehydes 3 via external irradiation. 
Extended irradiation with RPR-3000 caused oxetanes 2 to convert to aldehydes 3. 
We believe this is an indirect effect, i.e. that irradiation with shorter wavelengths causes 
the formation of catalytic amount of HCl, which further accelerates metathesis in cases, 
where Ar = Ph or Bz. Experimentally, oxetanes cyclorevert much slower in reagent grade 
DCM in the dark. Irradiation with RPR-3000 accelerates the cycloreversion. It is 
conceivable that cycloreversion is accelerated via direct excitation of oxetane's aromatic 
moiety at shorter wavelengths, but it is unlikely: addition of 1% pyridine as proton 
scavenger does not affect photo cycloaddition but completely inhibits cycloreversion.  In 
this series of experiments the oxetanes were simply irradiated with RPR-3000 for 24 
hours in dichloromethane. 
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syn-7-Benzoyl-6-phenylbicyclo[2.2.1]hept-5-ene-endo-2-carboxaldehyde 
(3a): from 0.05 g (0.165 mmol) of 2a in 2 mL of DCM: 0.021 g (42%) (hexane/EtOAc 
gradient 30:1 to 10:1). 1H NMR (400 MHz, CDCl3) δ = 9.35 (d, J = 2.6 Hz, 1H), 7.94 (d, 
J = 7.6 Hz, 2H), 7.60 (t, J = 7.3 Hz, 1H), 7.49 (t, J = 7.6 Hz, 2H), 7.42 (d, J = 7.6 Hz, 
2H), 7.33 (t, J = 7.3 Hz, 2H), 7.25 (d, J = 7.3 Hz, 1H), 6.67 (d, J = 3.4 Hz, 1H), 4.07 
(dddd, J = 3.2, 1.6, 1.6, 1.6 Hz, 1H), 3.50 (dt, J = 1.6, 1.6 Hz, 1H), 3.43 (dddd, J = 3.5, 
3.5, 1.8, 1.8 Hz, 1H), 3.27 (dddd, J = 8.8, 3.4, 3.4, 3.4 Hz, 1H), 2.07 (ddd, J = 12.5, 8.95, 
3.7 Hz, 1H), 1.69 (ddd, J = 12.5, 3.9, 1.7 Hz, 1H). 13C NMR (400 MHz, CDCl3) δ = 
203.94, 198.63, 145.44, 135.94, 134.48, 133.55, 130.66, 129.00, 128.94, 128.83, 128.52, 
128.36, 128.13, 125.20, 66.34, 49.89, 47.87, 46.09, 26.03. 
 syn-7,8-Diphenylbicyclo[3.2.1]oct-6-ene-endo-2-carboxaldehyde (3e): 
from 0.058 g (0.20 mmol) of 2e in 2 mL of DCM: 0.045 g (78%) (hexane/EtOAc 
gradient 40:1 to 20:1) as a 2.6:1 mixture of epimerized aldehydes. 1H NMR (400 MHz, 
CDCl3) δ = 9.38 (d, J = 1.4 Hz, 1H), 9.10* (s, 1H, epimer), 7.43 (d, J = 7.4 Hz, 2H), 
7.36-7.14 (m, 8H), 6.53 (d, J = 3.4 Hz, 1H), 3.93 (d, J = 4.7 Hz, 1H), 3.60 (dd, J = 4.7, 
4.7 Hz, 1H), 3.18 (m, 1H), 2.53 (m, 1H), 1.71 (m, J = 12.5, 5.8, 2.1 Hz, 1H), 1.63 (m, 
1H), 1.33 (m, 2H). HRMS (ESI) calcd for C21H20NaO+ (MNa+) 311.1406, found 
311.1395. 
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 7-Phenylbicyclo[3.2.1]oct-6-ene-endo-2-carboxaldehyde (3f): from 0.046 
g (0.217 mmol) of 2f in 2 mL of DCM: 0.031 g (68%) (hexane/EtOAc gradient 40:1 to 
20:1) as a mixture of epimerized aldehydes. 1H NMR (400 MHz, CDCl3) δ = 9.38 (d, J = 
2.2 Hz, 1H), 9.08* (s, 1H, epimer), 7.41 (d, J = 7.7 Hz, 2H), 7.29 (t, J = 7.4 Hz, 2H), 
7.21 (t, J = 7.4 Hz, 1H), 6.36 (d, J = 3.1 Hz, 1H), 3.47 (d, J = 5.4 Hz, 1H), 2.79 (dddd, J 
= 5.9, 3.0, 3.0, 3.0 Hz, 1H), 2.43 (dddd, J = 11.5, 5.5, 2.3, 2.3 Hz, 1H), 2.34 (ddd, J = 
10.3, 5.2, 5.2 Hz, 1H), 1.84 (m, 1H), 1.70 (m, 1H), 1.62 (d, J = 10.2 Hz, 1H), 1.57 (d, J = 
9.8 Hz, 1H), overlaps with 1.57 (m, 1H). 
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Chapter Three: Oxametathesis in the chromone series 
A. Introduction. 
This chapter describes our efforts to further explore new dienes, which we 
employed to dramatically increase the complexity of new polycyclic oxetanes. The D.-A. 
adducts of 1,4-naphthoquinone with cyclic dienes are known to undergo photoinduced 
[2+2] cycloaddition A → B, disrupting the aromatic system and producing a 
cyclohexadiene moiety [32]. Coxon, Marchand and co-workers studied facial selectivity 
in the D.-A. reactions of B, which primarily produced compound C as a result of an 
attack by a dienophile at the face containing the carbonyl groups [33]: 
 
It was rather unexpected to realize that 1,4-naphthoquinones are the only aromatic 
ketones that are reported to form polycyclic dienes of type B in intramolecular [2+2] 
photo-cycloadditions. 
Very few benzo-fused aromatic ketones have been reported as good dienophiles 
for the first, i.e. D.-A. step (→ A).  For example, chromones had received very little 
attention, until Hsung reported the first stereoselective [4+2] cycloaddition reactions of 3-
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cyanochromone derivatives with electron-rich dienes [34]. We hypothesized that this or 
similar re-generated diene can be used instead of simple cyclopentadiene or 
cyclohexadiene. 
B. Results and discussion. 
This chapter describes another high-yielding photoprotolytic transformation. 
Herein we developed a tandem ground state – excited state [4π+2π]◦[2π+2π] sequence, 
where the second photochemical Paternò-Büchi (P.-B.) step in a strained polycyclic 
molecular framework is accompanied by an acid-catalyzed fragmentation.    
Our basis for the present study was (a) to estimate the feasibility of the 
intramolecular [2+2] photoinduced cycloaddition in the D.-A. adducts of chromone 
derivatives, and (b) to determine whether secondary D.-A. addition, the P.-B. step and the 
following “one-pot” protolytic oxametathesis is possible (Scheme 25): 
 
Scheme 25. A tandem ground state – excited state [4π+2π]◦[2π+2π] sequence [35].  
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Our first attempts were unsuccessful, since in the first D.-A. step unsubstituted 
chromone was not reactive. Only one example of a similar reaction was reported by 
Richard Hsung in 1997 using 3-cyanochromone [34]. The 3-cyano-group certainly makes 
the chromone a much more reactive dienophile. While the unsubstituted chromone is not 
reactive, we found that its “formal” D.-A. adducts with cyclic dienes can still be obtained 
in moderate to good yields of 55-70% via the reactions of chromone-3-carboxylic acid, 
because the immediate products of this cycloaddition, β-keto acids, undergo thermal 
decarboxylation into 1b,c (Scheme 25).  
D.-A. adducts 1 undergo clean and quantitative photocyclization into dienes 2 
upon irradiation in a Rayonet photoreactor (Figure 11A) with RPR-3500 lamps (a 
broadband UV source with λ = 350 ± 50 nm) or a UVLED-based illuminator with five 
250 mW @ 365 nm Nichia chips (Figure 11B).  This is the first example of the tandem 
D.-A. reaction followed by an aryl-alkene [2π+2π] photocyclization involving an aromatic 
ketone other than a 1,4-naphthoquinone. 
 
Figure 11. (A) A Rayonet photoreactor with RPR-3500 lamps; (B) a UVLED-
based illuminator with five 250 mW @ 365 nm Nichia chips. 
 60 
Dienes 2 react with dienophiles such as vinyl phenyl ketone, generated in situ, to 
give D.-A. adducts 3. The facial selectivity of this second Diels-Alder step is the same as 
1,4-naphthoquinone adducts, i.e. the dienophile is approaching from the "ketone" face. 
The culmination of this chain of reactions is the P.-B. step, leading to quantitative 
formation of structurally unique oxetanes 4 outfitted with various functional groups. This 
step is the most critical part of the synthesis, where the strain is captured into the 
polycyclic scaffold. Such congested systems in the presence of HCl undergo 
cycloreversion to an alternative alkene-carbonyl pair 5, which we refer to as an alkene-
carbonyl oxametathesis [30, 35] (Scheme 26): 
 
Scheme 26. An alkene-carbonyl oxametathesis in chromone series [35].  
At first, in the presence of a catalytic amount of HCl-dioxane (4.0 M) in 
dichloromethane, we observed that oxetanes 4 undergo cycloreversion forming aldehydes 
5 in nearly quantitative yields. Further acidolysis of initially produced aldehydes 5 caused 
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their epimerization and rearrangement yielding aldehydes 6 containing a cyclopropyl ring 
(Scheme 26 and Scheme 27): 
  
Scheme 27. Photoprotolytic oxametathesis of oxetane 4a leading to the initial 
formation of a mixture of epimers 5a following by formylcyclopropane 6a. 
We believe that products 6 (analogous to 5t described in chapter two) can be 
formed as a result of a secondary electrophilic attack of H+ on the newly formed styrene 
moiety followed by nucleophilic participation of the intermediate enol (Scheme 27). To 
avoid the formation of complicated mixtures, this reaction can be carried out in the 
presence of a strong Lewis acid, like BF3·Et2O, or a large excess of HCl. In those cases 
we observed exclusively the formation of formylcyclopropanes 6.  
When the cycloreversion is carried out in alcohols as solvents, acetals of type 7 
are formed in high yields (Scheme 26). We observed that the formation of 
formylcyclopropanes 6 is reversible and products 7 could also be obtained from 
aldehydes 6, which were treated with HCl in the presence of methanol and ethylene 
glycol.  
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It is worth mentioning that the regio- and stereochemical outcome of the overall 
synthetic sequence from chromones 1 to products 5, 6 and 7 is not decided at the 
photoprotolytic oxametathesis step. The configuration inherent in 3 is simply passed on 
to rearranged products 5, 6 and 7. 
At this point two remarkable reactions that we discovered unexpectedly should be 
mentioned. In the first case we observed that irradiation of some acetals 7 resulted in 
formation of pure compounds, which were missing double bonds. X-ray diffraction 
confirmed that an oxirane ring was forming (Scheme 28). This prominent photo-
epoxidation example provides another opportunity to increase functional diversity. The 
exact mechanism remains unknown [54]. It is unclear whether this reaction occurs 
through the formation of a peroxyepoxide or through photosensitization, but the products 
are formed in high yields (> 85 % by NMR).  
 
Scheme 28. (A) Photo-epoxidation example of acetal 7a; (B) the ORTEP drawing 
of X-ray structure of 8a.  
Another striking observation was that the chromone-based polycyclic dienes 2, 
while being heated in a pressure vessel, underwent the D.-A. cyclodimerization yielding a 
single diastereomeric product 9 containing 20 stereocenters (Scheme 29).  
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Scheme 29. (A) The D.-A. dimerization of 2a-c; (B) the ORTEP drawing of the 
X-Ray structure of 9a. 
This is an opportunity to create topological diversity. The framework is unique 
and cannot be synthesized using other simple synthetic methods. 
Unlike adducts 2, 1,4-naphthoquinone-based caged diene B (page 57) was 
reluctant to undergo the dimerization. The comparative electronic population analysis in 
B and 2a is relevant to this failure of B to dimerize.  Figure 12 shows that atoms in the 
diene fragment of B are depleted of electronic density to a much greater extent (the 
cumulative positive charge of the moiety is 1.16 vs 0.405 in 2a). The electronic density in 
2a is much less depleted and it is also appropriately polarized with the "dienophile" 
double bond being more electrophilic [35]. 
 
Figure 12. Calculated charges in the diene fragment of B and 2a [35]. 
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In conclusion, we have confirmed that the Diels-Alder adducts of chromones are 
capable of photoinduced alkene-arene [2+2] cycloaddition producing different dienes, 
which can dimerize or can be introduced into a double-tandem 
[4π+2π]◦[2π+2π]◦[4π+2π]◦[2π+2π] synthetic sequence, followed by an acid-catalyzed 
oxametathesis, leading to expeditious growth of molecular complexity over a few 
experimentally simple steps.  The appealing feature of this approach is that the first D.-A. 
step controls the stereochemical outcome of the entire sequence [35]. 
C. Experimental section. 
Common solvents were purchased from Pharmco and used as is, except for THF, 
which was refluxed over and distilled from potassium benzophenone ketyl prior to use. 
Common reagents were purchased from Aldrich or TCI America and used without 
additional purification unless indicated otherwise. NMR spectra were recorded at 25oC on 
a Bruker Avance III 500 MHz or Varian Mercury 400 MHz instrument in CDCl3 with 
TMS as an internal standard (unless noted otherwise). X-Ray structures were obtained 
with a Bruker APEX II instrument (see Appendix B). High resolution mass spectra were 
obtained on the MDS SCIEX/Applied Biosystems API QSTARTM Pulsar i Hybrid 
LC/MS/MS System mass spectrometer by Dr. Shuji Kato from the University of Colorado 
at Boulder. 
1. Preparation of the Diels-Alder adducts (1): 
A solution of chromone (1.0 eq) and 1,3-cyclohexadiene (or freshly distilled 1,3-
cyclopentadiene) (5.0 eq) in 15 mL of 1,2-dichlorobenzene was heated in a bomb at 200-
210oC (for 1,3-cyclohexadiene) and 130-140oC (for 1,3-cyclopentadiene) overnight. 
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After the reaction was cooled to room temperature, the solvent was removed on a high 
vacuum pump. The crude reaction mixture was purified on a silica gel column using a 
mixture of hexane and EtOAc as an eluent. All the X-ray structures can be found in 
Appendix B. 
endo-4,5-Benzo-7-cyano-3-oxatricyclo[6.2.2.02,7]dodec-9-ene-6-one 
(1a): from 2.50 g of 3-cyanochromone (14.6 mmol) and 7.0 mL of 1,3-cyclohexadiene 
(73.0 mmol) at 200oC (hexane/EtOAc gradient 20:1→5:1): 2.19 g (60%). 1H NMR (500 
MHz, CDCl3) δ = 7.69 (dd, J = 7.9, 1.8 Hz, 1H), 7.45 (ddd, J = 8.5, 7.2, 1.8 Hz, 1H), 
6.94 (t, J = 7.5 Hz, 1H), 6.80 (ddd, J = 8.0, 7.1, 1.1 Hz, 1H), 6.26 (dd, J = 8.3, 1.1 Hz, 
1H), 6.14 (t, J = 7.3 Hz, 1H), 5.06 (ddd, J = 7.9, 6.4, 1.2 Hz, 1H), 3.50 (d, J = 2.8 Hz, 
1H), 3.12 (m, 1H), 2.15 (m, 1H), 1.75 (m, 1H), 1.38 (m, 2H). 13C NMR (400 MHz, 
CDCl3) δ = 184.35, 159.82, 137.71, 133.64, 132.14, 127.58, 121.89, 120.07, 118.34, 
118.08, 82.88, 50.44, 39.73, 37.08, 21.25, 21.08. exo-4,5-benzo-7-cyano-3-
oxatricyclo[6.2.2.02,7]dodec-9-ene-6-one: (< 3%). 1H NMR (500 MHz, CDCl3) δ = 7.85 
(dd, J = 8.0, 1.7 Hz, 1H), 7.55 (ddd, J = 8.5, 7.2, 1.8 Hz, 1H), 7.03 (ddd, J = 8.0, 7.2, 1.0 
Hz, 1H), 6.95 (dd, J = 8.5, 1.1 Hz, 1H), 6.58 (m, J = 8.5, 5.9 Hz, 1H), 6.48 (ddd, J = 8.0, 
6.9, 1.4 Hz, 1H), 4.77 (dd, J = 3.6, 1.7 Hz, 1H), 3.47 (m, 1H), 3.12 (m, 1H), 1.71-1.65 
(m, J = 12.8, 9.7, 4.1, 2.5 Hz, 1H), 1.46-1.40 (m, 1H), 1.28-1.22 (m, 1H), 1.20-1.13 (m, 
1H). 
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endo-4,5-Benzo-3-oxatricyclo[6.2.2.02,7]dodec-9-ene-6-one (1b): from 
2.00 g of chromone-3-carboxylic acid (10.5 mmol) and 5.0 mL of 1,3-cyclohexadiene 
(52.5 mmol) at 200oC (hexane/EtOAc gradient 30:1→10:1): 1.67 g (70%). 1H NMR (500 
MHz, CDCl3) δ = 7.68 (dd, J = 7.9, 1.8 Hz, 1H), 7.36 (ddd, J = 8.4, 7.1, 1.8 Hz, 1H), 
6.95 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 6.91 (dd, J = 8.4, 1.0 Hz, 1H), 6.28 (ddd, J = 8.0, 
6.5, 1.3 Hz, 1H), 6.20 (t, J = 7.2 Hz, 1H), 4.95 (dd, J = 9.4, 3.3 Hz, 1H), 3.27 (m, 1H), 
3.12 (m, 1H), 2.86 (dd, J = 9.4, 2.1 Hz, 1H), 1.62 (dddd, J = 12.3, 9.5, 3.0, 3.0 Hz, 1H), 
1.54 (dddd, J = 12.5, 9.8, 4.6, 1.8 Hz, 1H), 1.37 (dddd, J = 12.1, 12.1, 3.6, 3.6 Hz, 1H), 
1.27 (dddd, J = 11.8, 11.8, 4.4, 2.8 Hz, 1H). 13C NMR (500 MHz, CDCl3) δ = 192.92, 
160.95, 136.32, 134.25, 132.27, 126.81, 120.85, 119.73, 117.75, 79.59, 50.73, 36.88, 
34.48, 25.54, 20.53. exo-4,5-benzo-3-oxatricyclo[6.2.2.02,7]dodec-9-ene-6-one: 0.67 g 
(28%). 1H NMR (500 MHz, CDCl3) δ = 7.81 (dd, J = 7.8, 1.8 Hz, 1H), 7.46 (ddd, J = 
8.3, 7.1, 1.8 Hz, 1H), 6.95 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 6.91 (dd, J = 8.4, 1.0 Hz, 1H), 
6.49 (m, J = 8.4, 6.2 Hz, 1H), 6.28 (m, J = 8.1, 6.8, 1.2 Hz, 1H), 4.64 (ddd, J = 11.0, 3.7, 
1.1 Hz, 1H), 3.23 (m, 1H), 3.02 (m, 1H), 2.59 (ddd, J = 11.0, 2.8, 1.8 Hz, 1H), 1.92 (m, 
1H), 1.48 (m, 1H), 1.17 (m, 2H). 
endo-4,5-Benzo-3-oxatricyclo[6.2.1.02,7]undec-9-ene-6-one (1c): from 
2.00 g of chromone-3-carboxylic acid (10.5 mmol) and 3.0 mL of 1,3-cyclopentadiene 
(36.8 mmol) at 135oC (hexane/EtOAc gradient 60:1→30:1): 1.23 g (55%). 1H NMR (500 
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MHz, CDCl3) δ = 7.69 (dd, J = 7.9, 1.7 Hz, 1H), 7.36 (ddd, J = 8.4, 7.1, 1.8 Hz, 1H), 
6.85 (ddd, J = 8.0, 7.2, 1.0 Hz, 1H), 6.74 (dd, J = 8.4, 1.0 Hz, 1H), 6.11 (m, 2H), 5.25 
(dd, J = 9.3, 4.0 Hz, 1H), 3.49 (m, 2H), 3.14 (dd, J = 9.2, 3.9 Hz, 1H), 1.46 (ddd, J = 9.2, 
1.9, 1.9 Hz, 1H), 1.36 (d, J = 9.2 Hz, 1H). 13C NMR (400 MHz, CDCl3) δ = 193.41, 
160.96, 137.20, 136.53, 134.53, 126.63, 120.56, 119.52, 117.67, 79.98, 49.94, 49.34, 
48.98, 45.18. exo-4,5-benzo-3-oxatricyclo[6.2.1.02,7]undec-9-ene-6-one: 0.56 g (25%). 
1H NMR (500 MHz, CDCl3) δ = 7.78 (dd, J = 7.9, 1.7 Hz, 1H), 7.42 (ddd, J = 8.6, 7.1, 
1.7 Hz, 1H), 6.92 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 6.88 (dd, J = 8.4, 1.0 Hz, 1H), 6.44 (dd, 
J = 5.7, 3.0 Hz, 1H), 6.10 (dd, J = 5.7, 3.2 Hz, 1H), 4.61 (ddd, J = 8.0, 1.3, 1.3 Hz, 1H), 
3.36 (m, 1H), 3.27 (m, 1H), 2.58 (dd, J = 8.0, 1.8 Hz, 1H), 1.67 (d, J = 9.4 Hz, 1H), 1.55 
(m, J = 9.4, 1.6 Hz, 1H). 13C NMR (400 MHz, CDCl3) δ = 192.86, 160.90, 141.78, 
136.55, 133.82, 127.12, 120.99, 120.08, 118.08, 80.10, 51.72, 48.44, 48.37, 45.28. 
2. Preparation of the [2+2] adducts (2): 
An approximately 10 mM solution of an endo-precursor 1 in benzene (or other 
specified solvents) was irradiated in Pyrex or glass reaction vessels in a Rayonet reactor 
equipped with RPR-3500 UV lamps (broadband 300-400 nm UV source with peak 
emission at 350 nm) for 24-48 hours. Irradiation resulted in a quantitative conversion to 
2, which were used without further purification (unless purification was required). 
15-Cyano-13-oxahexacyclo[6.4.4.0.02,7.03,14.06,15]hexadec-9,11-diene-
16-one (2a): from 2.23 g of 1a (8.9 mmol) in 1.0 L of benzene, irradiation for 24 hrs 
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(hexane/EtOAc gradient 15:1→5:1): 1.23 g (55%). 1H NMR (400 MHz, CDCl3) δ = 6.00 
(dd, J = 9.6, 5.8 Hz, 1H), 5.95 (ddd, J = 9.8, 5.8, 1.0 Hz, 1H), 5.54 (d, J = 9.6 Hz, 1H), 
5.45 (d, J = 9.8 Hz, 1H), 4.75 (d, J = 4.2 Hz, 1H), 3.43 (ddd, J = 8.0, 5.6, 1.4 Hz, 1H), 
2.86 (dd, J = 8.3, 5.0 Hz, 1H), 2.30 (m, 1H), 2.24 (m, 1H), 2.00-1.91 (m, 3H), 1.60-1.54 
(m, 1H). 13C NMR (400 MHz, CDCl3) δ = 199.51, 126.26, 125.70, 121.68, 120.50, 
117.25, 84.04, 81.97, 56.43, 53.31, 50.74, 43.04, 36.47, 36.03, 15.82, 14.19. 
13-Oxahexacyclo[6.4.4.0.02,7.03,14.06,15]hexadec-9,11-diene-16-one (2b): 
from 1.50 g of 1b (6.6 mmol) in 1.0 L of benzene, irradiation for 24 hrs (hexane/EtOAc 
gradient 20:1→10:1): 1.05 g (70%). 1H NMR (500 MHz, CDCl3) δ = 5.95-5.88 (m, 2H), 
5.53 (d, J = 9.4 Hz, 1H), 5.42 (d, J = 9.7 Hz, 1H), 4.60 (dd, J = 8.0, 4.2 Hz, 1H), 3.38 
(ddd, J = 7.8, 5.6, 1.5 Hz, 1H), 2.78 (ddd, J = 8.1, 4.8, 2.2 Hz, 1H), 2.73 (ddd, J = 8.1, 
3.4, 2.4 Hz, 1H), 2.09 (m, 1H), 1.94 (m, 1H), 1.92-1.86 (m, 1H), 1.82-1.75 (m, 1H), 1.73-
1.66 (m, 1H), 1.52-1.45 (dddd, J = 14.0, 11.8, 5.7, 2.5 Hz, 1H). 13C NMR (500 MHz, 
CDCl3) δ = 210.10, 125.83, 124.82, 122.58, 122.27, 83.29, 78.73, 57.42, 52.74, 52.30, 
45.11, 36.14, 31.31, 17.69, 15.24. 
12-Oxahexacyclo[5.4.4.0.02,6.03,13.05,14]pentadec-8,10-diene-15-one (2c): 
from 0.89 g of 1c (4.2 mmol) in 1.0 L of benzene, irradiation for 24 hrs: 0.88 g (> 90%). 
1H NMR (500 MHz, CDCl3) δ = 6.00 (dd, J = 9.5, 5.7 Hz, 1H), 5.95 (ddd, J = 9.9, 5.7, 
1.0 Hz, 1H), 5.63 (d, J = 9.5 Hz, 1H), 5.49 (d, J = 9.9 Hz, 1H), 5.02 (dd, J = 8.4, 4.0 Hz, 
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1H), 3.42 (ddd, J = 7.8, 6.0, 1.3 Hz, 1H), 2.91 (m, 1H), 2.82 (ddd, J = 8.0, 5.4, 1.9 Hz, 
1H), 2.75 (m, 1H), 2.61 (ddd, J = 8.4, 4.3, 1.9 Hz, 1H), 1.80 (d, J = 11.3 Hz, 1H), 1.51 
(d, J = 11.5 Hz, 1H). 13C NMR (500 MHz, CDCl3) δ = 211.52, 125.38, 124.62, 122.28, 
122.28, 87.05, 83.06, 56.87, 56.29, 55.03, 48.44, 46.25, 42.57, 33.80. 
3. Preparation of the Diels-Alder adducts (3): 
A solution of 2 (1.0 eq) and 3-chloropropiophenone (1.3 eq) in the mixture of 10 
mL of pyridine was heated in a bomb at 130-140oC overnight. After the reaction was 
cooled to room temperature, the solvent was removed on a high vacuum pump. The crude 
reaction mixture was purified on a silica gel flash column using a mixture of hexane and 
EtOAc (or EtOH) as an eluent. NOTE: We attempted to further purify reaction mixtures 
by chromatography. The Diels-Alder adducts are not stable on silica gel and endo-
adducts rearrange into various exo-derivatives (16R(S)→16S(R)) due to the presence of 
H+. To avoid this complication we passed 2 mL of pyridine through the column before 
filtration. 
1R(S), 2S(R), 11S(R), 12R(S), 16R(S)-16-Benzoyl-9-cyano-3-
oxaheptacyclo[10.2.2.12,5.18,11.02,11.04,9.017,18]octadec-13-ene-10-one (3a): from 1.13 g 
of 2a (4.5 mmol) and 1.00 g of 3-chloropropiophenone (5.9 mmol) at 140oC 
(hexane/EtOAc gradient 20:1→1:1): 0.86 g (50%). 1H NMR (400 MHz, CDCl3) δ = 8.06 
(m, 2H), 7.54 (t, J = 7.3 Hz, 1H), 7.45 (m, 2H), 6.39 (ddd, J = 8.3, 7.2, 1.3 Hz, 1H), 6.19 
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(dd, J = 8.3, 6.3 Hz, 1H), 4.80 (d, J = 4.0 Hz, 1H), 4.43 (ddd, J = 9.6, 4.8, 2.1 Hz, 1H), 
3.13 (ddd, J = 6.4, 1.8, 1.8 Hz, 1H), 2.83 (m, 1H), 2.68 (ddd, J = 7.4, 5.8, 1.5 Hz, 1H), 
2.3 (m, 1H), 2.16 (m, 1H), 2.11 (dd, J = 7.6, 5.0 Hz, 1H), 2.04-1.94 (m, 1H), 1.93-1.85 
(m, 4H), 1.54-1.46 (m, 1H). 13C NMR (400 MHz, CDCl3) δ = 203.20, 200.49, 147.47, 
136.13, 133.39, 133.21, 131.37, 128.99, 128.94, 117.32, 91.34, 83.36, 57.80, 52.61, 
40.17, 36.57, 35.43, 35.09, 33.84, 33.77, 21.93, 16.18, 14.28. HRMS (ESI) calcd for 
C25H21NNaO3+ (MNa+) 406.1414, found 406.1425. 
1R(S), 2S(R), 11S(R), 12R(S), 16R(S)-16-Benzoyl-3-
oxaheptacyclo[10.2.2.12,5.18,11.02,11.04,9.017,18]octadec-13-ene-10-one (3b): from 2.24 g 
of 2b (9.9 mmol) and 2.16 g of 3-chloropropiophenone (12.8 mmol) at 140oC 
(hexane/EtOAc gradient 20:1→10:1): 1.24 g (35%). 1H NMR (500 MHz, CDCl3) δ = 
8.11 (m, 2H), 7.51 (t, J = 7.3 Hz, 1H), 7.44 (m, 2H), 6.37 (ddd, J = 8.3, 7.2, 1.2 Hz, 1H), 
6.17 (dd, J = 8.5, 6.1 Hz, 1H), 4.65 (ddd, J = 7.7, 4.2, 1.5 Hz, 1H), 4.50 (ddd, J = 9.7, 
4.8, 2.1 Hz, 1H), 3.05 (ddd, J = 6.4, 1.7, 1.7 Hz, 1H), 2.78 (m, 1H), 2.62-2.57 (m, 2H), 
2.02 (m, 1H), 2.01-1.96 (m, 2H), 1.93 (m, 1H), 1.87 (ddd, J = 12.9, 4.8, 3.2 Hz, 1H), 
1.84-1.79 (m, 1H), 1.77-1.70 (m, 1H), 1.69-1.63 (m, 1H), 1.44-1.38 (m, 1H). 13C NMR 
(400 MHz, CDCl3) δ = 213.80, 201.26, 136.41, 133.19, 132.93, 131.51, 129.08, 128.80, 
90.22, 79.93, 58.14, 52.06, 41.26, 40.37, 35.80, 35.25, 35.06, 34.03, 31.20, 22.17, 18.10, 
15.31. HRMS (ESI) calcd for C24H23O3+ (MH+) 359.1642, found 359.1657. 
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1R(S), 2S(R), 10S(R), 11R(S), 15R(S)-15-Benzoyl-3-
oxaheptacyclo[9.2.2.12,5.17,10.02,10.04,8.016,17]heptadec-12-ene-9-one (3c): from 0.92 g of 
2c (4.3 mmol) and 0.95 g of 3-chloropropiophenone (5.6 mmol) at 140oC (hexane/EtOAc 
gradient 20:1→10:1): 0.54 g (36%). 1H NMR (500 MHz, CDCl3) δ = 8.12 (m, 2H), 7.52 
(t, J = 7.4 Hz, 1H), 7.44 (m, 2H), 6.37 (ddd, J = 8.3, 7.2, 1.3 Hz, 1H), 6.16 (dd, J = 8.5, 
6.1 Hz, 1H), 5.10 (ddd, J = 8.0, 3.7, 1.6 Hz, 1H), 4.46 (ddd, J = 9.6, 4.9, 2.2 Hz, 1H), 
3.10 (ddd, J = 6.4, 1.8, 1.8 Hz, 1H), 2.81 (m, 1H), 2.79-2.74 (m, 2H), 2.63 (m, 1H), 2.50 
(ddd, J = 8.0, 4.3, 1.9 Hz, 1H), 2.13 (m, 1H), 1.96 (ddd, J = 12.7, 9.7, 2.4 Hz, 1H), 1.88 
(ddd, J = 12.8, 4.9, 3.2 Hz, 1H), 1.79 (d, J = 11.4 Hz, 1H), 1.56 (d, J = 11. 4Hz, 1H). 13C 
NMR (500 MHz, CDCl3) δ = 214.58, 201.28, 136.41, 133.37, 132.95, 131.60, 129.10, 
128.79, 90.61, 88.10, 57.18, 54.25, 47.88, 47.17, 42.11, 40.34, 38.23, 36.34, 35.93, 34.16, 
22.45. HRMS (ESI) calcd for C23H21O3+ (MH+) 345.1485, found 345.1479. 
4. Preparation of the Paternò–Büchi adducts (4): 
Approximately 1-3 mM solution of a precursor 3 in benzene was irradiated in 
Pyrex or glass reaction vessels in a Rayonet reactor equipped with RPR-3500 UV lamps 
(broadband 300-400 nm UV source with peak emission at 350 nm) for 48-72 hours. 
Irradiation resulted in a quantitative conversion to 4, which were used without further 
purification. NOTE: We attempted to further purify reaction mixtures by 
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chromatography. The strained polycyclic oxetanes 4 are not stable on silica gel, 
producing various amounts of aldehydes 5 via oxametathesis.   
9-Cyano-15-phenyl-3,14-
dioxanonacyclo[10.4.2.12,5.18,11.02,11.04,9.013,16.015,18.019,20]icosa-10-one (4a): from 1.50 g 
of 3a (3.9 mmol) in 1.5 L of benzene, irradiation for 72 hrs: (> 85%). 1H NMR (500 
MHz, CDCl3) δ = 7.38-7.36 (m, 4H), overlaps 7.36-7.32 (m, 1H), 4.80 (m, 1H), 4.72 (d, J 
= 4.0 Hz, 1H), 3.50 (dddd, J = 5.5, 3.5, 1.7, 1.7 Hz, 1H), 2.95-2.91 (m, 2H), 2.74 (ddd, J 
= 6.5, 1.8, 1.8 Hz, 1H), 2.54 (dd, J = 7.6, 5.2 Hz, 1H), 2.36 (m, 1H), 2.26 (m, 1H), 2.12 
(ddd, J = 6.2, 6.2, 1.3 Hz, 1H), 2.01-1.90 (m, 4H), 1.81 (ddd, J = 13.2, 6.7, 1.9 Hz, 1H), 
1.63-1.56 (m, 1H). 13C NMR (500 MHz, CDCl3) δ = 202.03, 136.31, 129.11, 128.75, 
127.15, 117.46, 101.10, 90.43, 81.47, 81.37, 56.84, 54.57, 53.16, 44.23, 39.63, 38.59, 
37.05, 36.12, 35.43, 32.27, 31.92, 15.92, 14.11. HRMS (ESI) calcd for C25H22NO3+ 
(MH+) 384.1594, found 384.1586. 
15-Phenyl-3,14-
dioxanonacyclo[10.4.2.12,5.18,11.02,11.04,9.013,16.015,18.019,20]icosa-10-one (4b): from 1.20 g 
of 3b (3.3 mmol) in 1.5 L of benzene, irradiation for 72 hrs: (> 85%). 1H NMR (500 
MHz, CDCl3) δ = 7.40-7.35 (m, 4H), overlaps 7.35-7.31 (m, 1H), 4.82 (m, 1H), 4.57 (dd, 
 73 
J = 8.0, 4.1 Hz, 1H), 3.49 (dddd, J = 5.5, 3.6, 1.8, 1.8 Hz, 1H), 2.91 (d, J = 6.4 Hz, 1H), 
2.86 (m, J = 7.6, 5.6, 1.2 Hz, 1H), 2.69 (ddd, J = 6.5, 1.8, 1.8 Hz, 1H), 2.63 (ddd, J = 
8.0, 3.3, 2.4 Hz, 1H), 2.42 (ddd, J = 7.5, 5.1, 2.3 Hz, 1H), 2.12 (m, 1H), 2.08 (m, J = 6.2, 
1.3 Hz, 1H), 2.03-2.00 (m, 1H), 1.99 (m, 1H), 1.86-1.68 (m, 4H), 1.51 (m, 1H).  13C 
NMR (500 MHz, CDCl3) δ = 213.30, 136.74, 128.89, 128.65, 127.18, 101.17, 89.48, 
82.08, 77.94, 57.63, 54.81, 52.45, 44.39, 40.63, 38.67, 37.15, 35.70, 33.52, 32.06, 31.03, 
17.78, 15.09. HRMS (ESI) calcd for C24H23O3+ (MH+) 359.1642, found 359.1629. 
14-Phenyl-3,13-
dioxanonacyclo[9.4.2.12,5.17,10.02,10.04,8.012,15.014,17.018,19]nonadec-9-one (4c): from 0.55 
g of 3c (1.6 mmol) in 1.5 L of benzene, irradiation for 48 hrs: (> 90%). 1H NMR (500 
MHz, CDCl3) δ = 7.40-7.35 (m, 4H), overlaps 7.35-7.31 (m, 1H), 5.04 (dd, J = 8.2, 4.1 
Hz, 1H), 4.80 (ddd, J = 3.6, 1.8, 0.8 Hz, 1H), 3.48 (dddd, J = 5.5, 3.6, 1.8, 1.8 Hz, 1H), 
3.03 (t, J = 6.7 Hz, 1H), 2.89 (m, 2H), 2.74 (ddd, J = 6.6, 1.8, 1.8 Hz, 1H), overlaps 2.72 
(m, 1H), 2.61-2.57 (m, 1H), overlaps 2.57-2.54 (ddd, J = 8.2, 4.2, 1.9 Hz, 1H), 2.10 (ddd, 
J = 6.2, 6.2, 1.4 Hz, 1H), 1.91 (dd, J = 12.8, 1.8 Hz, 1H), 1.87 (d, J = 11.3 Hz, 1H), 1.79 
(ddd, J = 12.9, 6.7, 1.9 Hz, 1H), 1.65 (d, J = 11.3 Hz, 1H). 13C NMR (400 MHz, CDCl3) 
δ = 214.04, 136.85, 128.89, 128.67, 127.20, 101.02, 90.06, 86.83, 81.86, 56.46, 54.82, 
54.68, 49.31, 47.00, 43.98, 42.34, 38.95, 37.22, 36.21, 35.68, 32.56. HRMS (ESI) calcd 
for C23H21O3+ (MH+) 345.1485, found 345.1472. 
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5. Preparation of the oxametathesis products (5-7): 
(A) HCl-catalyzed formation of aldehydes 5: To a solution of oxetane 4 in 
DCM, a catalytic amount of HCl (4.0 M solution in dioxane) was added. The resulting 
mixture was stirred at room temperature for 24 h, washed twice with 5% solution of 
NaOH and water, concentrated, and purified on a silica gel column using hexane–ethyl 
acetate (or hexane–ethanol for the cyano-containing products). Usually this method 
produces an inseparable mixture of 5 and 6. 
 (B1) BF3 or (B2) HCl-catalyzed formation of aldehydes 6: BF3·Et2O (small 
molar excess per heteroatom in 4) or >10-fold excess of HCl (4.0 M solution in dioxane) 
was added to a solution of oxetane 4 in DCM and stirred overnight at room temperature, 
washed twice with 5% solution of NaOH and water. The crude aldehyde 6 was purified 
on a silica gel column using hexane–ethyl acetate as an eluent.  For cyano-containing 
aldehydes hexane–ethanol was used as the eluent. 
 (C) Oxametathesis in alcohols yielding acetals 7: Oxetane 4 was dissolved in a 
5% HCl solution in methanol, 4-bromobenzyl alcohol/DCM or ethylene glycol/THF and 
stirred for 24 h. The resulting mixture was evaporated, dissolved in DCM, washed twice 
with 5% solution of NaOH and water. The crude acetals 7 were purified on a silica gel 
column using hexane–ethyl acetate as an eluent. For cyano-containing acetals hexane–
ethanol was used as the eluent. To avoid the hydrolysis of the cyano-containing acetals 2 
mL of pyridine were passed through the column before purification. 
 75 
 1S(R), 8S(R), 9R(S), 12R(S), 13R(S)-15-Cyano-14-oxo-11-phenyl-
17-oxaheptacyclo[6.5.4.19,12.01,8.02,7.03,15.06,16]octadec-10-ene-13-carboxaldehyde (5a): 
(method A) from 217 mg (0.56 mmol) of 4a and 0.28 mL of HCl (4.0 M, 1.13 mmol) in 
DCM: forms a mixture of  5a and 6a (55.6% and 17.8% by NMR). 1H NMR (500 MHz, 
CDCl3) δ = 9.90 (s, 1H), 7.47 (d, J = 7.4 Hz, 2H), 7.34 (t, J = 7.2 Hz, 2H), 7.29 (t, J = 
7.3 Hz, 1H), 6.30 (d, J = 3.4 Hz, 1H), 4.70 (d, J = 4.1 Hz, 1H), 3.82 (dd, J = 5.8, 4.7 Hz, 
1H), 3.39 (d, J = 4.5 Hz, 1H), 2.86 (ddd, J = 8.5, 5.7, 1.5 Hz, 1H), 2.82 (dd, J = 4.8, 3.6 
Hz, 1H), 2.64 (dd, J = 8.6, 4.8 Hz, 1H), 2.43-2.38 (m, 2H), 2.19 (m, 1H), 2.00-1.85 (m, 
3H), 1.77 (d, J = 11.2 Hz, 1H), 1.57-1.50 (m, 1H). 13C NMR (500 MHz, CDCl3) δ = 
202.62, 200.08, 148.28, 134.45, 129.12, 128.98, 128.17, 126.63, 117.38, 87.81, 82.41, 
56.60, 51.71, 46.95, 43.56, 40.48, 39.41, 37.51, 36.12, 35.03, 33.46, 16.01, 14.28. HRMS 
(ESI) calcd for C25H22NO3+ (MH+) 384.1594, found 384.1590. 
1S(R), 8S(R), 9R(S), 12R(S), 13R(S)-14-Oxo-11-phenyl-17-
oxaheptacyclo[6.5.4.19,12.01,8.02,7.03,15.06,16]octadec-10-ene-13-carboxaldehyde (5b):  
(method A) from 30 mg (0.08 mmol) of 4b and 43 µL of HCl (4.0 M, 0.17 mmol) in 
DCM: forms a mixture of  5b, 5b* (epimer) and 6b (39.0%, 4.3% and 24.2% by NMR).  
Attempts to purify the mixture failed. 
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1S(R), 2R(S), 5R(S), 6R(S), 7S(R)-16-Oxo-4-phenyl-13-
oxaheptacyclo[5.5.4.12,5.01,7.08,12.09,15.011,14]heptadec-3-ene-6-carboxaldehyde (5c): 
(method A) from 140 mg (0.41 mmol) of 4c and 0.20 mL of HCl (4.0 M, 0.81 mmol) in 
DCM: forms a mixture of trace amount of 5c and 6c. Attempts to purify the mixture 
failed. 1H NMR (500 MHz, CDCl3) δ = 9.45 (d, J = 1.1 Hz, 1H), 7.44 (d, J = 7.2 Hz, 
2H), 7.31 (t, J = 7.5 Hz, 2H), 7.25 (m, 1H) overlaps with CDCl3, 6.44 (d, J = 3.3 Hz, 
1H), 4.96 (dd, J = 8.2, 4.1 Hz, 1H), 3.73 (dd, J = 5.7, 4.3 Hz, 1H), 3.20 (dd, J = 8.1, 5.9 
Hz, 1H), 2.93 (dd, J = 5.0, 3.4 Hz, 1H), 2.85 (m, 1H), 2.81 (dd, J = 4.2, 1.0 Hz, 1H), 
2.63-2.57 (m, 2H), 2.44 (ddd, J = 8.4, 5.3, 2.3 Hz, 1H), 2.38 (ddd, J = 11.0, 5.7, 5.0 Hz, 
1H), 1.88 (d, J = 11.6 Hz, 1H), 1.85 (d, J = 11.4 Hz, 1H), 1.67 (d, J = 11.4 Hz, 1H). 
1S(R), 8S(R), 9R(S), 10S(R), 13R(S)-16-Cyano-17-oxo-11-phenyl-
14-oxaoctacyclo[6.5.4.110,13.01,8.02,7.09,11.03,15.06,16]octadec-9-carboxaldehyde (6a): 
(method B1) from 390 mg (1.02 mmol) of 4a and 2.00 mL of BF3·Et2O (48%, 15.86 
mmol) in DCM (hexane/EtOH 10:1, then DCM/MeOH 2:1): 223 mg (57%). (method B2) 
from 200 mg (0.52 mmol) of 4a and 2.61 mL of HCl (4.0 M, 10.43 mmol) in DCM 
(hexane/EtOH 10:1, then DCM/MeOH 2:1): 278 mg (71%). 1H NMR (500 MHz, CDCl3) 
δ = 8.41 (s, 1H), 7.38-7.30 (m, 5H), 4.74 (d, J = 4.1 Hz, 1H), 3.16 (ddd, J = 7.8, 5.9, 1.3 
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Hz, 1H), 2.89 (d, J = 2.9 Hz, 1H), 2.82 (m, 1H), 2.69 (dd, J = 7.9, 5.0 Hz, 1H), 2.52 (m, 
1H), 2.27-2.18 (m, 5H), 2.11-2.04 (m, 1H), 2.02-1.96 (m, 2H), 1.72-1.65 (m, 1H). 13C 
NMR (500 MHz, CDCl3) δ = 200.43, 198.84, 137.60, 129.27, 128.99, 128.01, 117.41, 
89.39, 82.69, 54.40, 52.37, 42.46, 40.09, 39.91, 37.74, 35.82, 35.73, 35.59, 34.57, 29.40, 
28.18, 15.86, 14.31. HRMS (ESI) calcd for C25H22NO3+ (MH+) 384.1594, found 
384.1592. 
1S(R), 8S(R), 9R(S), 10S(R), 13R(S)-17-Oxo-11-phenyl-14-
oxaoctacyclo[6.5.4.110,13.01,8.02,7.09,11.03,15.06,16]octadec-9-carboxaldehyde (6b): 
(method B1) from 40 mg (0.11 mmol) of 4b and 0.20 mL of BF3·Et2O (48%, 1.59 mmol) 
in DCM (hexane/EtOH 10:1, then DCM/MeOH 2:1): 18 mg (45%). 1H NMR (500 MHz, 
CDCl3) δ = 8.39 (s, 1H), 7.30 (m, 4H), 7.24 (m, 1H) overlaps with CDCl3, 4.56 (dd, J = 
8.1, 4.3 Hz, 1H), 3.05 (ddd, J = 7.8, 5.8, 1.3 Hz, 1H), 2.81 (d, J = 2.9 Hz, 1H), 2.66 (ddd, 
J = 8.2, 3.4, 2.2 Hz, 1H), 2.56 (ddd, J = 7.4, 4.9, 2.3 Hz, 1H), 2.51 (d, J = 12.3 Hz, 1H), 
2.43 (m, 1H), 2.19-2.13 (m, 4H), 2.06 (m, 1H), 1.94-1.87 (m, 1H), 1.84-1.72 (m, 2H), 
1.57 (m, 1H). 13C NMR (500 MHz, CDCl3) δ = 199.53, 197.40, 138.40, 129.13, 129.11, 
127.71, 88.52, 79.38, 55.16, 51.68, 42.39, 41.30, 40.08, 38.07, 36.00, 35.93, 35.91, 30.81, 
29.71, 28.31, 17.78, 15.36. HRMS (ESI) calcd for C24H23O3+ (MH+) 359.1642, found 
359.1630. 
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1S(R), 2R(S), 3S(R), 6R(S), 7S(R)-13-Oxo-4-phenyl-16-
oxaoctacyclo[5.5.4.13,6.01,7.02,4.08,12.09,15.011,14]heptadec-2-carboxaldehyde (6c): 
(method B1) and (method B2) failed. Under those conditions oxetane 4c produced 
complicated mixture of inseparable compounds.  
 1S(R), 8S(R), 9R(S), 12R(S), 13R(S)-15-Cyano-13-
dimethoxymethyl-11-phenyl-17-oxaheptacyclo[6.5.4.19,12.01,8.02,7.03,15.06,16]octadec-
10-ene-14-one (7a): (method C) from 320 mg (0.83 mmol) of 4a and 3.13 mL of HCl 
(4.0 M, 12.52 mmol) in MeOH (hexane/EtOH 10:1, then DCM/MeOH 2:1): 258 mg 
(59%). 1H NMR (500 MHz, CDCl3) δ = 7.51 (d, J = 7.4 Hz, 2H), 7.33 (t, J = 7.6 Hz, 
2H), 7.26 (t, J = 7.3 Hz, 1H), 6.28 (d, J = 3.6 Hz, 1H), 4.67 (d, J = 4.1 Hz, 1H), 3.84 (d, 
J = 9.7 Hz, 1H), 3.29 (t, J = 5.3 Hz, 1H), 2.92 (dd, J = 9.7, 4.8 Hz, 1H), 2.87 (s, 3H) 
overlaps with 2.85 (ddd, J = 8.5, 5.8, 1.4 Hz, 1H), 2.79 (s, 3H), 2.72 (dd, J = 4.7, 3.8 Hz, 
1H), 2.36 (dd, J = 8.5, 4.8 Hz, 1H), 2.30 (ddd, J = 11.1, 5.9, 5.1 Hz, 1H), 2.18 (m, 1H) 
overlaps with 2.15 (m, 1H), 1.96-1.87 (m, 3H), 1.67 (d, J = 11.2 Hz, 1H), 1.54-1.48 (m, 
1H). 1H NMR (500 MHz, C6D6) δ = 7.45 (d, J = 7.6 Hz, 2H), 7.17 (m, 2H) overlaps with 
C6D6, 7.08 (t, J = 7.4 Hz, 1H), 5.87 (d, J = 3.6 Hz, 1H), 4.35 (d, J = 4.1 Hz, 1H), 3.82 (d, 
J = 9.3 Hz, 1H), 3.18-3.13 (m, 2H), 2.70 (s, 3H), 2.66 (s, 3H), 2.55 (dd, J = 4.7, 3.8 Hz, 
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1H), 2.19 (ddd, J = 8.5, 5.7, 1.4 Hz, 1H), 2.05 (ddd, J = 10.9, 5.4, 5.4 Hz, 1H), 2.01 (m, 
1H), 1.92 (dd, J = 8.5, 4.8 Hz, 1H), 1.73 (d, J = 11.1 Hz, 1H), 1.66-1.59 (m, 1H), 1.53 
(m, 1H), 1.31-1.26 (m, 2H), 0.96-0.89 (m, 1H). 13C NMR (500 MHz, CDCl3) δ = 203.29, 
149.49, 136.08, 128.61, 128.51, 128.20, 126.70, 117.79, 101.99, 88.02, 82.16, 57.93, 
53.10, 52.16, 50.05, 43.55, 40.48, 39.31, 38.26, 35.94, 35.23, 34.76, 33.21, 16.14, 14.43. 
HRMS (ESI) calcd for C27H27NNaO4+ (MNa+) 452.1832, found 452.1810. 
 1S(R), 8S(R), 9R(S), 12R(S), 13R(S)-13-Dimethoxymethyl-11-
phenyl-17-oxaheptacyclo[6.5.4.19,12.01,8.02,7.03,15.06,16]octadec-10-ene-14-one (7b): 
(method C) from 91 mg (0.25 mmol) of 4b and 0.32 mL of HCl (4.0 M, 1.27 mmol) in 
MeOH (hexane/EtOH 20:1→10:1): 83 mg (81%). 1H NMR (500 MHz, CDCl3) δ = 7.53 
(d, J = 7.4 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.24 (t, J = 7.4 Hz, 1H) overlaps with 
CDCl3, 6.28 (d, J = 3.5 Hz, 1H), 4.53 (ddd, J = 8.2, 4.3, 1.3 Hz, 1H), 3.85 (d, J = 9.8 Hz, 
1H), 3.27 (t, J = 5.3 Hz, 1H), 2.88 (dd, J = 9.9, 4.8 Hz, 1H) overlaps with 2.87 (s, 3H), 
2.79 (ddd, J = 8.5, 5.8, 1.5 Hz, 1H), 2.76 (s, 3H),  2.70 (dd, J = 4.8, 3.7 Hz, 1H), 2.64 
(ddd, J = 8.3, 3.4, 2.2 Hz, 1H), 2.28-2.23 (ddd, J = 11.0, 5.3, 5.3 Hz, 1H) overlaps with 
2.28-2.23 (m, 1H), 2.04 (m, 1H), 1.89-1.74 (m, 3H), 1.71-1.65 (m, 1H) overlaps with 
1.67 (d, J = 10.9 Hz, 1H), 1.48-1.41 (m, 1H). 13C NMR (500 MHz, CDCl3) δ = 213.35, 
149.23, 136.60, 129.12, 128.47, 127.85, 126.74, 102.38, 87.06, 78.80, 58.51, 53.16, 
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51.25, 49.75, 43.96, 41.66, 39.66, 38.39, 35.43, 34.38, 34.26, 30.55, 18.00, 15.46. HRMS 
(ESI) calcd for C26H28NaO4+ (MNa+) 427.1880, found 427.1898. 
 1S(R), 2R(S), 5R(S), 6R(S), 7S(R)-6-Dimethoxymethyl-4-phenyl-13-
oxaheptacyclo[5.5.4.12,5.01,7.08,12.09,15.011,14]heptadec-3-ene-16-one (7c): (method C) 
failed. Under those conditions oxetane 4c produced complicated mixture. 
O
O
Ph
NC
O
O
 1S(R), 8S(R), 9R(S), 12R(S), 13R(S)-15-Cyano-13-(1,3-dioxolan-2-
yl)-11-phenyl-17-oxaheptacyclo[6.5.4.19,12.01,8.02,7.03,15.06,16]octadec-10-ene-14-one  
(7a-1): (method C) from 190 mg (0.50 mmol) of 4a and 1.24 mL of HCl (4.0 M, 4.95 
mmol) in ethylene glycol/THF mixture (10/3) (hexane/EtOH 20:1→10:1): 148 mg 
(70%). 1H NMR (500 MHz, CDCl3) δ = 7.63 (d, J = 7.3 Hz, 2H), 7.33 (t, J = 7.5 Hz, 
2H), 7.25 (t, J = 7.4 Hz, 1H) overlaps with CDCl3, 6.44 (d, J = 3.6 Hz, 1H), 4.67 (d, J = 
4.1 Hz, 1H), 4.46 (d, J = 9.1 Hz, 1H), 3.92-3.88 (m, 1H), 3.65 (m, 2H), 3.55-3.51 (m, 
1H), 3.34 (dd, J = 5.7, 4.8 Hz, 1H), 2.82 (ddd, J = 8.4, 5.7, 1.4 Hz, 1H), 2.75 (dd, J = 
4.7, 3.8 Hz, 1H), 2.70 (dd, J = 9.1, 4.6 Hz, 1H), 2.39 (dd, J = 8.4, 4.8 Hz, 1H), 2.27 (m, 
2H), 2.17 (m, 1H), 1.97-1.86 (m, 3H), 1.65 (d, J = 11.1 Hz, 1H), 1.52-1.45 (m, 1H) 
overlaps with HOD. 13C NMR (500 MHz, CDCl3) δ = 203.09, 148.35, 135.36, 128.64, 
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128.23, 127.98, 126.39, 117.91, 103.61, 87.58, 82.29, 65.02, 64.53, 57.15, 51.98, 43.43, 
40.47, 38.66, 38.25, 38.20, 35.56, 35.19, 33.02, 16.09, 14.46. HRMS (ESI) calcd for 
C27H25NNaO4+ (MNa+) 450.1676, found 450.1678. 
 1S(R), 8S(R), 9R(S), 12R(S), 13R(S)-13-(1,3-Dioxalan-2-yl)-11-
phenyl-17-oxaheptacyclo[6.5.4.19,12.01,8.02,7.03,15.06,16]octadec-10-ene-14-one  (7b-1): 
(method C) from 180 mg (0.50 mmol) of 4b and 0.32 mL of HCl (4.0 M, 1.26 mmol) in 
ethylene glycol/THF mixture (10/3)  (hexane/EtOAc 25:1): 158 mg (78%). 1H NMR (500 
MHz, CDCl3) δ = 7.64 (d, J = 7.3 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.24 (t, J = 7.3 Hz, 
1H) overlaps with CDCl3, 6.46 (d, J = 3.6 Hz, 1H), 4.53 (ddd, J = 8.1, 4.2, 1.4 Hz, 1H), 
4.47 (d, J = 9.1 Hz, 1H), 3.92-3.87 (m, 1H), 3.66-3.59 (m, 2H), 3.53-3.49 (m, 1H), 3.32 
(dd, J = 5.7, 4.7 Hz, 1H), 2.76 (ddd, J = 8.2, 5.6, 1.5 Hz, 1H), 2.72 (dd, J = 4.6, 3.9 Hz, 
1H), 2.68 (dd, J = 9.1, 4.6 Hz, 1H), 2.63 (ddd, J = 8.2, 3.3, 2.1 Hz, 1H), 2.28 (ddd, J = 
8.3, 4.7, 2.1 Hz, 1H), 2.24 (ddd, J = 11.0, 5.5, 5.5 Hz, 1H), 2.04 (m, 1H), 1.91 (m, 1H), 
1.88-1.81 (m, 1H), 1.79-1.72 (m, 1H), 1.70-1.63 (m, 1H) overlaps with 1.66 (d, J = 10.8 
Hz, 1H), 1.45-1.38 (dddd, J = 13.8, 11.8, 5.9, 2.5 Hz, 1H). 13C NMR (500 MHz, CDCl3) 
δ = 213.24, 148.08, 135.89, 128.63, 128.51, 127.88, 126.41, 104.01, 86.60, 78.97, 64.75, 
64.33, 57.68, 51.08, 43.85, 41.66, 38.98, 38.47, 37.61, 35.37, 33.99, 30.18, 17.98, 15.49. 
HRMS (ESI) calcd for C26H27O4+ (MH+) 403.1904, found 403.1903. 
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1S(R), 8S(R), 9R(S), 12R(S), 13R(S)-15-Cyano-13-bis-(4-
bromobenzyloxymethyl)-11-phenyl-17-
oxaheptacyclo[6.5.4.19,12.01,8.02,7.03,15.06,16]octadec-10-ene-14-one  (7b-2): (method C) 
from 200 mg (0.56 mmol) of 4b, 0.37 g (1.95 mmol) of 4-bromobenzyl alcohol and 0.35 
mL of HCl (4.0 M, 1.39 mmol) in DCM (hexane/EtOAc 20:1→10:1): 215 mg (54%). 1H 
NMR (500 MHz, CDCl3) δ = 7.46-7.43 (m, 4H), 7.28 (d, J = 8.4 Hz, 2H), 7.22-7.17 (m, 
3H), 7.09 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 2H), 6.27 (d, J = 3.5 Hz, 1H), 4.52 
(ddd, J = 8.2, 4.3, 1.3 Hz, 1H), 4.29 (d, J = 12.0 Hz, 1H) overlaps with 4.27 (d, J = 9.9 
Hz, 1H), 4.10 (m, 2H), 3.51 (d, J = 12.1 Hz, 1H), 3.34 (dd, J = 5.7, 4.8 Hz, 1H), 3.12 
(dd, J = 9.9, 4.7 Hz, 1H), 2.79 (ddd, J = 8.3, 5.7, 1.4 Hz, 1H), 2.72 (dd, J = 4.6, 3.7 Hz, 
1H), 2.59 (ddd, J = 8.1, 2.5, 2.5 Hz, 1H), 2.29 (ddd, J = 11.0, 5.5, 5.5 Hz, 1H), 2.18 (ddd, 
J = 8.4, 4.3, 2.0 Hz, 1H), 2.04 (m, 1H), 1.88-1.80 (m, 1H), 1.76-1.69 (m, 1H) overlaps 
with 1.71 (d, J = 11.0 Hz, 1H), 1.58-1.55 (m, 2H), 1.35-1.28 (m, 1H). 13C NMR (500 
MHz, CDCl3) δ = 213.53, 148.98, 137.51, 136.95, 136.70, 131.49, 131.46, 129.70, 
129.59, 128.48, 128.43, 127.85, 126.73, 121.43, 121.09, 100.47, 86.96, 78.78, 65.40, 
63.48, 58.39, 51.08, 43.94, 41.63, 39.96, 38.30, 35.33, 34.82, 34.09, 30.34, 17.81, 15.31. 
HRMS (ESI) calcd for C38H38Br2NO4+ (MNH4+) 732.1147, found 732.1149. 
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1S(R), 2R(S), 5R(S), 6R(S), 7S(R)-6-(1,3-Dioxolan-2-yl)-4-phenyl-13-
oxaheptacyclo[5.5.4.12,5.01,7.08,12.09,15.011,14]heptadec-3-ene-16-one (7c-1): (method C 
produced a mixture of 7c-1 and 7c-2 3:1) from 210 mg (0.61 mmol) of 4c and 0.30 mL of 
HCl (4.0 M, 1.22 mmol) in ethylene glycol/THF mixture (10/3) (hexane/EtOAc 
20:1→10:1, then hexane/EtOH 10:1 to get 7c-2): 71 mg (< 30%, major loss is on the 
column). 1H NMR (500 MHz, CDCl3) δ = 7.63 (d, J = 7.3 Hz, 2H), 7.32 (t, J = 7.6 Hz, 
2H), 7.23 (t, J = 7.3 Hz, 1H) overlaps with CDCl3, 6.47 (d, J = 3.6 Hz, 1H), 4.99 (dd, J = 
8.2, 4.0 Hz, 1H), 4.49 (d, J = 9.1 Hz, 1H), 3.91-3.88 (m, 1H), 3.68-3.61 (m, 2H), 3.55-
3.51 (m, 1H), 3.33 (dd, J = 5.6, 4.8 Hz, 1H), 2.90 (ddd, J = 7.9, 6.2, 1.4 Hz, 1H), 2.75 
(m, 2H), 2.67 (dd, J = 9.1, 4.6 Hz, 1H), 2.62-2.58 (ddd, J = 8.2, 4.3, 1.8 Hz, 1H) overlaps 
with  2.57 (m, 1H), 2.51 (ddd, J = 8.4, 5.2, 1.7 Hz, 1H), 2.25 (ddd, J = 10.9, 5.5, 5.5 Hz, 
1H), 1.84 (d, J = 11.3 Hz, 1H), 1.65 (d, J = 10.8 Hz, 1H) overlaps with 1.62 (d, J = 11.3 
Hz, 1H). 13C NMR (500 MHz, CDCl3) δ = 214.75, 148.08, 135.85, 128.78, 128.51, 
127.90, 126.43, 103.85, 87.18, 86.44, 64.85, 64.34, 56.77, 54.25, 48.16, 47.36, 43.92, 
42.08, 38.96, 38.79, 38.29, 37.67, 36.32. HRMS (ESI) calcd for C25H25O4+ (MH+) 
389.1747, found 389.1761. 
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 1S(R), 2R(S), 5R(S), 6R(S), 7S(R)-6-(bis-(2-
hydroxyethoxy)methyl)-4-phenyl-13-
oxaheptacyclo[5.5.4.12,5.01,7.08,12.09,15.011,14]heptadec-3-ene-16-one (7c-2): 
(hexane/EtOH 10:1): 23 mg (< 10%). 1H NMR (500 MHz, CDCl3) δ = 7.48 (d, J = 7.3 
Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 7.24 (t, J = 7.3 Hz, 1H) overlaps with CDCl3, 6.28 (d, J 
= 3.5 Hz, 1H), 5.00 (dd, J = 8.3, 4.0 Hz, 1H), 4.15 (d, J = 9.6 Hz, 1H), 3.65 (ddd, J = 
11.9, 7.6, 2.8 Hz, 1H), 3.56 (ddd, J = 11.9, 4.8, 2.9 Hz, 1H), 3.51-3.43 (m, 2H), 3.40 
(ddd, J = 10.2, 7.7, 2.9 Hz, 1H), 3.28 (dd, J = 5.8, 4.9 Hz, 1H) overlaps with 3.26 (m, 
2H), 2.96 (ddd, J = 7.8, 6.3, 1.2 Hz, 1H) overlaps with 2.94 (dd, J = 9.7, 4.6 Hz, 1H), 
2.78 (m, 1H), 2.74 (dd, J = 4.7, 3.7 Hz, 1H), 2.68 (ddd, J = 10.0, 4.8, 2.8 Hz, 1H), 2.62 
(ddd, J = 8.4, 4.3, 1.8 Hz, 1H), 2.58 (m, 1H), 2.55 (ddd, J = 8.2, 5.4, 1.7 Hz, 1H), 2.30 
(ddd, J = 11.0, 5.5, 5.5 Hz, 1H), 1.86 (d, J = 11.3 Hz, 1H), 1.67 (d, J = 11.2 Hz, 1H) 
overlaps with 1.66 (d, J = 11.0 Hz, 1H). 13C NMR (500 MHz, CDCl3) δ = 215.41, 
149.21, 136.88, 129.72, 128.57, 128.03, 126.72, 101.02, 87.20, 86.96, 66.09, 64.35, 
62.21, 62.18, 57.66, 54.44, 48.18, 47.43, 44.07, 42.29, 39.95, 38.82, 37.82, 36.42, 35.80. 
HRMS (ESI) calcd for C27H30NaO6+ (MNa+) 473.1935, found 473.1938. 
6. Preparation of the oxiranes (8): 
Approximately 2.0-50 mM solution of a precursor 7 in benzene or DCM was 
irradiated in Pyrex or glass reaction vessels in a Rayonet reactor equipped with RPR-
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3500 UV lamps (broadband 300-400 nm UV source with peak emission at 350 nm) for 3-
24 hours. Irradiation resulted in a quantitative conversion to 8. The resulting crude 
product was purified on a silica gel column using a mixture of hexane and EtOH as an 
eluent. 
1S(R), 2R(S), 11S(R), 12R(S), 13S(R), 14S(R), 16S(R)-9-Cyano-12-
dimethoxymethyl-14-phenyl-3,15-
dioxaoctacyclo[11.3.1.12,5.18,11.02,11.04,9.014,16.018,19]nonadec-10-one (8a): from 46 mg of 
7a (0.11 mmol) in 0.6-2.0 mL of benzene or DCM (C6D6 or CDCl3 for an NMR 
experiment), irradiation for 5-24 hrs. 1H NMR (500 MHz, CDCl3) δ = 7.51 (m, 2H), 7.45-
7.38 (m, 3H), 4.70 (d, J = 4.2 Hz, 1H), 3.94 (s, 1H), 3.57 (d, J = 10.0 Hz, 1H), 3.42 (ddd, 
J = 8.6, 5.9, 1.2 Hz, 1H), 3.01 (t, J = 5.5 Hz, 1H), 2.88 (dd, J = 10.0, 5.0 Hz, 1H), 2.81 
(s, 3H), 2.69 (s, 3H), 2.51 (dd, J = 4.7, 1.5 Hz, 1H), 2.45 (dd, J = 8.6, 4.8 Hz, 1H), 2.30 
(m, 1H), 2.18 (m, 1H), 2.06-1.96 (m, 3H), 1.91 (ddd, J = 11.9, 5.9, 5.0 Hz, 1H), 1.65-
1.59 (m, 1H) overlaps with HOD, 1.08 (d, J = 12.0 Hz, 1H). 13C NMR (500 MHz, 
CDCl3) δ = 201.76, 135.56, 129.11, 128.83, 117.23, 100.21, 90.95, 80.88, 65.88, 58.22, 
57.22, 53.32, 51.53 (m), 49.45, 48.26 (m), 38.61, 38.51, 36.67, 36.18, 35.33, 35.21, 
32.67, 27.67, 15.68, 14.04. 1H NMR (500 MHz, C6D6) δ = 7.30 (m, 2H), 7.09-7.03 (m, 
3H), 4.26 (d, J = 4.2 Hz, 1H), 3.58 (d, J = 10.0 Hz, 1H), 3.47 (s, 1H), 3.05 (dd, J = 10.0, 
5.0 Hz, 1H), 2.94 (dd, J = 6.0, 5.0 Hz, 1H), 2.64 (s, 3H), 2.58 (ddd, J  = 8.5, 5.7, 1.2 Hz, 
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1H), 2.48 (s, 3H), 2.32 (dd, J = 4.6, 1.3 Hz, 1H), 2.12 (dd, J = 8.6, 4.8 Hz, 1H), 2.02 (m, 
1H), 1.90 (ddd, J = 11.5, 6.0, 5.0 Hz, 1H), 1.64-1.57 (m, 1H), 1.44 (m, 1H), 1.30-1.26 
(m, 2H), 1.10 (d, J = 11.8 Hz, 1H), 0.91-0.83 (m, 1H). 13C NMR (500 MHz, C6D6) δ = 
202.15, 137.13, 129.09, 129.05, 127.86, 117.82, 100.61, 91.28, 81.28, 66.05, 58.29, 
57.78, 53.17, 52.48, 49.14, 39.43, 38.63, 37.37, 36.64, 35.87, 35.51, 33.07, 28.35, 16.07, 
14.28. HRMS (ESI) calcd for C27H27KNO5+ (MK+) 484.1521, found 484.1530. 
7. Preparation of the dimers (9): 
A solution of 2 in 5-10 mL of 1,2-dichlorobenzene was heated in a bomb at 200-
210oC for 24-72 hours. After the reaction was cooled to room temperature, the solvent 
was removed on a high vacuum pump. The crude reaction mixture was purified on a 
silica gel column using a mixture of hexane and EtOAc (hexane/EtOH and DCM/MeOH 
in case of 2a) as an eluent. 
1S(R), 2R(S), 5R(S), 14R(S), 15S(R), 16S(R), 17R(S), 
26R(S)-7,24-Dicyano-13,18-
dioxatridecacyclo[14.10.2.15,8.111,14.117,20.123,26.02,15.05,14.07,12.017,26.019,24.029,30.031,32]dot
riaconta-3,27-diene-6,25-dione (9a): from 0.46 g of 2a (1.8 mmol) in 10 mL of 1,2-
dichlorobenzene at 210oC for 72 hrs (hexane/EtOH gradient 10:1→1:1 and DCM/MeOH 
5:1): 0.15 g (33%). 1H NMR (500 MHz, CDCl3) δ = 6.19 (ddd, J = 8.0, 6.4, 1.1 Hz, 1H), 
6.13 (ddd, J = 8.1, 6.9, 1.4 Hz, 1H), 5.75 (dd, J = 10.4, 2.8 Hz, 1H), 5.55 (dd, J = 10.4, 
2.3 Hz, 1H), 4.71 (d, J = 4.1 Hz, 1H), 4.64 (d, J = 4.1 Hz, 1H), 3.38 (dddd, J = 9.1, 2.7, 
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2.7, 2.7 Hz, 1H), 3.15 (d, J = 6.8 Hz, 1H), 2.81 (ddd, J = 6.3, 2.7, 1.5 Hz, 1H), 2.74 (ddd, 
J = 8.3, 5.5, 1.2 Hz, 1H), 2.64 (ddd, J = 7.4, 5.8, 1.4 Hz, 1H), 2.50 (dd, J = 9.1, 1.5 Hz, 
1H), 2.25 (m, 3H), 2.15 (dd, J = 8.4, 5.2 Hz, 1H), 2.11 (m, 1H) overlaps with 2.08 (dd, J 
= 7.7, 5.0 Hz, 1H), 1.94-1.82 (m, 6H), 1.57-1.45 (m, 2H). 13C NMR (400 MHz, CDCl3) δ 
= 202.75, 201.31, 133.35, 133.33, 131.83, 120.07, 117.40, 117.38, 91.20, 85.42, 83.12, 
80.50, 56.91, 55.50, 53.30, 52.59, 43.30, 39.67, 37.13, 37.00, 36.41, 35.86, 35.80, 35.74, 
35.16, 35.10, 34.00, 33.79, 16.05, 15.93, 14.23, 14.06. HRMS (ESI) calcd for 
C32H30N3O4+ (MNH4+) 520.2231, found 520.2232. 
 1S(R), 2R(S), 5R(S), 14R(S), 15S(R), 16S(R), 17R(S), 26R(S)-
13,18-
Dioxatridecacyclo[14.10.2.15,8.111,14.117,20.123,26.02,15.05,14.07,12.017,26.019,24.029,30.031,32]dot
riaconta-3,27-diene-6,25-dione (9b): from 170 mg of 2b (0.75 mmol) in 5 mL of 1,2-
dichlorobenzene at 200oC for 24 hrs (hexane/EtOAc gradient 20:1→4:1): 41 mg (24%). 
1H NMR (500 MHz, CDCl3) δ = 6.20 (m, J = 7.3 Hz, 1H), 6.12 (m, J = 7.5 Hz, 1H), 5.71 
(dd, J = 10.5, 2.8 Hz, 1H), 5.54 (dd, J = 10.3, 2.2 Hz, 1H), 4.56 (dd, J = 7.6, 4.1 Hz, 
1H), 4.47 (dd, J = 8.0, 4.0 Hz, 1H), 3.39 (dddd, J = 8.6, 2.7, 2.7, 2.7 Hz, 1H), 3.15 (d, J 
= 6.7 Hz, 1H), 2.73 (d, J = 6.3 Hz, 1H), 2.66 (dd, J = 8.3, 5.6 Hz, 1H), 2.57-2.49 (m, 
4H), 2.10 (m, 1H), 2.02 (ddd, J = 7.8, 5.1, 2.4 Hz, 1H), 1.98 (m, 1H), 1.94 (m, 1H), 1.90 
(m, 2H), 1.85-1.69 (m, 4H), 1.67-1.59 (m, 2H), 1.47-1.36 (m, 2H). 13C NMR (500 MHz, 
CDCl3) δ = 213.87, 212.78, 133.40, 132.98, 131.77, 121.21, 90.38, 84.79, 79.65, 77.02, 
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57.53, 56.47, 52.91, 52.18, 44.71, 40.80, 37.74, 37.40, 37.37, 36.54, 35.90, 35.36, 35.11, 
34.25, 31.20, 30.09, 18.08, 17.90, 15.37, 15.18. HRMS (ESI) calcd for C30H29O4+ (MH+) 
453.2060, found 453.2077. 
 1S(R), 2R(S), 5R(S), 14R(S), 15S(R), 16S(R), 17R(S), 26R(S)-
13,18-
Dioxatridecacyclo[14.10.2.18,11.120,23.02,15.05,9.05,14.07,12.010,14.017,21.017,26.019.24.022,26]tria
conta-3,27-diene-6,25-dione (9c): from 0.56 g of 2c (2.6 mmol) in 10 mL of 1,2-
dichlorobenzene at 210oC for 48 hrs (hexane/EtOAc gradient 20:1→10:1): 0.45 g (80%). 
1H NMR (500 MHz, CDCl3) δ = 6.20 (ddd, J = 7.9, 6.5, 1.1 Hz, 1H), 6.11 (ddd, J = 8.2, 
7.0, 1.3 Hz, 1H), 5.71 (dd, J = 10.4, 2.8 Hz, 1H), 5.54 (dd, J = 10.4, 2.3 Hz, 1H), 5.02 
(ddd, J = 8.0, 3.1, 2.2 Hz, 1H), 4.94 (dd, J = 8.4, 3.8 Hz, 1H), 3.35 (dddd, J = 9.1, 2.7, 
2.7, 2.7 Hz, 1H), 3.18 (d, J = 6.9 Hz, 1H), 2.85-2.79 (m, 2H), 2.76 (ddd, J = 6.4, 2.7, 1.4 
Hz, 1H), 2.73-2.69 (m, 2H), 2.59 (m, 2H), 2.51 (dd, J = 9.3, 1.5 Hz, 1H), 2.47 (ddd, J = 
8.4, 4.2, 2.0 Hz, 1H), 2.42 (ddd, J = 8.0, 4.2, 1.9 Hz, 1H), 2.20 (ddd, J = 7.8, 5.6, 2.0 Hz, 
1H), 2.09 (m, 1H), 1.81 (d, J = 11.3 Hz, 1H), 1.75 (d, J = 11.3 Hz, 1H), 1.61 (d, J = 11.3 
Hz, 1H), 1.52 (d, J = 11.3 Hz, 1H). 1H NMR (500 MHz, C6D6) δ = 6.21 (ddd, J = 8.2, 
7.0, 1.3 Hz, 1H), 6.04 (ddd, J = 7.8, 6.5, 1.2 Hz, 1H), 5.75-5.68 (m, 2H), 4.59 (dd, J = 
8.0, 4.0 Hz, 1H), 4.53 (ddd, J = 8.5, 2.6, 2.6 Hz, 1H), 3.80 (dddd, J = 9.3, 2.5, 2.5, 2.5 
Hz, 1H), 3.50 (d, J = 7.0 Hz, 1H), 2.84 (dd, J = 9.3, 1.6 Hz, 1H), 2.64 (ddd, J = 6.3, 2.8, 
1.4 Hz, 1H), 2.27 (ddd, J = 7.4, 6.2, 1.2 Hz, 1H), 2.23-2.18 (m, 3H), 2.17-2.13 (m, 2H), 
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2.05 (m, 1H), 1.99 (m, 1H), 1.78 (m, J = 5.5, 2.5 Hz, 1H), 1.62 (ddd, J = 7.4, 5.5, 1.9 Hz, 
1H), 1.14-1.10 (m, 2H), 0.97 (m, 2H). 13C NMR (500 MHz, CDCl3) δ = 214.68, 214.07, 
133.72, 132.94, 131.74, 121.28, 90.69, 87.79, 85.40, 84.86, 56.42, 55.27, 54.96, 54.31, 
51.27, 48.22, 47.29, 47.22, 41.99, 41.24, 40.80, 38.34, 37.88, 37.33, 37.15, 36.62, 36.21, 
34.03. HRMS (ESI) calcd for C28H25O4+ (MH+) 425.1747, found 425.1748. 
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Chapter Four: Photoprotolytic transformations in the 
aliphatic series 
A. Introduction. 
Polycyclic enones resulting from the Diels-Alder adducts of aliphatic unsaturated 
ketones undergo photocyclizations to furnish remarkably strained oxetane systems. These 
systems were extensively studied by Sauers and co-workers in 1972 - 1974 [36], who 
discovered the multitude of synthetic applications that they could offer. This research, 
however, came to a dead end when they introduced cyclic ketones to the system, giving a 
fused norbornene derivative containing a tricyclo[5.2.1.02,6] core. 
 
They found that these systems were unable to undergo the Paternò-Büchí cycloaddition 
that had been observed in so many other analogs. It was discovered that upon irradiation 
tricyclo[5.2.1.04,9]undecan-5-one was produced instead of the expected oxetane [36b]. 
This finding could be explained based on the fact that n-orbital of the carbonyl group in 
such a highly strained and rigid tricycle simply cannot reach the double bond. Instead, 
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energy transfer from the excited carbonyl to the double bond occurs first, which causes 
further alpha-H abstraction by the double bond and subsequent collapse of a newly 
formed 1,5-diradical. Upon further investigation, we were able to find that when the 
system was provided with a bit more conformational flexibility, a profound range of 
possibilities opened up. 
B. Results and discussion. 
First, we decided to prepare model aliphatic oxetanes with a “flexible” or “free” 
methyl group based on the D.-A. adducts of cyclohexadiene or cyclopentadiene with 
methyl vinyl ketone. Upon addition of HCl the expected oxametathesis occurred (Scheme 
30), similar to the results observed in aromatic series [30] and chromone-based series 
[34].  
 
Scheme 30. An alkene-carbonyl oxametathesis in “flexible” aliphatic series. 
These results might not have a very significant synthetic application, yet they confirm the 
generality of the methodology we have developed in the past two years.  
We further proposed, that polycyclic scaffolds resulting from the D.-A. adducts of 
cyclic ketones may have the capability of undergoing photocyclization to furnish 
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remarkably strained oxetane systems. Although Sauer’s observation was discouraging, 
upon additional investigation we were able to find that systems with more conformational 
freedom were highly reactive. Probing new combinations of adducts not only gave us the 
opportunity to make highly strained oxetane systems, but also elucidation of the 
mechanism of their protolytic ring opening provided a great deal of insight into how the 
strain affects the system. We aimed to harness this installed strain as a means for 
synthesizing unique aliphatic polycycles (Scheme 31): 
 
Scheme 31. Polycyclic scaffolds resulting from the D.-A. adducts of aliphatic 
ketones (1)  and the P.-B. photocyclization (2). 
After synthesizing “6-6 adduct” 1e (Experimental Section, page 103) based on 
cyclohexadiene and 2-cyclohexen-1-one, it was converted into oxetane 2e upon 
irradiation. We found that, upon the addition of HCl, oxetane 2e opened to give the 
secondary carbocation rather than tertiary. We suppose this is due to the inability of the 
structure to accommodate a planar conformation at the tertiary center. Upon nucleophilic 
attack, 1,2-alkyl shift occurred to give the final product 5e-1, which we were able to 
confirm by X-ray diffraction (Scheme 32):  
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Scheme 32. A plausible mechanism of the formation of 5e-1. 
However, the situation changed dramatically when another “5-7 adduct” 1c 
(Experimental Section, page 102) was synthesized.  Its oxetane, 2c, opened in an 
orthogonal way. The formation of a tertiary carbocation was preferred likely because of 
the extra flexibility offered by the installed seven-membered ring (Scheme 33): 
  
Scheme 33. A plausible mechanism of the formation of 5c. 
Such a tertiary carbocation resembles the tricyclooctane core (Figure 13). These 
tricyclo[3.3.0.03,7]octanes are known to have very high ring strain energies [37].  
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Figure 13. Tertiary tricyclo[3.3.0.03,7]octanyl cation formed during the formation 
of rearranged product 5c. 
The carbocation (Figure 13), which most likely was produced during the 
formation of 5c, as a result of high ring strain, rearranged notably producing a new 
cyclobutane. The X-ray structure of 5c and the mechanism of the rearrangement are 
shown in Scheme 33. 
With this in mind, we have synthesized a variety of adducts from very simple 
starting dienes and dienophiles using the same basic procedure throughout (Figure 14-1). 
The starting materials were combined in a bomb with a minimal amount of 
dichlorobenzene as the solvent. They were then heated to roughly 200oC overnight. After 
purification by column chromatography, the pure product was irradiated in an RPR-3000 
broadband (250 - 300 nm) Rayonet photoreactor. The oxetanes were then treated with a 
variety of acidic conditions (Lewis acids, formic acid, HCl, etc.) and the ring opening 
products were isolated via column chromatography (for more details please see 
Experimental Section, page 100-115).  
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Figure 14-1. Various rearranged products obtained from polycyclic oxetanes 2.  
We also discovered that, in reactions with weak dienophiles, cyclooctatetraene 
(COT) often yielded 2:1 adducts possessing the fluxional bicyclo[5.1.0]octadiene moiety. 
They undergo a fast, nearly degenerate Cope rearrangement with an activation barrier 
similar to that of the parent dihydrobullvalene. Irradiation, conditioned to excite the 
carbonyl moiety, induces the intramolecular P.-B. cyclization yielding endo-oxetanes and 
significantly changing the Cope-averaged NMR spectra (Figure 14-1 and 14-2). 
Hypothetically, due to the reversible nature of the oxetane formation, this system may 
offer a way of controlling molecular properties with a photoinduced switch [38]. 
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Figure 14-2. NMR changes upon photoconversion of the D.-A. adduct (1:1) to the 
P.-B. adduct (1:4) [38]. 
The next logical step was to study strained oxetanes containing more than one 
oxetane unit. Benzoquinone’s bis-D.-A. adducts with cyclopentadiene and 
cyclohexadiene were known before [39]. However, the photochemistry of these 
promising compounds had not been studied and it was not known whether they form 
oxetanes upon irradiation. We were able to synthesize several bis-adducts using 
cyclopentadiene, cyclohexadiene, and cyclooctatetraene as the dienes. Successful 
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irradiation results were found in the case of adducts of benzoquinone with 
cyclohexadiene 3b (Scheme 34): 
 
Scheme 34. Preparation of bis-oxetane 4b and its ORTEP drawing.  
Surprisingly dioxetane molecules 4b pack in a crystal lattice in such a way that 
they form six-pointed geometric figure, also known as a hexagram. Such unusual packing 
leads to channel formation (a diameter of 0.7 – 0.9 nm; see Figure 15) throughout the 
crystal lattice where a solvent molecule (here, CH3CN) can be trapped.  
d = 0.7-0.9 nm
 
Figure 15. Packing of bis-oxetane 4b in a crystal lattice.  
It should be noted that in our work we also used computational prediction for 1H 
and 13C NMR’s of unknown compounds. It was especially important for cases when X-
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ray data were not available. The geometry was optimized at the B3LYP/6-311+G(d,p) 
level and then a single point calculation at the mPW1PW91/6-311+G(d,p) level was 
performed. To illustrate the accuracy of this approach (especially for rigid molecules with 
restricted conformational freedom) two NMR spectra of bis-oxetane 4b are shown below 
(Figure 16). The upper spectrum is the experimental 1H NMR. The lower NMR spectrum 
predicted at the mPW1PW91/6-311+G(d,p)//B3LYP/6-311+G(d,p) level of theory 
matches the experimental data almost perfectly. 
experiment
predicted
 
Figure 16. Experimental and predicted 1H NMR spectra.  
When bis-oxetane 4b was treated with HCl in DCM, the isolated products turned 
out to be quite surprising. Unlike oxetanes 2, bis-oxetane 4b underwent several 
competing rearrangements. The major products are starting material 3b and two isomeric 
dienes 6b-0. The structures of 6b-0 were tentatively assigned based on the NMR data and 
by analogy with the X-ray structure of chlorohydrin 6b-2. Two other products (6b-1 and 
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6b-2) contained a chlorine atom and somewhat resembled what we observed in case of 2e 
previously mentioned (Scheme 32). Compound 6b-3, which was obtained and 
characterized by Teresa Arisco, was formed as a result of quite an unusual 
rearrangement, leading to the incorporation of a spiro connection into the scaffold 
(Scheme 35). The yields of products 6b-1, 6b-2 and 6b-3 never exceeded 10%. 
 
Scheme 35. Protolytic transformations of bis-oxetane 4b.  
A plausible mechanism for the formation of 6b-1 and 6b-2 involves protolytic 
cycloreversion to the mono-oxetane A (Scheme 36, Part I), occuring through 1,2-alkyl 
migration and nucleophilic attack similar to the ring opening of “6-6” oxetane 2e (for 
references see Scheme 32). Intermediate A can undergo the retro-P.-B. reaction yielding 
product 6b-1 (Scheme 36, Part II). We suggested that cyclopropane B is the key 
intermediate in the formation of chlorohydrine 6b-2 (Scheme 36, Part III). Acid-
catalyzed cyclopropyl ring opening in B followed by the Grob fragmentation gives cis-
fused alkene, which equilibrates via enol into 6b-2. All structures (6b-1, 6b-2 and 6b-3) 
were confirmed by X-ray crystallography. 
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Scheme 36. A plausible mechanism for the formation of 6b-1 and 6b-2 from 4b.  
These results have elucidated how two simple steps - synthesizing the adducts and 
irradiating them to get various oxetanes - can offer expeditious access to highly complex 
aliphatic scaffolds from very simple and inexpensive starting materials. The first two 
steps are relatively clean and require very simple purification in some cases and often no 
purification at all. In case of bis-oxetane 4b, the ring opening produced several products, 
requiring delicate separation. 
C. Experimental section. 
Common solvents were purchased from Pharmco and used as is, except for THF, 
which was refluxed over and distilled from potassium benzophenone ketyl prior to use. 
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Common reagents were purchased from Aldrich or TCI America and used without 
additional purification, unless indicated otherwise. NMR spectra were recorded at 25oC 
on a Bruker Avance III 500 MHz or Varian Mercury 400 MHz instrument in CDCl3 with 
TMS as an internal standard (unless noted otherwise). X-Ray structures were obtained 
with a Bruker APEX II instrument (see Appendix C). High resolution mass spectra were 
obtained on the MDS SCIEX/Applied Biosystems API QSTARTM Pulsar i Hybrid 
LC/MS/MS System mass spectrometer by Dr. Shuji Kato from the University of Colorado 
at Boulder. 
1. Preparation of the Diels-Alder adducts (1 and 3): 
A solution of dienophile (1.0 eq) and diene (2.0-5.0 eq) in 5-10 mL of 1,2-
dichlorobenzene (or xylenes) was heated in a bomb at 170-210oC for 24-72 h. After the 
reaction was cooled to room temperature, the solvent was removed on a high vacuum 
pump. The crude reaction mixture was purified on a silica gel column using a mixture of 
hexane and EtOAc as an eluent. 
O
 2-Acetyl-5-norbornene (mixture of the endo- and exo-isomers) (1a): Was 
purchased from Aldrich. 
O endo-Tricyclo[6.2.1.02,7]undec-9-ene-3-one (1b): from 3.0 g of 2-
cyclohexen-1-one (31.2 mmol) and 5.2 g of 1,3-cyclopentadiene (78.0 mmol) at 170oC 
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(hexane/EtOAc gradient 30:1→20:1): 2.0 g (39%, endo:exo = 3:1 by NMR). 1H NMR 
(400 MHz, CDCl3) δ = 6.13 (dd, J = 5.7, 2.9 Hz, 1H), 5.97 (dd, J = 5.6, 3.0 Hz, 1H), 
3.22 (m, 1H), 2.83 (m, 1H), 2.70-2.60 (m, 2H), 2.31-2.24 (dddddd, J = 18.5, 6.1, 2.7, 1.6, 
0.8, 0.8 Hz, 1H), 1.96-1.84 (m, 2H), 1.79-1.62 (m, 2H), 1.40 (ddd, J = 8.3, 1.9, 1.9 Hz, 
1H), 1.26 (d, J = 8.3 Hz, 1H), 0.72 (dddd, J = 12.8, 12.8, 11.0, 3.2 Hz, 1H). 13C NMR 
(400 MHz, CDCl3) δ = 215.57, 137.83, 135.11, 51.84, 48.53, 46.73, 45.39, 41.59, 39.57, 
28.19, 22.00. 
O endo-Tricyclo[7.2.1.02,8]dodec-10-ene-3-one (1c): from 0.5 g of 2-
cyclohepten-1-one (4.54 mmol) and 1.2 g of 1,3-cyclopentadiene (18.2 mmol) at 170oC 
(hexane/EtOAc gradient 30:1→20:1): 0.17 g (21%, endo:exo = 2:1 by NMR). 1H NMR 
(400 MHz, CDCl3) δ = 6.36 (dd, J = 5.6, 2.9 Hz, 1H), 5.89 (dd, J = 5.6, 3.0 Hz, 1H), 
3.15 (dd, J = 10.2, 3.3 Hz, 1H), 2.97 (m, 1H), 2.67 (m, 1H), 2.46-2.37 (m, 2H), 2.18 
(ddd, J = 15.5, 10.6, 2.7 Hz, 1H), 1.93-1.84 (m, 1H), 1.75-1.69 (m, 1H), 1.67-1.44 (m, 
3H), 1.40 (ddd, J = 8.3, 1.8, 1.8 Hz, 1H), 1.28 (dd, J = 8.3 Hz, 1H), 0.72 (dddd, J = 14.3, 
12.6, 11.7, 4.5 Hz, 1H). 13C NMR (400 MHz, CDCl3) δ = 213.81, 137.72, 132.50, 58.47, 
48.76, 48.02, 45.04, 42.85, 41.70, 30.63, 27.46, 23.10. 
 endo-6-Acetylbicyclo[2.2.2]oct-2-ene (1d): from 0.84 g of methyl vinyl 
ketone (12.0 mmol) and 1.44 g of 1,3-cyclohexadiene (18.0 mmol) at 160oC for 48 h 
(hexane/EtOAc gradient 40:1→30:1): 0.68 g (38%, endo:exo = 6:1 by NMR). 1H NMR 
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(500 MHz, CDCl3) δ = 6.26 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 6.08 (ddd, J = 7.8, 6.8, 1.2 
Hz, 1H), 2.88 (m, 1H), 2.64 (ddd, J = 8.7, 6.6, 2.1 Hz, 1H), 2.58 (m, 1H), 2.09 (s, 3H), 
1.63 (m, 2H), 1.61-1.55 (m, 1H), 1.51-1.45 (m, 1H), 1.30 (dddd, J = 12.0, 12.0, 3.6, 3.6 
Hz, 1H), 1.26-1.21 (m, 1H). 13C NMR (500 MHz, CDCl3) δ = 210.05, 135.40, 131.24, 
51.76, 32.29, 29.76, 28.87, 28.53, 26.07, 24.72. 
O endo-Tricyclo[6.2.2.02,7]dodec-9-ene-3-one (1e): from 2.0 g of 2-
cyclohexen-1-one (20.8 mmol) and 3.3 g of 1,3-cyclohexadiene (41.6 mmol) at 200oC 
(hexane/EtOAc gradient 30:1→20:1): 1.1 g (30%). 1H NMR (400 MHz, CDCl3) δ = 6.23 
(t, J = 7.3 Hz, 1H), 6.10 (t, J = 7.3 Hz, 1H), 3.06 (m, 1H), 2.51 (dd, J = 10.8. 2.5 Hz, 
1H), 2.44 (m, 1H) overlaps with 2.38 (m, 1H) overlaps with 2.33 (m, 1H), 2.07 (dddd, J 
= 18.4, 10.6, 7.4, 1.0 Hz, 1H), 1.79-1.70 (m, 3H), 1.58-1.45 (m, 2H), 1.26 (m, 2H), 0.98-
0.87 (m, 1H). 13C NMR (400 MHz, CDCl3) δ = 214.74, 134.63, 133.25, 53.12, 42.41, 
38.95, 36.02, 31.34, 29.80, 26.15, 24.17, 20.99. 
endo-Tricyclo[7.2.2.02,8]tridec-10-ene-3-one (1f): from 1.0 g of 2-
cyclohepten-1-one (9.1 mmol) and 1.5 g of 1,3-cyclohexadiene (18.2 mmol) at 200oC for 
48 h (hexane/EtOAc 40:1): 0.17 g (10%). 1H NMR (500 MHz, CDCl3) δ = 6.33 (t, J = 
7.3 Hz, 1H), 5.99 (t, J = 7.3 Hz, 1H), 2.91 (dd, J = 10.6, 1.4 Hz, 1H), 2.73 (m, 1H), 2.38-
2.30 (m, 2H), 2.23 (ddd, J = 14.4, 10.0, 3.0 Hz, 1H), 2.09 (dddd, J = 12.5, 10.5, 2.0, 2.0 
Hz, 1H), 1.88-1.80 (m, 1H), 1.67-1.60 (m, 1H), 1.57-1.36 (m, 5H), 1.24 (dddd, J = 12.0, 
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12.0, 3.4, 3.4 Hz, 1H), overlaps with 1.17 (dddd, J = 11.7, 11.7, 4.3, 3.1 Hz, 1H), 0.93 
(dddd, J = 14.6, 11.8, 11.8, 3.8 Hz, 1H). 13C NMR (400 MHz, CDCl3) δ = 213.35, 
134.58, 130.65, 57.94, 43.52, 41.99, 38.30, 33.24, 31.27, 28.43, 25.66, 24.35, 23.84. 
A solution of 1,4-benzoquinone (1.0 eq) and diene (2.0 eq) in 1,2-
dichlorobenzene or DCM was heated in a bomb at 170-200oC for 24 h (or stirred at room 
temperature in DCM overnight). After the reaction was cooled to room temperature, the 
solvent was removed on a high vacuum pump. The crude reaction mixture was used 
either without further purification or was recrystallized. 
1S(R), 2R(S), 4R(S), 5S(R), 8R(S), 9S(R), 11S(R), 12R(S)-
Pentacyclo[10.2.1.15,8.02,11.04,9]hexadeca-6,13-diene-3,10-dione (3a): from 4.0 g of 1,4-
benzoquinone (37.0 mmol) and 6.1 g of 1,3-cyclopentadiene (92.5 mmol) in 30 mL of 
DCM for 24 h: 8.9 g (100%). 1H NMR (500 MHz, CDCl3) δ = 6.16 (dd, J = 1.8, 1.88 Hz, 
4H), 3.33 (m, 4H), 2.84 (m, 4H), 1.43 (ddd, J = 1.8, 1.8 8.6 Hz, 2H), 1.26 (d, J = 8.5 Hz, 
2H). 13C NMR (500 MHz, CDCl3) δ = 212.85, 136.57, 53.41, 49.78, 48.45. 
1S(R), 2R(S), 4R(S), 5S(R), 8R(S), 9S(R), 11S(R), 12R(S)-
Pentacyclo[10.2.2.25,8.02,11.04,9]octadeca-6,13-diene-3,10-dione (3b): from 2.0 g of 1,4-
benzoquinone (18.5 mmol) and 3.0 g of 1,3-cyclohexadiene (37.0 mmol) in 15 mL of 
1,2-dichlorobenzene for 24 h (recrystallized from hot CH3CN): 3.9 g (79%). 1H NMR 
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(400 MHz, CDCl3) δ = 6.30 (m, 4H), 2.96 (m, 4H), 2.76 (m, 4H), 1.55-1.48 (m, 4H), 
1.30-1.25 (m, 4H). 13C NMR (400 MHz, CDCl3) δ = 210.85, 134.00, 53.78, 32.60, 24.66. 
2. Preparation of the Paternò–Büchi adducts (2 and 4): 
Approximately 3-10 mM solution of a precursor 1 in CH3CN (or benzene) was 
irradiated in quartz reaction vessels in a Rayonet reactor equipped with RPR-3000 UV 
lamps (broadband 250-350 nm UV source with peak emission at 300 nm) for 24-72 
hours. Irradiation resulted in a nearly quantitative conversion to 2 (70-90% by NMR), 
which were used without further purification. NOTE: We attempted to further purify 
reaction mixtures by chromatography. The strained polycyclic oxetanes 2 are not stable 
on silica gel, producing various amounts of rearranged products. To avoid this 
complication to some extent in some cases we passed 2 mL of pyridine through the 
column before column purification (hexane:EtOAc, 20:1→5:1). 
 4-Methyl-3-oxatetracyclo[4.2.1.02,5.04,8]nonane (2a): from 300 mg of 1a (2.2 
mmol) in 600 mL of benzene, irradiation for 24 h: (> 80% by NMR of initial endo-2-
acetyl-5-norbornene). 1H NMR (500 MHz, CDCl3) δ = 4.61 (dd, J = 3.6, 2.3 Hz, 1H), 
2.78 (dddd, J = 3.7, 3.7, 1.8, 1.8 Hz, 1H), 2.65 (m, 1H), 2.23 (m, 1H), 1.97 (m, 1H), 1.73 
(ddd, J = 10.6, 2.4, 2.4 Hz, 1H), 1.60 (ddd, J = 10.5, 2.3, 2.3 Hz, 1H), 1.57-1.51 (m, 2H), 
1.44 (s, 3H). 
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O 2-Oxapentacyclo[6.4.0.01,4.03,7.05,9]dodecane (2b): from 200 mg of 1b 
(1.23 mmol) in 525 mL of benzene (or CH3CN), irradiation for 48 h: (> 80% by NMR). 
1H NMR (500 MHz, CDCl3) δ = 4.73 (dd, J = 3.5, 2.3 Hz, 1H), 2.72 (m, 1H), 2.61 (m, 
1H), 2.23 (ddd, J = 2.9, 2.9, 2.9 Hz, 1H), 2.01-1.95 (m, 2H), 1.88 (ddd, J = 11.9, 11.9, 
4.8 Hz, 1H) overlaps with 1.84 (m, 1H), 1.75-1.67 (m, 2H), 1.67-1.59 (m, 2H), 1.56 
(dddd, J = 14.2, 14.2, 6.0, 3.1 Hz, 1H), 1.42-1.35 (m, 1H). 13C NMR (500 MHz, CDCl3) 
δ = 99.73, 88.03, 55.74, 53.73, 47.02, 43.57, 41.55, 39.86, 29.23, 26.36, 20.36. 
O
 2-Oxapentacyclo[6.5.0.01,4.03,7.05,9]tridecane (2c): from 170 mg of 1c 
(1.06 mmol) in 30 mL of CH3CN, irradiation for 24 h: (2c rearranged mostly into 5c 
while being irradiated and on the column). 
O
 4-Methyl-3-oxatetracyclo[4.2.2.02,5.04,8]decane (2d): from 300 mg of 1d 
(2.00 mmol) in 700 mL of benzene, irradiation for 18 h: (> 88% by NMR). 1H NMR (500 
MHz, CDCl3) δ = 4.37 (dd, J = 3.4, 2.1 Hz, 1H), 2.82 (dddd, J = 5.6, 3.6, 1.8, 1.8 Hz, 
1H), 2.36 (m, 1H), 2.05 (d, J = 6.7 Hz, 1H), 1.86 (dddd, J = 13.9, 10.0, 10.0, 2.0 Hz, 
1H), 1.78 (m, 1H), 1.67 (ddd, J = 9.5, 9.5, 4.0 Hz, 1H) overlaps with 1.66-1.63 (m, 2H), 
1.52 (ddd, J = 13.4, 9.7, 4.6 Hz, 1H) overlaps with 1.49 (s, 3H), 1.09 (m, 1H). 13C NMR 
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(500 MHz, CDCl3) δ = 97.64, 82.50, 56.86, 44.87, 39.49, 32.95, 28.57, 24.50, 17.52 
overlaps with 17.52. 
O
 2-Oxapentacyclo[7.4.0.01,4.03,8.05,10]tridecane (2e): from 1.0 g of 1e (5.67 
mmol) in 0.5 L of CH3CN, irradiation for 48 h: (> 95% by NMR). 1H NMR (400 MHz, 
CDCl3) δ = 4.40 (dd, J = 3.7, 1.8 Hz, 1H), 2.69 (dddd, J = 5.6, 3.6, 1.8, 1.8 Hz, 1H), 2.39 
(m, 1H), 2.09 (m, 1H), 2.00-1.95 (m, 1H), 1.90 (ddd, J = 11.5, 11.5, 5.0 Hz, 1H), 1.82 
(m, 1H) overlaps with 1.85-1.76 (dddd, J = 13.8, 10.0, 10.0, 2.3 Hz, 1H), 1.68 (m, 1H), 
1.62 (m, 2H), 1.54-1.47 (m, 2H), 1.44-1.32 (m, 2H), 1.14 (dddd, J = 12.6, 10.0, 10.0, 1.8 
Hz, 1H). 13C NMR (400 MHz, CDCl3) δ = 98.58, 83.89, 54.59, 48.24, 44.67, 39.87, 
34.77, 29.31, 29.29, 24.54, 20.46, 17.77. 
 2-Oxapentacyclo[7.5.0.01,4.03,8.05,10]tetradecane (2f): from 120 mg of 1f 
(0.63 mmol) in 80 mL of CH3CN, irradiation for 72 h: (> 65% by NMR, 2f rearranged 
partially into 5f while being irradiated). 1H NMR (500 MHz, CDCl3) δ = 4.26 (dd, J = 
3.4, 2.1 Hz, 1H), 2.76 (dddd, J = 5.6, 3.7, 1.8, 1.8 Hz, 1H), 2.39 (m, 1H), 2.20-2.13 (m, 
3H), 1.94 (dddd, J = 14.2, 6.4, 2.2, 1.1 Hz, 1H), 1.85 (dddd, J = 14.0, 9.7, 9.7, 2.0 Hz, 
1H), 1.73 (ddd, J = 14.3, 7.3, 7.3 Hz, 1H), 1.67-1.63 (m, 1H) overlaps with HOD and 
1.63-1.53 (m, 3H), 1.48 (m, 1H), 1.38-1.23 (m, 2H), 1.13 (dddd, J = 12.5, 9.6, 9.6, 1.2 
Hz, 1H) overlaps with 1.07 (m, 1H). 13C NMR (400 MHz, CDCl3) δ = 101.10, 81.73, 
58.71, 46.76, 45.57, 42.49, 34.61, 34.33, 33.30, 25.39, 25.17, 24.26, 17.98. 
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(4b*): (formed as an intermediate). 1H NMR (400 MHz, CDCl3) δ = 6.32 
(dd, J = 7.4, 7.4 Hz, 1H), 6.14 (dd, J = 7.2, 7.2 Hz, 1H), 4.56 (m, 1H), 3.22 (m, 1H), 2.83 
(m, 2H), 2.68 (d, J = 9.5 Hz, 1H), 2.56 (dd, J = 9.5, 3.4 Hz, 1H), 2.51 (m, 1H) overlaps 
with 2.50 (m, 1H), 2.43 (m, 1H), 1.78 (m, 1H), 1.72 (m, 2H), 1.67-1.50 (m, 3H) overlaps 
with HOD, 1.33 (m, 1H), 1.27-1.12 (m, 2H). 13C NMR (400 MHz, CDCl3) δ = 214.17, 
135.16, 133.45, 97.12, 83.87, 59.33, 55.36, 50.37, 41.40, 39.77, 38.25, 34.22, 33.87, 
29.35, 26.88, 24.05, 22.77, 17.17. 
O
O
(4b): From 300 mg of 3b (1.12 mmol) in 600 mL of CH3CN, irradiation 
for 48 h: (> 95% by NMR). 1H NMR (400 MHz, CDCl3) δ = 4.39 (m, 1H), 2.86 (dddd, J 
= 5.5, 3.6, 1.8, 1.8 Hz, 1H), 2.43 (d, J = 2.1 Hz, 1H), 2.38 (m, 1H), 2.17-2.14 (m, 1H) 
overlaps with 2.13 (dddd, J = 7.8, 4.1, 2.0, 2.0 Hz, 1H), 1.84 (dddd, J = 13.9, 10.1, 10.1, 
2.3 Hz, 1H), 1.70 (ddd, J = 3.7, 10.0, 13.7 Hz, 1H), 1.59 (ddd, J = 13.3, 9.7, 4.0 Hz, 1H), 
1.18 (dddd, J = 13.1, 10.0, 10.0, 1.9 Hz, 1H). 13C NMR (400 MHz, CDCl3) δ = 99.74, 
83.59, 54.84, 46.02, 44.47, 38.38, 34.83, 23.21, 17.80. 
3. Preparation of the rearranged products (5 and 6): 
(A) HCl-catalyzed formation of the rearranged adducts: To a solution of 
oxetane 2 or 4b in DCM, HCl (4.0 M solution in dioxane) was added. The resulting 
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mixture was stirred at room temperature for 24 h, DCM was removed on a high-vacuum 
pump, then purified on a silica gel column using hexane–ethyl acetate (or hexane–
ethanol).  
 (B) Rawal’s conditions [27]. 
 2-Methylbicyclo[2.2.1]hept-2-ene-6-carboxaldehyde (5a): (method A) 
from 100 mL (3.7 mM) in benzene of 2a (0.37 mmol) and 0.3 mL of HCl (1.20 mmol) 
(hexane/EtOAc 40:1): (all the attempts to purify a mixture of epimerized aldehydes 
failed). 
OH
Cl
2-Chlorotetracyclo[6.2.1.03,7.03,9]undecan-10-ol (5b): (method A) from 200 
mg of 2b (1.23 mmol) and 0.62 mL of HCl (2.47 mmol) in DCM (hexane/EtOAc 
30:1→10:1): (> 90% by NMR). 1H NMR (500 MHz, CDCl3) δ = 4.37 (s, 1H), 4.05 (d, J 
= 10.6 Hz, 1H), 2.81 (d, J = 10.6 Hz, OH), 2.72 (m, 1H), 2.59 (ddd, J = 4.0, 1.9, 1.9 Hz, 
1H), 2.08 (dd, J = 6.9, 4.1 Hz, 1H) overlaps with 2.06 (m, 1H), 1.94-1.72 (m, 7H), 1.44 
(d, J = 12.7 Hz, 1H). 1H NMR (500 MHz, CD3OD) δ = 4.29 (s, 1H), 4.05 (s, 1H), 2.61 
(m, 1H), 2.51 (ddd, J = 4.0, 1.9, 1.9 Hz, 1H), 2.08 (m, 1H) overlaps with 2.05 (dd, J = 
6.9, 4.2 Hz, 1H), 1.93-1.87 (m, 3H), 1.85-1.73 (m, 4H), 1.47 (d, J = 12.6 Hz, 1H). 13C 
NMR (500 MHz, CDCl3) δ = 83.44, 70.22, 60.68, 53.30, 48.81, 47.72, 35.43, 33.86, 
33.12, 31.68, 26.57. 13C NMR (500 MHz, CD3OD) δ = 83.27, 69.51, 62.30, 54.78, 51.03, 
49.15 overlaps with CD3OD, 36.36, 35.24, 34.02, 32.86, 27.73. 
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 2-Chlorotetracyclo[7.2.1.03,8.03,10]dodecan-11-ol (5c): (method A) from 
0.17 mg of 2c (0.96 mmol) and 0.3 mL of HCl (1.20 mmol) in DCM (hexane/EtOAc 
40:1→20:1): (> 90% by NMR). 1H NMR (500 MHz, CDCl3) δ = 4.28 (s, 1H), 4.11 (d, J 
= 10.0 Hz, 1H), 2.87 (m, 1H), 2.73 (m, 1H), 2.63 (d, J = 9.9 Hz, OH), 1.97 (m, 1H), 1.89 
(dd, J = 7.1, 4.5 Hz, 1H), 1.84-1.79 (m, 2H) overlaps with 1.79 (ddd, J = 12.5, 7.2, 3.5 
Hz, 1H), 1.63 (m, 1H), 1.53 (dd, J = 10.6, 7.5 Hz, 1H), 1.47 (dd, J = 12.5, 1.0 Hz, 1H), 
1.42-1.35 (m, 2H), 1.27 (dddd, J = 13.7, 13.7, 10.6, 3.5 Hz, 1H), 1.06-0.97 (m, 1H). 1H 
NMR (500 MHz, CD3OD) δ = 4.13 (s, 1H), 4.06 (s, 1H), 2.77 (m, 1H), 2.57 (m, 1H), 
1.92 (m, 1H), 1.81 (m, 2H), 1.72 (m, 2H), 1.59 (m, 1H), 1.51 (dd, J = 10.6, 7.5 Hz, 1H), 
1.44 (dd, J = 12.4, 1.1 Hz, 1H), 1.38-1.22 (m, 3H), 1.01 (m, 1H). 13C NMR (500 MHz, 
CDCl3) δ = 84.18, 75.04, 49.61 overlaps with 49.61, 47.89, 44.76, 36.27, 33.46, 30.07, 
29.61, 24.06, 23.43. 13C NMR (500 MHz, CD3OD) δ = 82.34, 72.73, 50.22, 49.47, 47.87 
overlaps with CD3OD, 44.29, 36.15, 32.91, 29.93, 28.96, 23.84, 23.30. 
O
 7-Methylbicyclo[3.2.1]oct-6-ene-2-carboxaldehyde (5d-1): (method A) from 
34 mg of 2d (0.23 mmol) and 0.1 mL of HCl (0.40 mmol) in DCM (hexane/EtOAc 40:1): 
(all the attempts to separate a mixture of epimerized aldehydes (endo:exo = 2.2:1) failed). 
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 7-Methyl-endo-2-(1,3-dioxolan-2-yl)bicyclo[3.2.1]oct-6-ene (5d-2): 
(method A) from 34 mg of 2d (0.23 mmol) and 0.1 mL of HCl (0.40 mmol) in 
THF/ethelyne glycol mixture (1:1) (hexane/EtOAc 40:1): (30 mg, 68%). 1H NMR (500 
MHz, CDCl3) δ = 5.48 (s, 1H), 4.53 (d, J = 7.3 Hz, 1H), 3.98-3.91 (m, 2H), 3.88-3.81 (m, 
2H), 2.47 (m, 2H), 2.10 (dddd, J = 10.2, 5.4, 5.4, 1.8 Hz, 1H), 1.81 (m, 3H), 1.69-1.61 
(m, 2H), 1.45-1.38 (m, 2H), 1.36 (d, J = 9.8 Hz, 2H). 13C NMR (500 MHz, CDCl3) δ = 
140.76, 127.41, 106.89, 64.78, 64.63, 46.41, 44.35, 41.59, 39.45, 24.48, 21.21, 17.37. 
HO
Cl
 2-Chlorotetracyclo[7.2.1.03,8.04,12]dodecan-4-ol (5e-1): (method A) from 
50 mg of 2e (0.28 mmol) and 0.1 mL of HCl (0.40 mmol) in DCM (hexane/EtOAc 
30:1→5:1, then hexane/EtOH 10:1→1:1): (20 mg, ~ 40%). 1H NMR (400 MHz, CDCl3) 
δ = 3.47 (d, J = 2.4 Hz, 1H), 2.89 (m, 1H), 2.64 (s, 1OH), 2.15-2.10 (m, 2H) overlaps 
with 2.10-2.01 (m, 1H), 1.94 (dd, J = 13.4, 6.5 Hz, 1H), 1.85-1.68 (m, 4H), 1.68-1.56 (m, 
3H) overlaps with HOD, 1.45 (dd, J = 13.3, 8.1 Hz, 1H) overlaps with 1.44-1.39 (m, 2H). 
1H NMR (400 MHz, CD3OD) δ = 3.39 (d, J = 2.6 Hz, 1H), 2.87 (m, 1H), 2.17 (dd, J = 
8.1, 5.5 Hz, 1H), 2.11-2.02 (m, 2H), 1.90-1.85 (m, 1H), 1.83-1.73 (m, 3H), 1.66 (m, 1H), 
1.63-1.55 (m, 3H), 1.53-1.42 (m, 3H). 13C NMR (400 MHz, CDCl3) δ = 87.91, 67.57, 
56.40, 55.92, 54.87, 47.96, 37.89, 32.91, 32.48, 29.09, 28.71, 18.98. HRMS (ESI) calcd 
for C12H17ClNaO+ (MNa+) 235.0860, found 235.0857. 
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 Tetracyclo[6.2.2.02,7.03,9]dodecan-3-ol (5e-2): (method B) from 0.5 g of 2e 
(2.84 mmol), 0.14 g of Li wire (20.17 mmol), 1.5 g of DBB (5.63 mmol) in THF at 0oC 
for 3 h, then 6.0 mL of Et3Al (5.96 mmol) -78oC for 6 h (hexane/EtOAc 60:1→20:1): 
(0.48 g, 95%). 1H NMR (400 MHz, CDCl3) δ = 2.18 (dddd, J = 10.9, 7.2, 1.9, 1.9 Hz, 
1H), 2.11 (m, 1H), 1.94-1.88 (m, 1H), 1.87-1.81 (m, 3H), 1.79-1.70 (m, 2H), 1.69-1.63 
(m, 1H), 1.60-1.49 (m, 5H), 1.47-1.40 (m, 2H), 1.31-1.22 (m, 2H). 13C NMR (400 MHz, 
CDCl3) δ = 85.75, 49.95, 46.08, 39.44, 36.23, 34.92, 32.92, 29.97, 28.54, 25.17, 24.54, 
19.97. HRMS (ESI) calcd for C12H18NaO+ (MNa+) 201.1250, found 201.1254. 
OH
Cl
 2-Chlorotetracyclo[7.2.2.03,8.03,10]tridecan-11-ol (5f): (method A) from 57 
mg of 2f (0.30 mmol) and 0.1 mL of HCl (0.40 mmol) in DCM (hexane/EtOAc 
40:1→30:1): (> 90% by NMR). 1H NMR (500 MHz, CDCl3) δ = 4.19 (d, J = 9.5 Hz, 
1H), 4.15 (s, 1H), 2.79 (m, 2H), 2.24 (d, J = 9.5 Hz, OH), 2.18 (ddd, J = 14.7, 9.3, 9.3 
Hz, 1H), 2.07 (dddd, J = 6.6, 6.6, 2.3, 2.3 Hz, 1H), 2.02-1.95 (m, 1H), 1.87-1.83 (m, 1H), 
1.78 (ddd, J = 14.6, 10.5, 8.8 Hz, 1H), 1.72-1.61 (m, 4H), 1.57-1.48 (m, 2H), 1.40-1.31 
(m, 2H), 1.24-1.17 (m, 1H). 1H NMR (500 MHz, CD3OD) δ = 4.18 (s, 1H), 4.05 (s, 1H), 
2.69 (d, J = 8.9 Hz, 1H), 2.62 (dd, J = 8.6, 2.3 Hz, 1H), 2.10 (ddd, J = 14.7, 9.2, 9.2 Hz, 
1H), 2.01-1.94 (m, 2H), 1.82-1.74 (m, 2H), 1.67-1.50 (m, 5H), 1.50-1.41 (m, 1H), 1.38-
1.27 (m, 2H), 1.23-1.14 (m, 1H). 13C NMR (500 MHz, CDCl3) δ = 80.02, 78.37, 52.70, 
 113 
48.35, 46.27, 40.82, 38.88, 30.29, 30.05, 27.69, 22.06, 20.97, 20.29. 13C NMR (500 
MHz, CD3OD) δ = 79.84, 78.38, 54.39, 49.86, 47.16, 42.98, 40.36, 31.82, 31.02, 28.91, 
23.47, 22.50, 21.53. 
(6b-0 minor product): from 1.18 g of 11 (4.40 mmol) and 4.4 mL of 
HCl (17.6 mmol) in DCM for 10 min (hexane/EtOAc 10:1→1:1): (< 5% by NMR). 1H 
NMR (500 MHz, CDCl3) δ = 5.96 (dd, J = 5.7, 2.8 Hz, 1H), 5.77 (dd, J = 5.7, 2.5 Hz, 
1H), 5.72 (dd, J = 5.7, 2.8 Hz, 1H), 5.66 (dd, J = 5.7, 2.7 Hz, 1H), 3.37 (ddd, J = 5.3, 2.6, 
2.6 Hz, 1H), 3.16 (ddd, J = 5.3, 2.5, 2.5 Hz, 1H), 2.78 (ddd, J = 10.6, 8.7, 5.7 Hz, 1H) 
overlaps with 2.74 (dd, J = 7.6, 2.4 Hz, 1H), 2.71-2.67 (m, 2H), 3.66-2.55 (m, 2H), 2.09-
2.04 (m, 1H) overlaps with 2.04 (dd, J = 14.3, 2.3 Hz, 1H) and overlaps with 2.03-1.98 
(dddd, J = 10.6, 5.4, 5.4, 2.1 Hz, 1H), 1.67 (ddd, J = 13.6, 10.7, 2.4 Hz, 1H), 1.63 (m, 
1H), 1.57-1.52 (m, 1H) overlaps with HOD, 1.46 (d, J = 10.3 Hz, 1H), 1.29 (d, J = 10.5 
Hz, 1H). 13C NMR (500 MHz, CDCl3) δ = 212.55, 210.45, 138.89, 135.48, 131.43, 
130.29, 48.56, 48.32, 44.70, 43.33, 43.31, 43.22, 41.53, 39.81, 38.19, 38.03, 25.43, 23.37. 
 (6b-0 major product): (40-50% by NMR). 1H NMR (500 MHz, 
CDCl3) δ = 6.36 (ddd, J = 8.0, 6.7, 1.2 Hz, 1H), 6.18 (ddd, J = 7.7, 6.6, 1.2 Hz, 1H), 5.92 
(dd, J = 5.7, 2.8 Hz, 1H), 5.85 (dd, J = 5.7, 2.8 Hz, 1H), 3.42 (m, 1H), 3.10 (ddd, J = 5.3, 
2.6, 2.6 Hz, 1H), 2.95 (m, 1H) overlaps with 2.92 (dd, J = 10.3, 2.4 Hz, 1H), 2.69 (dd, J = 
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10.2, 2.4 Hz, 1H), 2.64 (dddd, J = 5.6, 2.8, 2.8, 2.8 Hz, 1H), 2.54 (ddd, J = 14.9, 10.54, 
5.9 Hz, 1H), 2.06 (dd, J = 14.8, 2.3 Hz, 1H), 1.94 (dddd, J = 10.6, 5.4, 5.4, 2.0 Hz, 1H), 
1.70 (ddd, J = 13.5, 10.6, 2.5 Hz, 1H), 1.64 (m, 1H), 1.56-1.48 (m, 2H), 1.37-1.26 (m, 
2H), 1.20 (d, J = 10.5 Hz, 1H). 13C NMR (500 MHz, CDCl3) δ = 210.49, 210.44, 135.77, 
134.89, 132.89, 130.84, 52.43, 51.91, 48.74, 43.27, 42.37, 38.53, 37.95, 36.25, 31.47, 
25.48, 23.85, 23.70. 
 (6b-1): (< 10% by NMR). 1H NMR (500 MHz, CDCl3) δ = 6.30 
(ddd, J = 8.2, 6.5, 1.3 Hz, 1H), 6.24 (ddd, J = 7.8, 6.4, 1.5 Hz, 1H), 3.50 (d, J = 2.2 Hz, 
1H), 3.26 (m, 2H), 2.94 (m, 1H), 2.79 (s, OH), 2.75 (dd, J = 10.0, 3.0 Hz, 1H), 2.62 (dd, J 
= 10.2, 1.6 Hz, 1H), 2.32 (ddd, J = 4.6, 4.6, 1.3 Hz, 1H), 2.12 (m, 2H), 2.05 (m, 1H), 1.81 
(m, 2H), 1.77 (m, 1H), 1.58-1.53 (m, 3H) overlaps with HOD 1.31 (m, 2H). 
(6b-2): (method A) from 1.18 g of 4b (4.40 mmol) and 4.4 mL of HCl 
(17.6 mmol) in DCM for 10 min (hexane/EtOAc 10:1→1:1): (< 10% by NMR). 1H NMR 
(400 MHz, CDCl3) δ = 5.98 (dd, J = 5.8, 2.7 Hz, 1H), 5.94 (dd, J = 5.7, 2.7 Hz, 1H), 
3.59 (d, J = 2.1 Hz, 1H), 3.13 (ddd, J = 5.3, 2.5, 2.5 Hz, 1H), 2.85 (m, 1H), 2.80 (s, 
1OH), 3.67 (m, 1H) overlaps with 2.66-2.61 (m, 1H), 2.32-2.29 (m, 2H), 2.15-2.06 (m, 
2H), 2.02 (dddd, J = 10.5, 5.4, 5.4, 2.1 Hz, 1H), 1.91-1.85 (m, 2H), 1.82 (m, 1H), 1.63-
1.55 (m, 3H), 1.29 (ddd, J = 13.3, 11.0, 2.3 Hz, 1H), 1.22 (d, J = 10.3 Hz, 1H). 13C NMR 
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(400 MHz, CDCl3) δ = 213.73, 133.94, 132.53, 87.57, 66.61, 59.43, 59.36, 52.37, 49.32, 
44.95, 44.93, 42.72, 42.56, 40.27, 38.53, 32.18, 30.26, 23.71. HRMS (ESI) calcd for 
C18H21ClNaO2+ (MNa+) 327.1122, found 327.1112. 
O
HO
O
(6b-3): (< 10% by NMR). 1H NMR (400 MHz, CDCl3) δ = 6.39 (ddd, J = 
8.0, 6.6, 1.2 Hz, 1H), 6.25 (ddd, J = 8.0, 6.5, 1.4 Hz, 1H), 5.25 (d, J = 4.9 Hz, 1H), 3.73 
(d, J = 3.1 Hz, 1H), 2.68 (m, 1H), 2.63 (m, 1H), 2.54 (d, J = 5.4 Hz, 1H), 2.46 (m, 1H) 
overlaps with 2.42 (dddd, J = 6.3, 2.1, 2.1, 2.1 Hz, 1H), 2.17 (dddd, J = 12.5, 9.9, 4.5, 
2.4 Hz, 1H) overlaps with 2.12 (d, J = 2.4 Hz, 1H), 2.04 (m, 1H), 1.96 (dd, J = 13.7, 1.8 
Hz, 1H) overlaps with 1.94-1.91 (m, 1H), 1.65 (ddd, J = 13.7, 3.5, 3.5 Hz, 1H), 1.59-1.51 
(m, 3H) overlaps with 1.51-1.38 (m, 2H), 1.17 (ddddd, J = 11.9, 11.9, 4.3, 2.9, 2.9 Hz, 
1H), 1.03 (dddd, J = 12.4, 12.4, 3.8, 3.8 Hz, 1H). 13C NMR (400 MHz, CDCl3) δ = 
134.47, 132.55, 101.76, 99.24, 79.64, 78.88, 48.46, 48.17, 43.13, 39.99, 38.84, 37.20, 
32.70, 30.38, 25.24, 22.81, 22.13, 18.38. HRMS (ESI) calcd for C18H22NaO3+ (MNa+) 
309.1461, found 309.1459. 
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Chapter Five: Photoinduced transformations in the 
Hetero-Diels-Alder adducts 
A. Introduction – Part I. 
The intramolecular Diels-Alder (IMDA) reaction of furans with internal (built-in) 
dienophiles is an effective method for the generation of highly functionalized polycyclic 
systems, which are attractive starting scaffolds for diversity oriented synthesis [40]. 
IMDA reactions between inactivated furans and dienophiles take place generally faster 
and at lower temperature compared to their intermolecular counterparts.  
When a furan is connected to a dienophile by a tether, the triene undergoes IMDA 
reaction with excellent stereocontrol to provide a tricyclic system [40a].  
 
As an extension of this work, we decided to also examine the IMDA reaction 
utilizing pyrrole as a diene partner to prepare tricyclic molecules with a 7-
azabicyclo[2.2.1]hept-2-ene moiety. Although there are plenty of examples of the inter-
molecular Diels-Alder cycloaddition reaction of N-protected pyrroles [41a-b], only a few 
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reports describing IMDA reaction cycloaddition of pyrrole have been published [41c]. 
This may be due to the aromatic character of the pyrrole ring.  
B. Results and discussion – Part I. 
With this in mind we hypothesized that polycyclic Hetero-Diels-Alder (H.-D.-A.) 
adducts containing an endo-aroyl group could react via [2+2] photo-cycloaddition and 
further undergo oxametathesis when exposed to acidic media producing highly 
functionalized and unique scaffolds (Scheme 37):  
 
Scheme 37: Oxametathesis of the hypothesized Hetero-Paternò-Büchi adducts.  
To prove this concept we first synthesized various furan- and pyrrol-based amines 
2, which were further coupled with 4-oxobutenoic acid 1. The resulting newly-formed 
conjugates immediately underwent IMDA cycloaddition to provide tricyclic compounds 
3 with an aroyl group in the endo-position (Scheme 38): 
 
Scheme 38: Preparation of Hetero-Diels-Alder adducts 3.  
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However, to our great disappointment, H.-D.-A. adducts 3 failed to undergo the 
P.-B. photocycloaddition. This could be due to the fact that a lactam’s five-membered 
ring makes tricycle 3 very rigid, which precludes the endo-aroyl group from reaching the 
double bond and reacting to form the desired P.-B. adducts. Numerous computational 
predictions confirmed that as well.  
C. Experimental section – Part I. 
1. Preparation of butenoic acids (1): 
 (2E)-4-oxo-4-phenylbut-2-enoic acid (trans-3-benzoylacrylic 
acid) (1a): To a mixture of 100 mL of anhydrous, thiophene-free benzene and 5 g (51 
mmol) of maleic anhydride at room temperature, there was added in small portions 13.75 
g (103 mmol) of aluminum chloride. The temperature rose to 40-45oC during the addition 
and the mixture was then refluxed for 3-4 hours. The reaction mixture was decomposed 
with ice and 1:1 hydrochloric acid, the resulting mixture was then extracted with DCM 
and washed over anhydrous Na2SO4. The organic solvent was removed under reduced 
pressure to afford 7.2 g (80%) of pure acid [42]. 1H NMR (500 MHz, CDCl3) δ = 8.02 (d, 
J = 7.7 Hz, 2H) overlaps with 8.01 (d, J = 15.5 Hz, 1H), 7.65 (t, J = 7.4 Hz, 1H), 7.54 (t, 
J = 7.7 Hz, 2H), 6.90 (d, J = 15.5 Hz, 1H).  
 (2E)-4-oxo-4-(2-thienyl)but-2-enoic acid (1b): A mixture of 3.5 
mL (32.4 mmol) of 2-acetylthiophene and 3.0 g of glyoxalic acid monohydrate (32.3 
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mmol) in 10 mL of glacial HOAc and 1 mL of conc. HCl was heated under reflux 
conditions for 8 h. The solvents were removed under reduced pressure, the residue was 
taken up in hexane/EtOAc/DCM/EtOH and the solid that formed was filtered and 
recrystallized [43]. 1H NMR (500 MHz, CDCl3) δ = 7.88 (dd, J = 3.9, 1.1 Hz, 1H), 7.86 
(d, J = 15.4 Hz, 1H), 7.79 (dd, J = 4.9, 1.1 Hz, 1H), 7.22 (dd, J = 4.9, 3.9 Hz, 1H), 6.95 
(d, J = 15.4 Hz, 1H).  
2. Preparation of the amines (2): 
An aldehyde (1.0-1.1 eq) was added to a stirred solution of an amine (1.0 eq) in 
anhydrous ethanol at room temperature. After complete formation of the imine (3 hours), 
excess sodium borohydride (2.0-2.5 eq) was added in three portions at 10oC. After 
complete addition, the reaction mixture was stirred overnight and then diluted with water 
(100 mL), acidified with aq. HCl to pH 1 and extracted with DCM. The aqueous layer 
was adjusted to pH 10 with 5% of aq. NaOH and after that extracted with DCM. The 
combined DCM layer was washed with brine, dried over anhydrous Na2SO4 and 
concentrated in vacuo [40b]. 
 N-Benzyl-N-(2-furylmethyl)amine (2a): from 2.85 mL of 
furfurylamine (32.3 mmol), 3.3 mL of benzaldehyde (32.4 mmol) and 2.5 g of NaBH4 
(66.1 mmol): 5.8 g (95%). 1H NMR (500 MHz, CDCl3) δ = 7.38 (dd, J = 1.8, 0.8 Hz, 
1H), 7.34 (s, 2H), 7.33 (s, 2H), 7.26 (m, 1H) overlaps with CDCl3, 6.32 (dd, J = 3.2, 1.8 
Hz, 1H), 6.19 (dd, J = 3.2, 0.8 Hz, 1H), 3.79 (s, 4H), 1.66 (br. s, NH).  
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 N-(2-Furylmethyl)-N-(2-thienylmethyl)amine (2b): from 1.0 mL 
of furfurylamine (11.3 mmol), 1.0 mL of 2-thiophenecarboxaldehyde (10.7 mmol) and 
0.82 g of NaBH4 (21.7 mmol): 2.0 g (97%). 1H NMR (500 MHz, CDCl3) δ = 7.38 (dd, J 
= 1.8, 0.8 Hz, 1H), 7.23 (dd, J = 5.0, 1.3 Hz, 1H), 6.96 (dd, J = 5.0, 3.5 Hz, 1H), 6.93 
(m, 1H), 6.33 (dd, J = 3.1, 1.9 Hz, 1H), 6.19 (d, J = 3.1, 0.8 Hz, 1H), 3.98 (m, 2H), 3.82 
(s, 2H), 1.69 (br. s, NH).  
 N-(2-Furylmethyl)-N-neopentylamine (2c): from 1.0 mL of 
furfurylamine (11.3 mmol), 1.1 mL of pivalaldehyde (10.1 mmol) and 1.0 g of NaBH4 
(26.4 mmol): 1.6 g (95%). 1H NMR (500 MHz, CDCl3) δ = 7.36 (dd, J = 1.8, 0.8 Hz, 
1H), 6.31 (dd, J = 3.1, 1.9 Hz, 1H), 6.16 (dd, J = 3.1, 0.8 Hz, 1H), 3.78 (s, 2H), 2.34 (s, 
2H), 1.34 (br. s, NH), 0.90 (s, 9H).  
 N-(2-Furylmethyl)-N-[(1S)-1-phenylethyl]amine (2d): from 2.0 mL 
of furfural (24.1 mmol), 3.1 mL of (S)-(−)-α-methylbenzylamine  (24.0 mmol) and 2.3 g 
of NaBH4 (60.8 mmol): 4.6 g (95%). 1H NMR (500 MHz, CDCl3) δ = 7.38 (dd, J = 1.8, 
0.8 Hz, 1H), 7.37 (m, 2H), 7.36 (s, 2H), 7.28 (m, 1H) overlaps with CDCl3, 6.32 (dd, J = 
3.1, 1.8 Hz, 1H), 6.13 (dd, J = 3.1, 0.8 Hz, 1H), 3.81 (q, J = 6.6 Hz, 1H), 3.69 (d, J = 
14.5 Hz, 1H), 3.60 (d, J = 14.5 Hz, 1H), 1.72 (br. s, NH), 1.39 (d, J = 6.6 Hz, 3H).  
 N-(tert-Butyl)-N-(2-furylmethyl)amine (2e): from 2.0 mL of furfural 
(24.1 mmol), 2.5 mL of tert-butylamine (23.8 mmol) and 2.3 g of NaBH4 (60.8 mmol): 
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3.5 g (95%). 1H NMR (500 MHz, CDCl3) δ = 7.35 (dd, J = 1.8, 0.8 Hz, 1H), 6.30 (dd, J 
= 3.2, 1.8 Hz, 1H), 6.16 (dd, J = 3.2, 0.8 Hz, 1H), 3.76 (s, 2H), 1.16 (s, 9H), 1.09 (br. s, 
NH).  
 N-(Benzyl)-N-(2-thienylmethyl)amine (2f): from 2.0 mL of 2-
thiophenecarboxaldehyde (21.4 mmol), 2.3 mL of benzylamine (21.1 mmol) and 2.3 g of 
NaBH4 (60.8 mmol): 4.1 g (95%). 1H NMR (500 MHz, CDCl3) δ = 7.34 (m, 2H), 7.33 
(m, 2H), 7.27 (m, 1H) overlaps with CDCl3, 7.22 (dd, J = 5.0, 1.2 Hz, 1H), 6.96 (dd, J = 
5.0, 3.4 Hz, 1H), 6.93 (m, 1H), 4.00 (m, 2H), 3.84 (s, 2H), 1.70 (br. s, NH).  
 N-Benzyl-N-{[1-(p-toluenesulfonyl)-1H-pyrrol-2-yl]methyl}amine 
(2g): from 0.5 g of 1-(p-toluenesulfonyl)pyrrole-2-aldehyde (2.0 mmol), 0.25 mL of 
benzylamine (2.3 mmol) and 0.2 g of NaBH4 (5.3 mmol): 0.65 g (95%). 1H NMR (500 
MHz, CDCl3) δ = 7.63 (d, J = 8.4 Hz, 2H), 7.33-7.26 (m, 5H) overlaps with CDCl3 and 
7.26-7.22 (m, 3H), 6.23 (t, J = 3.3 Hz, 1H), 6.17 (m, 1H), 3.80 (s, 2H), 3.70 (s, 2H), 2.38 
(s, 3H), 1.80 (br. s, NH). 
 N-(1-Methylpropyl)-N-{[1-(p-toluenesulfonyl)-1H-pyrrol-2-
yl]methyl}amine (2h): from 1.0 g of 1-(p-toluenesulfonyl)pyrrole-2-aldehyde (4.0 
mmol), 0.4 mL of sec-butylamine (4.0 mmol) and 0.38 g of NaBH4 (10.0 mmol): 1.16 g 
(95%). 1H NMR (500 MHz, CDCl3) δ = 7.68 (d, J = 8.4 Hz, 2H), 7.30-7.27 (m, 3H), 6.22 
(t, J = 3.3 Hz, 1H), 6.15 (m, 1H), 3.82 (d, J = 14.9 Hz, 1H), 3.75 (d, J = 14.9 Hz, 1H), 
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2.49 (m, 1H), 2.40 (s, 3H), 1.66 (br. s, NH), 1.42 (m, 1H), 1.28 (m, 1H), 0.98 (d, J = 6.3 
Hz, 3H), 0.85 (t, J = 7.5 Hz, 3H). 
 N-Cyclohexyl-N-{[1-(p-toluenesulfonyl)-1H-pyrrol-2-
yl]methyl}amine (2i): from 1.0 g of 1-(p-toluenesulfonyl)pyrrole-2-aldehyde (4.0 
mmol), 0.5 mL of cyclohexylamine (4.4 mmol) and 0.38 g of NaBH4 (10.0 mmol): 1.26 g 
(95%). 1H NMR (500 MHz, CDCl3) δ = 7.68 (d, J = 8.4 Hz, 2H), 7.30-2.27 (m, 3H), 6.22 
(t, J = 3.3 Hz, 1H), 6.15 (m, 1H), 3.81 (s, 2H), 2.40 (s, 3H), 2.36 (dddd, J = 10.5, 10.5, 
3.8, 3.8 Hz, 1H), 1.77 (m, 2H), 1.73-1.64 (m, 2H) overlaps with 1.66 (br. s, NH), 1.59 (m, 
1H), 1.24-1.12 (m, 3H), 1.04 (m, 2H). 
3. Preparation of the Diels-Alder adducts (3): 
(A) To a solution of dienophile acid 1 (1 eq) in DCM was added EDC or DIC (0.5 
eq) and HOBt (cat.), the mixture was stirred at room temperature for 45 min. The amine 2 
was added to the solution of the solution of pre-activated acid (0.5 eq) in DCM and then 
DIEA (1 eq) and DMAP (cat.) were added to the reaction mixture. After the amine was 
consumed, the reaction mixture was diluted with DCM and washed with NaOH (5%), 
aqueous HCl (5%) and brine. The organic layer was dried, filtered, and evaporated to 
give the crude compound, which was purified by silica gel chromatography (eluted with 
hexane/EtOAc = 20:1→4:1) [40a, 41].  
(B) The amine 2 (1.0 eq) was dissolved in THF or ether, the solution was cooled 
to -78OC. Acryloyl chloride (1.2 eq) was then added and the resulting mixture was stirred 
for 10-20 min at -78OC to room temperature. The reaction mixture was washed with H2O 
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x 2 (50 mL) and extracted with DCM. The organic layer was dried over anhydrous 
NaSO4. The crude product was purified by silica gel chromatography (eluted with 
hexane/EtOH = 30:1→10:1).  
All the X-ray structures can be found in Appendix D. 
O
N
O
Bn
O Ph
 endo-6-Benzoyl-3-benzyl-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-
ene (3a-1): from 1.00 g of (2E)-4-oxo-4-phenylbut-2-enoic acid (1a) (5.68 mmol), 0.44 
mL of DIC (2.84 mmol), 0.53 g of N-benzyl-N-(2-furylmethyl)amine (2a) (2.83 mmol) 
and 1.0 mL of DIEA (5.74 mmol) (hexane/EtOAc gradient 4:1→2:1): 0.63 g (65%). 1H 
NMR (500 MHz, CDCl3) δ = 8.26 (d, J = 7.3 Hz, 2H), 7.61 (t, J = 7.4 Hz, 1H), 7.52 (t, J 
= 7.7 Hz, 2H), 7.36 (t, J = 7.2 Hz, 2H), 7.31-7.26 (m, 3H), 6.45 (d, J = 5.8 Hz, 1H), 6.36 
(dd, J = 5.8, 1.6 Hz, 1H), 5.34 (dd, J = 4.5, 1.6 Hz, 1H), 4.61 (d, J = 14.9 Hz, 1H), 4.55 
(d, J = 14.9 Hz, 1H), 4.36 (dd, J = 4.5, 3.9 Hz, 1H), 3.87 (d, J = 11.9 Hz, 1H), 3.59 (d, J 
= 11.9 Hz, 1H), 3.09 (d, J = 3.9 Hz, 1H). 13C NMR (500 MHz, CDCl3) δ = 196.99, 
173.04, 136.10, 136.08, 135.87, 133.61 (two overlapping peaks), 128.92, 128.83, 128.80, 
127.92, 127.71, 90.62, 81.40, 51.57, 51.45, 48.78, 46.75. HRMS (ESI) calcd for 
C22H19NNaO3+ (MNa+) 368.1257, found 368.1269. 
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 3-Benzyl-endo-6-thienoyl-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-
ene (3a-2): from 1.39 g of (2E)-4-oxo-4-(2-thienyl)but-2-enoic acid (1b) (7.63 mmol), 
0.73 g of EDC (3.81 mmol), 0.71 g of 2a (3.79 mmol) and 1.33 mL of DIEA (7.64 mmol) 
(hexane/EtOAc gradient 20:1→2:1): 0.47 g (35%). 1H NMR (500 MHz, CDCl3) δ = 8.47 
(dd, J = 3.9, 1.0 Hz, 1H), 7.68 (dd, J = 4.9, 1.0 Hz, 1H), 7.36 (m, 2H), 7.32-7.26 (m, 3H) 
overlaps with CDCl3, 7.20 (dd, J = 4.9, 3.9 Hz, 1H), 6.48 (dd, J = 5.8, 1.6 Hz, 1H), 6.44 
(d, J = 5.8 Hz, 1H), 5.33 (dd, J = 4.4, 1.6 Hz, 1H), 4.62 (d, J = 15.0 Hz, 1H), 4.53 (d, J = 
15.0 Hz, 1H), 4.21 (dd, J = 4.4, 4.0 Hz, 1H), 3.87 (d, J = 11.9 Hz, 1H), 3.59 (d, J = 11.9 
Hz, 1H), 3.03 (d, J = 4.0 Hz, 1H). 13C NMR (500 MHz, CDCl3) δ = 190.09, 172.90, 
143.58, 136.55, 135.80, 134.54, 134.44, 133.40, 128.86, 128.75, 127.94, 127.76, 90.50, 
81.38, 52.05 overlaps with 52.04, 48.84, 46.80. HRMS (ESI) calcd for C20H17NNaO3S+ 
(MNa+) 374.0821, found 374.0821. 
O
N
O
O Ph
S
 endo-6-Benzoyl-3-(2-thienylmethyl)-4-oxo-10-oxa-3-
azatricyclo[5.2.1.01,5]dec-8-ene (3b): from 1.00 g of 1a (5.68 mmol), 0.5 mL of DIC 
(3.23 mmol), 0.55 g of 2b (2.85 mmol) and 1.0 mL of DIEA (5.74 mmol) (hexane/EtOAc 
gradient 20:1→10:1): 0.50 g (50%). 1H NMR (500 MHz, CDCl3) δ = 8.24 (d, J = 7.2 Hz, 
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2H), 7.60 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.6 Hz, 2H), 7.26 (dd, J = 5.0, 1.3 Hz, 1H) 
overlaps with CDCl3, 7.01 (m, 1H), 6.97 (dd, J = 5.0, 3.4 Hz, 1H), 6.45 (d, J = 5.8 Hz, 
1H), 6.35 (dd, J = 5.8, 1.6 Hz, 1H), 5.32 (dd, J = 4.5, 1.6 Hz, 1H), 4.83 (d, J = 15.4 Hz, 
1H), 4.65 (d, J = 15.4 Hz, 1H), 4.33 (dd, J = 4.5, 3.9 Hz, 1H), 3.95 (d, J = 11.8 Hz, 1H), 
3.67 (d, J = 11.8 Hz, 1H), 3.06 (d, J = 3.9 Hz, 1H). 13C NMR (500 MHz, CDCl3) δ = 
196.92, 172.65, 138.27, 136.09 overlaps with 136.08, 133.62, 133.59, 128.90, 128.80, 
127.00, 126.82, 125.73, 90.55, 81.38, 51.50, 51.43, 48.68, 41.41. HRMS (ESI) calcd for 
C20H17NNaO3S+ (MNa+) 374.0821, found 374.0822. 
O
N
O
O Ph
 endo-6-Benzoyl-3-neopentyl-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-
8-ene (3c-1): from 1.00 g of 1a (5.68 mmol), 0.54 g of EDC (2.82 mmol), 0.50 g of 2c 
(2.99 mmol) and 1.0 mL of DIEA (5.74 mmol) (hexane/EtOAc gradient 20:1→10:1): 
0.27 g (29%). 1H NMR (500 MHz, CDCl3) δ = 8.25 (d, J = 7.2 Hz, 2H), 7.59 (t, J = 7.3 
Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 6.49 (d, J = 5.8 Hz, 1H), 6.38 (dd, J = 5.8, 1.6 Hz, 
1H), 5.32 (dd, J = 4.5, 1.6 Hz, 1H), 4.29 (dd, J = 4.5, 3.8 Hz, 1H), 4.16 (d, J = 11.9 Hz, 
1H), 3.78 (d, J = 11.9 Hz, 1H), 3.37 (d, J = 13.8 Hz, 1H), 3.03 (d, J = 3.8 Hz, 1H), 2.97 
(d, J = 13.8 Hz, 1H), 1.00 (s, 9H). 13C NMR (500 MHz, CDCl3) δ = 197.19, 173.91, 
136.18, 136.12, 133.54 (two overlapping peaks), 128.93, 128.76, 90.90, 81.40, 55.73, 
52.71, 51.80, 51.10, 33.92, 28.34. HRMS (ESI) calcd for C20H23NNaO3+ (MNa+) 
348.1570, found 348.1554. 
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 3-Neopentyl-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene (3c-2): 
(procedure B) from 0.21 mL of acryloyl chloride (2.58 mmol) and 0.40 g of 2c (2.39 
mmol) at -78oC (hexane/EtOH gradient 20:1→10:1): 40 mg (8%). 1H NMR (500 MHz, 
CDCl3) δ = 6.43 (d, J = 5.8 Hz, 1H), 6.41 (dd, J = 5.8, 1.6 Hz, 1H), 5.07 (dd, J = 4.6, 1.6 
Hz, 1H), 4.16 (d, J = 11.8 Hz, 1H), 3.78 (d, J = 11.8 Hz, 1H), 3.35 (d, J = 13.8 Hz, 1H), 
2.93 (d, J = 13.8 Hz, 1H), 2.47 (dd, J = 8.8, 3.5 Hz, 1H), 2.20 (ddd, J = 11.8, 4.5, 3.6 Hz, 
1H), 1.59 (dd, J = 11.8, 8.8 Hz, 1H), 0.99 (s, 9H). 13C NMR (500 MHz, CDCl3) δ = 
175.00, 137.09, 133.19, 89.29, 79.07, 55.57, 52.90, 47.15, 33.93, 28.32, 28.23. 
O
N
O
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*
 endo-6-Benzoyl-3-[(1S)-1-phenylethyl]-4-oxo-10-oxa-3-
azatricyclo[5.2.1.01,5]dec-8-ene (inseparable mixture of two diastereomers) (3d-1): from 
0.50 g of 1a (2.84 mmol), 0.54 g of EDC (2.82 mmol), 0.57 g of 2d (2.83 mmol) and 0.5 
mL of DIEA (2.87 mmol) (hexane/EtOAc gradient 20:1→4:1): 0.40 g (40%). 
(diastereomer a) 1H NMR (500 MHz, CDCl3) δ = 8.26 (m, 2H), 7.60 (m, 1H), 7.51 (m, 
2H), 7.40-7.30 (m, 4H), 7.26 (m, 1H) overlaps with CDCl3, 6.46 (d, J = 5.8 Hz, 1H), 6.35 
(dd, J = 5.7, 1.6 Hz, 1H), 5.58 (q, J = 7.1 Hz, 1H), 5.32 (d, J = 4.5 Hz, 1H), 4.35 (dd, J = 
4.5, 3.8 Hz, 1H), 3.89 (d, J = 11.8 Hz, 1H), 3.45 (d, J = 11.8 Hz, 1H), 3.10 (d, J = 3.8 
Hz, 1H), 1.60 (d, J = 7.2 Hz, 3H). (diastereomer b) 1H NMR (500 MHz, CDCl3) δ = 8.26 
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(m, 2H), 7.60 (m, 1H), 7.51 (m, 2H), 7.40-7.30 (m, 4H), 7.26 (m, 1H) overlaps with 
CDCl3, 6.38 (d, J = 5.8 Hz, 1H), 6.34 (dd, J = 5.7, 1.6 Hz, 1H), 5.59 (q, J = 7.1 Hz, 1H), 
5.32 (d, J = 4.5 Hz, 1H), 4.34 (dd, J = 4.5, 3.8 Hz, 1H), 3.61 (d, J = 11.9 Hz, 1H), 3.48 
(d, J = 11.9 Hz, 1H), 3.04 (d, J = 3.8 Hz, 1H), 1.57 (d, J = 7.1 Hz, 3H). HRMS (ESI) 
calcd for C23H21NNaO3+ (MNa+) 382.1414, found 382.1420. 
O
N
O
Ph
*
 3-[(1S)-1-Phenylethyl]-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene 
(separable mixture of two diastereomers) (3d-2): (procedure B) from 0.20 mL of acryloyl 
chloride (2.46 mmol) and 0.40 g of 2d (1.99 mmol) at -78oC (hexane/EtOAc gradient 
20:1→10:1): 76 mg (15%). (diastereomer a) 1H NMR (500 MHz, CDCl3) δ = 7.35-7.22 
(m, 5H) overlaps with CDCl3, 6.38 (m, 2H), 5.54 (q, J = 7.2 Hz, 1H), 5.06 (d, J = 4.5 Hz, 
1H), 3.87 (d, J = 11.6 Hz, 1H), 3.43 (d, J = 11.6 Hz, 1H), 2.51 (dd, J = 8.8, 3.5 Hz, 1H), 
2.24 (ddd, J = 11.8, 4.5, 3.6 Hz, 1H), 1.60 (dd, J = 11.8, 8.8 Hz, 1H) overlaps with 1.59 
(d, J = 7.2 Hz, 3H). 13C NMR (500 MHz, CDCl3) δ = 173.70, 139.84, 137.14, 133.22, 
128.55, 127.28, 126.69, 88.91, 79.01, 48.67, 47.95, 44.78, 28.10, 16.97. 
N
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 endo-6-Benzoyl-3-benzyl-10-(p-toluenesulfonyl)-4-oxo-3,10-
diazatricyclo[5.2.1.01,5]dec-8-ene (3g): (all the attempts to prepare the compound 
failed). 
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 endo-6-Benzoyl-3-(1-methylpropyl)-10-(p-toluenesulfonyl)-4-oxo-3,10-
diazatricyclo[5.2.1.01,5]dec-8-ene (inseparable mixture of two diastereomers) (3h): from 
0.71 g of 1a (4.03 mmol), 0.40 g of EDC (2.09 mmol), 0.62 g of 2h (2.02 mmol) and 0.7 
mL of DIEA (4.02 mmol) (recrystallized from hexane/EtOAc/EtOH/DCM mixture): 0.43 
g (46%). (diastereomer a) 1H NMR (500 MHz, CDCl3) δ = 8.24 (m, 2H), 7.59 (m, 1H), 
7.55-7.48 (m, 4H), 7.27 (m, 2H), 5.94 (d, J = 5.7 Hz, 1H), 5.88 (dd, J = 5.7, 2.1 Hz, 1H), 
5.10 (dd, J = 4.0, 2.0 Hz, 1H), 4.53 (d, J = 11.7 Hz, 1H), 4.33 (t, J = 4.1 Hz, 1H), 4.17 
(m, 1H), 3.70 (d, J = 11.7 Hz, 1H), 2.96 (d, J = 4.2 Hz, 1H), 2.41 (s, 3H), 1.63 (m, 2H), 
1.53 (m, 2H), 1.16 (d, J = 6.8 Hz, 1H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (500 MHz, 
CDCl3) δ = 196.67, 171.39, 144.10, 136.56, 135.45, 133.97, 133.77, 131.94, 129.92, 
129.07, 128.84, 127.99, 76.17, 67.39, 54.77, 48.94, 48.42, 41.66, 27.40, 21.59, 17.39, 
11.17. (diastereomer b) 1H NMR (500 MHz, CDCl3) δ = 8.24 (m, 2H), 7.59 (m, 1H), 
7.55-7.48 (m, 4H), 7.27 (m, 2H), 5.88 (d, J = 5.7 Hz, 1H), 5.85 (dd, J = 5.7, 2.0 Hz, 1H), 
5.08 (dd, J = 4.0, 2.0 Hz, 1H), 4.53 (d, J = 11.7 Hz, 1H), 4.33 (t, J = 4.1 Hz, 1H), 4.17 
(m, 1H), 3.76 (d, J = 11.7 Hz, 1H), 2.91 (d, J = 4.3 Hz, 1H), 2.42 (s, 3H), 1.63 (m, 2H), 
1.53 (m, 2H), 1.20 (d, J = 6.9 Hz, 1H), 0.97 (t, J = 7.3 Hz, 3H). 13C NMR (500 MHz, 
CDCl3) δ = 196.83, 171.32, 144.12, 136.44, 135.40, 134.05, 133.77 (overlaps with 
diastereomer a), 131.62, 129.94, 129.12, 128.80, 128.10, 75.97, 67.39 (overlaps with 
diastereomer a), 55.16, 49.23, 48.60, 42.03, 26.91, 21.59 (overlaps with diastereomer a), 
18.00, 11.31. HRMS (ESI) calcd for C26H29N2O4S+ (MH+) 465.1843, found 465.1839. 
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 3-Cyclohexyl-endo-6-benzoyl-10-(p-toluenesulfonyl)-4-oxo-3,10-
diazatricyclo[5.2.1.01,5]dec-8-ene (3i): from 0.71 g of 1a (4.03 mmol), 0.40 g of EDC 
(2.09 mmol), 0.62 g of 2i (1.86 mmol) and 0.7 mL of DIEA (4.02 mmol) (recrystallized 
from Hex/EtOAc/EtOH/DCM mixture): 0.34 g (37%). 1H NMR (500 MHz, CDCl3) δ = 
8.26 (d, J = 7.2 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.55 (d, J = 8.3 Hz, 2H), 7.49 (t, J = 
7.7 Hz, 2H), 7.27 (d, J = 7.4 Hz, 2H) overlaps with CDCl3, 5.93 (m, 2H), 5.10 (dd, J = 
3.8, 1.4 Hz, 1H), 4.54 (d, J = 11.7 Hz, 1H), 4.31 (t, J = 4.1 Hz, 1H), 3.98 (m, 1H), 3.76 
(d, J = 11.7 Hz, 1H), 2.90 (d, J = 4.2 Hz, 1H), 2.42 (s, 3H), 1.83-1.75 (m, 3H), 1.68 (m, 
2H), 1.47-1.32 (m, 4H), 1.13 (m, 1H). 13C NMR (500 MHz, CDCl3) δ = 196.84, 170.95, 
144.09, 136.60, 135.40, 134.27, 133.75, 131.83, 129.90, 129.10, 128.79, 127.99, 76.23, 
67.27, 54.93, 51.16, 48.66, 42.65, 30.65, 29.64, 25.60, 25.39, 25.33, 21.58. HRMS (ESI) 
calcd for C28H30N2NaO4S+ (MNa+) 513.1818, found 513.1832. 
D. Results and discussion – Part II. 
Since furan- and pyrrol-based H.-D.-A. adducts did not produce the desired 
photochemical outcome, we decided to explore another approach to the D.-A. adducts 
containing one or multiple hetero-atoms in the bicyclic framework.  
It is known that thioaldehydes and thioketones can react with various dienes 
yielding the H.-D.-A. adducts [44]. Given that thiocarbonyl compounds are unstable and 
tend to dimerize, they were generated in situ through the Bunte salts 1 (see Experimental 
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Section, page 133) and immediately reacted with freshly distilled cyclopentadiene 
(Scheme 39).  
  
Scheme 39. Preparation of the H.-D.-A. adducts through the Bunte salts. 
In most cases the formation of exo-adducts 2 was predominant. Endo-derivatives also are 
prone to rearrange into exo-products on a silica gel column. From our previous 
experience we learned that exo-adducts are usually photochemically inactive, therefore 
we were determined to focus only on the endo-adducts. But to our surprise exo-3-
benzoyl-2-thiabicyclo[2.2.1]hept-5-enes 2 upon irradiation in a Rayonet photoreactor 
with RPR-3500 lamps or a UVLED-based illuminator with five 250 mW @ 365 nm 
Nichia chips rearranged giving thiirane 5a-1 as a major product (Scheme 40): 
 
Scheme 40. Photolysis of exo- and endo-H.-D.-A. adducts 2.  
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A plausible mechanism for the formation of 5a-1 involves a homolytic C-S bond 
fragmentation forming two radicals, which then react with the double bond, producing 
the final product. The thiirane and cyclopropyl rings are in a syn-configuration with 
respect to each other (Scheme 41): 
 
Scheme 41. A plausible mechanism for the formation of thiirane 5a-1. 
Upon further investigation we discovered that endo-adduct 2a did not undergo 
[2+2] cycloaddition forming an oxetane upon irradiation. Instead it produces 29% of 
disulfide 5a-2 along with thiirane 5a-1 discussed previously (Scheme 40). 
 
Scheme 42. A plausible mechanism for the formation of disulfide 5a-2. 
We suggest that D.-A. adduct 2 upon photolysis experiences homolytic C-S bond 
fragmentation along with C-O cleavage producing a 1,2-diradical. Only the endo-isomer 
produces product 5a-2, because in this case the oxygen radical is properly positioned to 
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react with the double bond. The thiol, which is formed after H-migration, further oxidizes 
either on the column or during the photolysis yielding disulfide 5a-2 (Scheme 42), the 
structure of which was confirmed by X-ray crystallography (see Appendix D).  
To better understand the mechanism and further explore the synthetic ability of 
this reaction we synthesized exo-S,S-dioxides 3 (see Experimental Section – Part II, page 
136-137) [45] and irradiated them with an appropriate UV source (Scheme 43).  
 
Scheme 43. Preparation of S,S-dioxide exo-3a and its photolysis.  
We found that in these cases a double bond was formed instead of a thiirane ring 
due to the extrusion of sulfur dioxide upon photolysis of product exo-3a. A plausible 
mechanism for this transformation is shown in Scheme 43. 
It should be mentioned that D.-A. adducts 4 containing 2-oxa-3-
azabicyclo[2.2.n]alk-5-ene framework [45] undergo rearrangement upon irradiation 
similar to exo-2a (Scheme 44) producing compound 7b-1. Although the irradiation of 3-
benzoyl-2-oxa-3-azabicyclo[2.2.2]oct-5-ene also resulted in the formation of amide 7b-2, 
which was not observed in previous cases, this rearrangement most likely occurs via 
homolytic N-O bond fragmentation followed by an intramolecular H-abstraction yielding 
7b-2 (Scheme 44).  
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Scheme 44. A plausible mechanism for the formation of amide 7b-2. 
In conclusion, we discovered that although both exo- and endo-Sulfa-D.-A. 
adducts do not undergo [2+2] cycloaddition, they are, nonetheless, photochemically 
active. Various products with defined stereochemistry can be produced upon photolysis.  
E. Experimental section – Part II. 
1. Preparation of the Bunte salts (1): 
Bromoacetophenone or 2-bromopropiophenone (1.0 eq) were dissolved in 10-50 
mL of MeOH. Sodium thiosulfate (1.2 eq) was added to the solution followed by a few 
milliliters of water. The resulting mixture was then refluxed overnight. MeOH and water 
were removed on a high vacuum pump to give the Bunte salt, which was used without 
further purification. 
 Sodium benzoylmethanethiosulfonate (1a): from 2.0 g of 
bromoacetophenone (0.010 mol) and 1.9 g of Na2S2O3 (0.012 mol). 1H NMR (400 MHz, 
CD3OD) δ = 8.05 (dd, J = 8.5, 1.3 Hz, 2H), 7.63 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.6 Hz, 
2H), 4.61 (s, 2H).  
 134 
 Sodium 1-benzoylethanethiosulfonate (1b): from 4 mL of 2-
bromopropiophenone (0.026 mol) and 5 g of Na2S2O3 (0.032 mol). 1H NMR (400 MHz, 
CD3OD) δ = 8.16 (d, J = 7.3 Hz, 2H), 7.61 (t, J = 7.4 Hz, 1H), 7.50 (t, J = 7.7 Hz, 2H), 
5.14 (q, J = 6.8 Hz, 1H), 1.70 (d, J = 6.8 Hz, 3H).  
2. Preparation of the Diels-Alder adducts (2): 
Triethylamine (10.0 eq) was added slowly with stirring to Bunte salt 1 (1.0 eq) in 
methanol containing cyclopentadiene (5.0 eq) and calcium chloride (1.0 eq) at room 
temperature. After 24 h, the mixture was acidified and extracted with DCM. The extract, 
after being freed from salts by washing successively with dilute hydrochloric acid, dilute 
sodium hydroxide, and water, contained the endo- and exo-adducts, which were separated 
by silica gel chromatography (eluted with hexane/EtOAc = 60:1→40:1) [44]. 
 exo-3-Benzoyl-2-thiabicyclo[2.2.1]hept-5-ene (exo-2a): from 5.5 mL of 
Et3N (39.46 mmol), 1.3 g of freshly distilled cyclopentadiene (19.67 mmol), 0.48 g of 
CaCl2 (4.33 mmol) and 1.0 g of 1a (3.93 mmol) (hexane/EtOAc gradient 60:1→40:1): 
before column purification - a mixture of exo- and endo-isomers by NMR, 58% and 42% 
respectively (mostly exo-adduct was recovered after the column). 1H NMR (400 MHz, 
CDCl3) δ = 7.95 (d, J = 7.3 Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.6 Hz, 2H), 
6.47 (dd, J = 5.5, 2.8 Hz, 1H), 6.09 (dd, J = 5.5, 3.2 Hz, 1H), 4.16 (m, 1H), 4.06 (m, 1H), 
3.67 (m, 1H), 1.89 (d, J = 9.5 Hz, 1H), 1.77 (ddd, J = 9.5, 2.2, 2.2 Hz, 1H). 13C NMR 
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(400 MHz, CDCl3) δ = 197.91, 138.79, 137.30, 133.48 overlaps with 133.47, 128.80, 
128.45, 53.12, 52.43, 49.50, 46.71. 
S
PhO
 endo-3-Benzoyl-2-thiabicyclo[2.2.1]hept-5-ene (endo-2a): 1H NMR (400 
MHz, CDCl3) δ = 7.94 (m, 2H), 7.55 (m, 1H), 7.45 (m, 2H), 6.38 (dd, J = 5.5, 2.9 Hz, 
1H), 6.15 (dd, J = 5.5, 3.0 Hz, 1H), 5.12 (d, J = 3.5 Hz, 1H), 4.08 (m, 1H), 3.79 (m, 1H), 
1.79 (m, 2H).  
 exo-3-Benzoyl-endo-3-methyl-2-thiabicyclo[2.2.1]hept-5-ene (exo-2b): 
from 5.5 mL of Et3N (39.46 mmol), 1.3 g of freshly distilled cyclopentadiene (19.67 
mmol), 0.48 g of CaCl2 (4.33 mmol) and 1.0 g of 1b (3.93 mmol) (hexane/EtOAc 
gradient 60:1→40:1): a mixture of exo- and endo-isomers by NMR, 66% and 34% 
respectively. 1H NMR (500 MHz, CDCl3) δ = 7.98 (m, 2H), 7.51 (m, 1H), 7.43 (m, 2H), 
6.58 (d, J = 5.5, 2.8 Hz, 1H), 6.07 (d, J = 5.5, 3.3 Hz, 1H), 4.08 (m, 1H), 3.88 (m, 1H), 
1.79 (ddd, J = 9.6, 2.3, 2.3 Hz, 1H), 1.74 (d, J = 9.6 Hz, 1H), 1.59 (s, 3H).  
S
PhO
 endo-3-Benzoyl-exo-3-methyl-2-thiabicyclo[2.2.1]hept-5-ene (endo-2b): 
All the attempts to obtain pure endo-2b failed. 1H NMR (500 MHz, CDCl3) δ = 7.90 (m, 
2H), 7.50 (m, 1H), 7.40 (m, 2H), 6.26 (d, J = 5.4, 2.8 Hz, 1H), 6.20 (d, J = 5.4, 3.1 Hz, 
1H), 4.07 (m, 1H), 3.52 (m, 1H), 2.02 (s, 3H), 1.98 (d, J = 9.5 Hz, 1H), 1.75 (ddd, J = 
9.5, 2.3, 2.3 Hz, 1H). 
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3. Preparation of the [SO2]-based adducts (3): 
A solution of MCPBA (2.1 eq, 77% max) in DCM was added to a stirring 
solution of exo-adduct 2 (1.0 eq) in DCM at -78OC, which was allowed to cool to room 
temperature overnight. The solution was washed with sat. solution of NaHCO3, brine and 
extracted with DCM, then dried over Na2SO4, filtered, and concentrated in vacuo, 
affording pure product as a pale yellow solid [45]. 
 exo-3-Benzoyl-2,2-dioxo-2-thiabicyclo[2.2.1]hept-5-ene (exo-3-benzoyl-
2-thiabicyclo[2.2.1]hept-5-ene S,S-dioxide) (exo-3a): from 0.79 g of MCPBA (77%) 
(3.53 mmol) and 0.34 g of exo-2a (1.57 mmol): 0.38 g (97%). 1H NMR (500 MHz, 
CDCl3) δ = 8.05 (d, J = 7.4 Hz, 2H), 7.64 (t, J = 7.4 Hz, 1H), 7.53 (t, J = 7.8 Hz, 2H), 
6.67 (dd, J = 5.6, 2.8 Hz, 1H), 6.47 (dd, J = 5.6, 3.1 Hz, 1H), 4.22 (d, J = 2.5 Hz, 1H), 
3.99 (m, 1H), 3.71 (m, 1H), 2.83 (d, J = 11.6 Hz, 1H), 2.47 (dddd, J = 11.6, 2.7, 2.7, 2.7 
Hz, 1H). 13C NMR (500 MHz, CDCl3) δ = 191.08, 141.99, 136.54, 134.30, 131.68, 
129.06, 128.68, 66.27, 59.44, 44.39, 44.17. 
SO2
PhO
 endo-3-Benzoyl-2,2-dioxo-2-thiabicyclo[2.2.1]hept-5-ene (endo-3a): All the 
attempts to obtain pure endo-3a failed. 
exo-3-Benzoyl-endo-3-methyl-2,2-dioxo-2-thiabicyclo[2.2.1]hept-5-ene 
(exo-3b): from 0.82 g of MCPBA (77%) (3.66 mmol) and 0.40 g of exo-2b (1.74 mmol): 
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0.45 g (99%). 1H NMR (500 MHz, CDCl3) δ = 7.96 (m, 2H), 7.56 (m, 1H), 7.48 (m, 2H), 
6.60 (dd, J = 5.7, 3.0 Hz, 1H), 6.41 (dd, J = 5.7, 3.2 Hz, 1H), 4.03 (m, 1H), 3.79 (m, 1H), 
2.61 (d, J = 11.6 Hz, 1H), 2.41 (ddd, J = 11.6, 3.4, 2.3 Hz, 1H), 1.63 (s, 3H). 13C NMR 
(500 MHz, CDCl3) δ = 195.32, 140.77, 134.37, 133.21, 131.53, 130.07, 128.40, 67.53, 
64.52, 49.88, 43.38, 23.22. 
SO2
PhO
 endo-3-Benzoyl-exo-3-methyl-2,2-dioxo-2-thiabicyclo[2.2.1]hept-5-ene 
(endo-3b): All the attempts to obtain pure endo-3b failed. 
4. Preparation of the [NO]-based adducts (4): 
Benzhydroxamic acid (N-hydroxybenzamide) (1.0 eq) was dissolved in i-
PrOH/H2O (acetone/H2O) mixture, cyclopentadiene (cyclohexadiene) was added 
dropwise (2.0-5.0 eq) followed by sodium periodate (1.1 eq). The resulting mixture was 
kept overnight at room temperature. After the reaction was completed, the mixture was 
washed with sat. solution of NaHCO3 and extracted with DCM. Organic solvent was 
removed under vacuum [46]. 
N
O
O
Ph
 3-Benzoyl-2-oxa-3-azabicyclo[2.2.1]hept-5-ene (4a): from 0.5 g of 
benzhydroxamic acid (3.65 mmol), 1.5 mL of cyclopentadiene (17.84 mmol) and 0.86 g 
of NaIO4 (4.02 mmol). 1H NMR (400 MHz, CDCl3) δ = 7.76 (d, J = 7.4 Hz, 2H), 7.48 (t, 
J = 7.4 Hz, 1H), 7.40 (t, J = 7.5 Hz, 2H), 6.51 (br. m, 1H), 6.38 (m, 1H), 5.34 (m, 1H) 
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overlaps with 5.30 (br. m, 1H), 2.13 (ddd, J = 8.7, 1.9, 1.9 Hz, 1H), 1.85 (d, J = 8.7 Hz, 
1H).  
 3-Benzoyl-2-oxa-3-azabicyclo[2.2.2]oct-5-ene (4b): from 0.5 g of 
benzhydroxamic acid (3.65 mmol), 1.0 mL of cyclopentadiene (10.50 mmol) and 0.86 g 
of NaIO4 (4.02 mmol). 1H NMR (400 MHz, CDCl3) δ = 7.65 (m, 2H), 7.44-7.36 (m, 3H), 
6.65 (br, m, 1H) overlaps with 6.55 (m, 1H), 4.81 (br. m, 1H), 2.31 (br. m, 1H) overlaps 
with 2.24 (m, 2H), 1.62-1.48 (m, 2H).  
5. Photolysis (5, 6, and 7): 
Approximately 0.01-0.1 M solution of a precursor 2 or 3 in benzene (or DCM) 
was irradiated in Pyrex vials in a Rayonet reactor equipped with RPR-3500 UV lamps 
(broadband 300-400 nm UV source with peak emission at 350 nm) or a UVLED-based 
illuminator with five 250 mW @ 365 nm Nichia chips. The products were separated by 
silica gel chromatography (eluted with hexane/EtOAc = 40:1→30:1). 
 1R(S), 2S(R), 4R(S), 6R(S), 7R(S)-7-Benzoyl-3-
thiatribicyclo[4.1.0.02,4]heptane (5a-1): quantitative conversion from exo-2a and ~ 29% 
conversion from endo-2a by NMR. 1H NMR (400 MHz, CDCl3) δ = 7.98 (m, 2H), 7.57 
(m, 1H), 7.47 (m, 2H), 3.77 (dd, J = 5.5, 4.2 Hz, 1H), 3.58 (ddd, J = 5.3, 2.2, 2.2 Hz, 
1H), 3.19 (dd, J = 2.9, 2.9 Hz, 1H), 2.52-2.44 (m, 2H), 2.41 (m, 1H), 2.12-2.07 (m, 1H). 
13C NMR (400 MHz, CDCl3) δ = 197.41, 137.31, 132.96, 128.53, 128.20, 46.20, 44.05, 
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37.49, 34.32, 31.48, 31.02. HRMS (ESI) calcd for C13H12NaOS+ (MNa+) 239.0501, found 
239.0490. 
 1S(R), 5R(S)-Di(3-phenyl-2-oxabicyclo[3.3.0]octa-3,7-diene-4-
yl)disulfide (5a-2): ~ 29% conversion by NMR from endo-2a with 29% of 5a-1, 16% of 
the unknown compound (possibly thiol) and 26% of the remaining endo-2a. 1H NMR 
(400 MHz, CDCl3) δ = 7.77 (m, 2H), 7.40-7.36 (m, 3H), 5.95 (dddd, J = 5.7, 2.3, 2.3, 1.1 
Hz, 1H), 5.62 (dddd, J = 5.7, 2.1, 2.1, 2.1 Hz, 1H), 4.54 (m, 1H), 3.07 (ddd, J = 9.1, 6.4, 
3.4 Hz, 1H), 2.52 (m, 2H). 13C NMR (400 MHz, CDCl3) δ = 160.44, 135.70, 129.96, 
129.26, 128.93, 128.19, 127.60, 104.54, 89.58, 46.28, 39.44. HRMS (ESI) calcd for 
C13H12NaOS+ (MNa+) 239.0501, found 239.0507. 
1R(S), 5S(R), 6R(S)-6-Benzylbicyclo[3.1.0]hex-2-ene (6a): All the 
attempts to obtain pure 6a failed, max 67% conversion (in 2 hours of irradiation by 
NMR). 1H NMR (500 MHz, CDCl3) δ = 7.95 (m, 2H), 7.55 (m, 1H), 7.46 (m, 2H), 6.05 
(dddd, J = 5.8, 2.0, 2.0, 2.0 Hz, 1H), 5.68 (m, 1H), 2.79 (dddd, J = 19.0, 6.4, 2.2, 2.2 Hz, 
1H), 2.68 (dddd, J = 6.4, 2.2, 2.2, 2.2 Hz, 1H), 2.56 (dddd, J = 19.0, 2.3, 2.3, 2.3 Hz, 
1H), 2.50 (ddd, J = 6.4, 6.4, 3.2 Hz, 1H), 2.02 (t, J = 2.7 Hz, 1H). 1H NMR (500 MHz, 
C6D6) δ = 7.89 (m, 2H), 7.13 (m, 1H), 7.06 (m, 2H), 5.76 (m, 1H), 5.35 (m, 1H), 2.71 
(dddd, J = 6.3, 2.2, 2.2, 2.2 Hz, 1H), 2.48 (ddd, J = 6.4, 6.4, 3.0 Hz, 1H), 2.39 (dddd, J = 
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18.8, 6.5, 2.2, 2.2 Hz, 1H), 2.14 (dddd, J = 18.8, 2.3, 2.3, 2.3 Hz, 1H), 1.84 (t, J = 2.7 
Hz, 1H).  
1R(S), 5S(R), 6R(S)-6-Benzyl-6-methylbicyclo[3.1.0]hex-2-ene (6b): All 
the attempts to obtain pure 6b failed, max 64% conversion (in 30 min by NMR). The 
product is photochemically unstable and disappears in a 1.5 hours. 
 1S(R), 2S(R), 4R(S), 6S(R)-7-Benzoyl-3-oxa-7-
azatricyclo[4.1.0.02,4]heptane (7a): eluted with hexane/EtOH = 20:1→5:1 (< 25% by 
NMR after 48 h of irradiation). 1H NMR (400 MHz, CDCl3) δ = 7.99 (m, 2H), 7.54 (m, 
1H), 7.45 (m, 2H), 3.79 (q, J = 2.7 Hz, 1H), 3.70 (dd, J = 2.1, 2.1 Hz, 1H), 3.50 (ddd, J 
= 4.6, 4.6, 2.6 Hz, 1H), 3.37 (dd, J = 4.5, 1.7 Hz, 1H), 2.42 (d, J = 15.9 Hz, 1H), 1.83 
(ddd, J = 15.9, 4.8, 3.0 Hz, 1H). 13C NMR (400 MHz, CDCl3) δ = 176.84, 133.28, 
132.51, 128.73, 128.41, 67.38, 53.36, 49.03, 40.99, 26.82. 
1S(R), 2S(R), 4R(S), 7S(R)-8-Benzoyl-3-oxa-8-
azatricyclo[5.1.0.02,4]octane (7b-1): eluted with hexane/EtOH = 20:1→10:1 (< 36% by 
NMR after 48 h of irradiation). 1H NMR (400 MHz, CDCl3) δ = 8.06 (m, 2H), 7.56 (m, 
1H), 7.46 (m, 2H), 3.49 (dd, J = 4.2, 3.2 Hz, 1H), 3.18 (ddd, J = 4.2, 2.6, 2.6 Hz, 1H), 
2.98 (dd, J = 6.2, 3.3 Hz, 1H), 2.68 (m, 1H), 1.95-1.89 (m, 4H).  
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4-Benzoylaminocyclohex-2-en-1-one (7b-2): eluted with hexane/EtOH = 
20:1→10:1 (~ 10% by NMR after 48 h of irradiation). 1H NMR (400 MHz, CDCl3) δ = 
7.80 (d, J = 6.9 Hz, 2H), 7.54 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.7 Hz, 2H), 6.90 (ddd, J = 
10.2, 2.6, 1.6 Hz, 1H), 6.35 (br. d, J = 7.8 Hz, NH), 6.08 (ddd, J = 10.2, 2.4, 0.8 Hz, 1H), 
5.10 (ddddd, J = 9.9, 8.3, 5.0, 2.5, 2.5 Hz, 1H), 2.61 (dddd, J = 16.9, 4.9, 4.9, 0.8 Hz, 
1H) overlaps with 2.53 (ddd, J = 16.9, 12.2, 4.7 Hz, 1H), 2.44 (ddddd, J = 12.7, 4.7, 4.7, 
4.7, 1.6 Hz, 1H), 2.03 (dddd, J = 12.8, 12.2, 10.0, 4.9 Hz, 1H). 13C NMR (400 MHz, 
CDCl3) δ = 198.03, 167.08, 150.52, 133.76, 131.97, 130.54, 128.73, 126.98, 46.24, 
36.24, 29.98.  
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Chapter Six: Direct screening of solution phase 
combinatorial libraries 
A. Introduction. 
So far the synthetic application of photochemistry has been illustrated. In 
addition, “light” can be used also for screening of libraries. 
High-throughput combinatorial chemistry is critical in modern drug discovery. 
Most massive high-throughput synthesis is achieved via the split-and-mix synthesis of 
libraries immobilized on polymeric support or beads [47]. Such one-bead/one-compound 
libraries are tested for the binding of biological targets through fluorescence-guided 
mechanical isolation of the beads. On the contrary, solution phase combinatorial 
chemistry holds even greater promise, as it is compatible with both divergent and 
convergent multistep synthesis, and not restricted to linear synthesis [48]. Its vast 
potential has not been fully recognized yet, due to the complexity of solution mixtures for 
binding. Although some deconvolution methods [49] have been developed to synthesize 
and screen soluble sub-libraries, all of them are time consuming, expensive and require 
multiple synthetic steps.  
With collaboration of Dr. Rudresha Kottani, we have developed a technique for 
direct screening of solution phase libraries outfitted with photolabile tags [50]. 
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B. Results and discussion.  
The concept was based on 2-alkyl-1,3-dithiane adducts of carbonyl compounds, 
which were capable of efficient photo-assisted cleavage. This can happen only in the 
presence of an external electron transfer sensitizer (ETS) [Appendix E, 5-7, 9]. Central to 
this approach is the concept involving binary molecular systems in which the sensitizer 
and the 2-alkyl-1,3-dithiane-based photocleavable moiety are tethered to the particular 
components of a host - guest molecular recognition pair [51]. In such pairs, photoassisted 
fragmentation is dependent on a molecular recognition event, which makes the system 
photolabile. This model has been developed into a methodology for screening of either 
unsupported encoded libraries or encoded libraries immobilized on nanosized carriers. 
Scheme 45 gives a general sketch for screening the micelle-solubilized library of ligands 
L, encoded with tags T. The receptor R is outfitted with an ETS, which is shown in 
Scheme 45 as S.  
 
Scheme 45. The concept of a methodology for screening of encoded libraries. 
 144 
Receptor R is incubated with the library of interest (A). The host - guest binding 
brings sensitizer S into the proximity of the adduct (B), which activates the release of 
dithiane tags upon irradiation (C-D). The main idea is to encode individual molecules. 
The n-th library member Ln can be encoded with a set of tags {T}m, for example, T1, T2, 
and T3. One portion of Ln molecules is encoded with T1, another portion is encoded with 
T2, and the last one is encoded with T3. This leads to the fact that Ln is present in the 
solution as three subpopulations: Ln–tether–T1, Ln–tether–T2, and Ln–tether–T3. All of the 
tags encoding individual molecules of the bound ligand are released into the solution 
upon irradiation, revealing the nature of the compound of interest. 
The tags should (a) be detectable at very low concentrations by standard 
analytical techniques; (b) not contain any functionality involved in biological 
interactions; (c) compatible with the synthetic steps; (d) be easy to separate from the 
aqueous environment; and (e) be available via a simple synthetic methodology. We found 
that 2-alkyl-1,3-dithianes meet those requirements and can be used for encoding in a 
binary fashion, where 1 indicates that free dithiane is present in the solution and 0 
indicates that no dithiane is found. 
We discovered that dithianes are especially appropriate for subpicomolar 
detection by GCMS. A better than 10:1 signal-to-noise ratio is achieved at a level of 500 
femtomoles of alkyl dithianes per injection. The adducts of 2-alkyl-1,3-dithianes and 4-
formylbenzoic acid were selected as a tagging unit because they add easily to aromatic 
aldehydes and the carboxylate acts as a handle to tie the tag to a ligand. A series of N-
hydroxysuccinimide esters 3 were prepared as demonstrated in Scheme 46A [50]. 
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Scheme 46. (A) Synthesis of N-hydroxysuccinimide esters 3. (B-D) Synthesis of 
a model minilibrary containing three members [50]. 
To prove the theory, we selected a model host-guest system, based on biotin-
avidin interaction, and synthesized a minilibrary of three members (Scheme 46B-D). 
Each compound was encoded with a set of three dithiane tags: carboxylates 4 were 
encoded with 2-pentyl, 2-heptyl and 2-octyl dithianes, sugars 6 (ethyl-, propyl-, and 
butyl), and biotins 10 (methyl-, hexyl-, and nonyl). 
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The receptor, avidin, was equipped with xanthone as an ETS [50]. The degree of 
immobilization was quantified by UV spectroscopy to be 0.77, indicating that each 
tetramer of avidin was carrying approximately three tethered molecules of xanthone 
carboxylates. A micellar detergent, dodecyl phosphocholine (DPC), was used preventing 
collisional quenching of avidin-tethered xanthone by unbound molecules. 
Approximately 0.5 mg per tagged compound was solubilized in a 0.6 mL aqueous 
solution containing 60 mg of DPC. To this clear, micellar solution, 0.5 mL of avidin - 
xanthone conjugate was added, so the final concentrations were 0.7 mM of each library 
member carrying one tag, 23 µM of protein, and 155 mM of DPC. The resulting micellar 
solution was incubated in an orbital shaker for 1 h, purged with argon for 45 min, and 
irradiated for 4 h by using a 335-nm filter. Then the mixture was extracted with 0.5 mL 
of hexane, concentrated to 100 µL and analyzed by GCMS (Figure 17):  
 
Figure 17. (A) The trace encoding biotin in binary 100100001 obtained after 
irradiation. (B) The trace for all nine alkyl dithianes at 1 pmol per injection [50]. 
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It is clearly shown that only the biotin-encoding tags (methyl-, hexyl-, and nonyl-
dithianes, binary 100100001, read from left to right), were identified in the 
chromatogram. The other six dithiane tags encoding glucosamine and aminoundecanoic 
acid were not apparent. 
The quantum yield of alkyldithiane photo-release from ketone adducts increases 
in increments of 2 - 3% in a homologous series, leveling off for the higher alkyls [52].  
The generality of this methodology is not restricted to the assemblies based on 
dithiane - aldehyde adducts. In general, any externally sensitized fragmentation reaction 
can be used in such binding assays. We obtained similar results with different tags 
containing thio-ortho-esters [53]. The model minilibrary was tagged with nine thio-ortho-
esters, three tags per library member (see Figure 18). The DPC micellar solution of the 
library was incubated with the avidin-xanthone conjugate, irradiated and extracted with 
hexane. The GCMS trace again showed only the dithianes encoding biotin. None of the 
other six dithianes were detected in the hexane extract after irradiation. 
 
Figure 18. Thio-ortho-esters-encoded biotin [50]. 
In conclusion, we developed an approach to encoding and screening of solution 
phase libraries based on the photorelease of externally sensitized photolabile tags. The 
encoding tags can be released into solution only when a binding event occurs between the 
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ligand and the receptor, equipped with an ETS. The released tags are analyzed in solution 
revealing the identity of the lead ligand or narrowing the range of potential leads. 
C. Experimental section. 
Common reagents were purchased from Sigma-Aldrich and used without further 
purification. THF was refluxed over and distilled from potassium benzophenone ketyl 
before use. 1H and 13C NMR spectra were recorded at 25°C on a Varian Mercury 400 
MHz instrument, in CDCl3, DMSO-d6, or CD3OD using TMS as an internal standard. 
Column chromatography was performed on silica gel, 70-230 mesh. The UV-visible 
spectra were recorded on a Beckman DU-640 spectrophotometer. Irradiations were 
carried out in a carousel Rayonet photo reactor equipped with RPR-3500 UV lamps (300- 
to 400-nm spectral distribution of irradiance density with a maximum at 350 nm) and a 
335-nm long-pass solution filter. Gas chromatography was performed on a Varian Saturn 
2100 T Ion-Trap instrument with electron ionization. Selective ion monitoring (m/z 119, 
74) was used to detect dithiane tags after fragmentation (for more details see supporting 
information [50] and [53]). 
1. Preparation of 2-alkyl-1,3-dithianes (1): 
To a solution of substituted aldehyde (66.9 mmol) and 1, 3-propanedithiol (66.9 
mmol) in methylene chloride (300 mL) was added BF3·Et2O (0.268 mol) and the 
resulting solution was stirred for 12 h at 25oC. The reaction mixture was washed with 
NaOH (2 x 200 mL, 5% aq. soln) and H2O (300 mL). The organic layer was dried over 
anhydrous Na2SO4 and the solvent was removed under vacuum and dried to obtain the 
desired compound. 
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 (1b): 91% Yield. 1H NMR (CDCl3, 400 MHz): δ = 4.01 (t, J = 6.79 Hz, 1H), 
2.92-2.81 (m, 4H), 2.18-2.09 (m, 1H), 1.91-1.76 (m, 3H), 1.10 (t, J = 7.44 Hz, 3H). 
 (1c): 87% Yield. 1H NMR (CDCl3, 400 MHz): δ = 4.08 (t, J = 6.93 Hz, 
1H), 2.92-2.79 (m, 4H), 2.15-2.08 (m, 1H), 1.91-1.80 (m, 1H), 1.75-1.70 (m, 2H), 1.57-
1.48 (m, 2H), 0.95 (t, J = 7.32 Hz, 3H); 
 (1d): 82% Yield. 1H NMR (CDCl3, 400 MHz): δ = 4.06 (t, J = 6.90 Hz, 
1H), 2.92-2.79 (m, 4H), 2.15-2.08 (m, 1H), 1.91-1.81 (m, 1H), 1.78-1.72 (m, 2H), 1.52-
1.45 (m, 2H), 1.38-1.29 (m, 2H), 0.92 (t, J = 7.29 Hz, 3H). 
 (1e): 94% Yield. 1H NMR (CDCl3, 400 MHz): δ = 4.03 (t, J = 6.90 
Hz, 1H), 2.92-2.79 (m, 4H), 2.15-2.08 (m, 1H), 1.92-1.80 (m, 1H), 1.77-1.71 (m, 2H), 
1.56-1.47 (m, 2H), 1.36-1.26 (m, 4H), 0.91 (t, J = 6.95 Hz, 3H). 
 (1f): 86% Yield. 1H NMR (CDCl3, 400 MHz): δ = 4.07 (t, J = 6.90 
Hz, 1H), 2.92-2.79 (m, 4H), 2.15-2.08 (m, 1H), 1.92-1.83 (m, 1H), 1.77-1.72 (m, 2H), 
1.54-1.46 (m, 2H), 1.34-1.24 (m, 6H), 0.90 (t, J = 6.79 Hz, 3H). 
 (1g): 91% Yield. 1H NMR (CDCl3, 400 MHz): δ = 4.06 (t, J = 
6.90 Hz, 1H), 2.91-2.78 (m, 4H), 2.14-2.07 (m, 1H), 1.91-1.80 (m, 1H), 1.76-1.71 (m, 
2H), 1.51-1.45 (m, 2H), 1.31-1.22 (m, 8H), 0.89 (t, J = 6.95 Hz, 3H). 
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 (1h): 93% Yield. 1H NMR (CDCl3, 400 MHz): δ = 4.05 (t, J 
= 6.89 Hz, 1H), 2.91-2.78 (m, 4H), 2.13-2.08 (m, 1H), 1.89-1.82 (m, 1H), 1.76-1.70 (m, 
2H), 1.52-1.45 (m, 2H), 1.30-1.23 (m, 10H), 0.88 (t, J = 6.82 Hz, 3H). 
 (1i): 90% Yield. 1H NMR (CDCl3, 400 MHz): δ = 4.06 (t, J 
= 6.89 Hz, 1H), 2.91-2.78 (m, 4H), 2.15-2.08 (m, 1H), 1.91-1.80 (m, 1H), 1.76-1.70 (m, 
2H), 1.52-1.47 (m, 2H), 1.32-1.22 (m, 12H), 0.89 (t, J = 6.88 Hz, 3H). 
2. Preparation of the Corey-Seebach adducts (2): 
n-BuLi (14.58 mL, 23.3 mmol, 1.6 M solution in THF) was added at -25oC to a 
solution of 2-alkyl-1,3-dithiane (23.3 mmol) in dry THF (40 mL) under nitrogen 
atmosphere. The resulting solution was stirred at this temperature for 2 h. The 
temperature was then reduced to -78oC and 4-formylbenzoic acid (0.5 g, 3.33 mmol) in 
20 mL of THF was added. After stirring at -78oC for an additional 2 hr, the solution was 
allowed to warm to room temperature. Saturated ammonium chloride (20 mL) was added, 
and the aqueous phase was extracted twice with 20 mL ethyl acetate. The aqueous layer 
was acidified with 5% HCl, extracted with ethyl acetate (100 mL), dried over Na2SO4 and 
the solvent was removed under vacuum. The crude product was crystallized from toluene 
to get pure compound. 
(2b): 96% Yield. 1H NMR (DMSO-d6, 400 MHz): δ = 7.85 (d, J 
= 8.34 Hz, 2H), 7.56 (d, J = 8.34 Hz, 2H), 5.68 (d, J = 4.50 Hz, 1H), 5.00 (d, J = 4.41 
 151 
Hz, 1H), 3.06-2.99 (m, 1H), 2.91-2.84(m, 1H), 2.70-2.58 (m, 2H), 1.85-1.76 (m, 2H), 
1.73-1.66 (m, 1H), 1.57-1.52 (m, 1H), 0.99 (t, J = 7.4 Hz, 3H). 13C NMR (DMSO-d6, 100 
MHz): δ = 168.00, 146.85, 130.24, 129.57, 128.49, 77.29, 58.95, 29.13, 26.46, 25.91, 
24.86, 9.81. 
(2c): 94% Yield. 1H NMR (DMSO-d6, 400 MHz): δ = 7.85 (d, J 
= 8.40 Hz, 2H), 7.55 (d, J = 8.28 Hz, 2H), 5.68 (d, J = 4.50 Hz, 1H), 5.01 (d, J = 4.50 
Hz, 1H), 3.06-3.03 (m, 1H), 2.90-2.87 (m, 1H), 2.68-2.59 (m, 2H), 1.84-1.83 (m, 1H), 
1.72-1.66 (m, 2H), 1.51-1.40 (m, 3H), 0.82 (t, J =  7.17 Hz, 3H); 13C NMR (DMSO-d6, 
100 MHz): δ = 168.01, 146.82, 130.25, 129.54, 128.52, 77.32, 58.37, 38.63, 26.64, 26.09, 
24.90, 18.16, 15.05. 
(2d): 92% Yield. 1H NMR (DMSO-d6, 400 MHz): δ = 7.85 (d, J 
= 8.32 Hz, 2H), 7.55 (d, J = 8.28 Hz, 2H), 5.68 (d, J = 4.48 Hz, 1H), 5.01 (d, J = 4.44 
Hz, 1H), 3.08-3.03 (m, 1H), 2.92-2.87 (m, 1H), 2.68-2.58 (m, 2H), 1.86-1.66 (m, 3H), 
1.49-1.40(m, 3H), 1.21-1.16 (m, 2H), 0.83 (t, J = 7.31Hz, 3H). 13C NMR (DMSO-d6, 
100 MHz): δ = 168.00, 146.86, 130.24, 129.55, 128.49, 77.33, 58.32, 36.11, 26.96, 26.62, 
26.08, 24.90, 23.31, 14.64. 
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3. Preparation of N-hydroxysuccinimide esters (3): 
A mixture of 4-[(2-alkyl-1,3-dithian-2-yl)(hydroxyl)methyl]benzoic acid (1.60 
mmol), N-hydroxysuccinimide (2.56 mmol) and EDC (2.08 mmol) was dissolved in 
THF:DCM (1:1.30 mL) and stirred for 24 h at room temperature. The solution was 
washed with 20 mL of water, 20 mL of saturated NaHCO3, followed by 10 mL of brine. 
Then the solution was dried over anhydrous Na2SO4 and the solvent was evaporated 
under vacuum to give the desired compound. 
 (3b): 94% Yield. 1H NMR (CDCl3, 400 MHz): δ = 8.07 (d, 
J = 8.41 Hz, 2H), 7.67 (d, J = 8.41 Hz, 2H), 5.21 (s, 1H), 3.46 (br. s, 1H), 3.19-3.12 (m, 
1H), 3.03-2.97 (m, 1H), 2.88-2.84 (m, 4H), 2.73-2.65 (m, 2H), 2.13-2.10 (m, 1H), 1.86-
1.77 (m, 2H), 1.24-1.17 (m, 1H), 1.02 (t, J = 7.41 Hz, 3H). 1H NMR (CD3OD, 400 
MHz): δ = 8.01 (d, J = 8.52 Hz, 2H), 7.72 (d, J = 8.39 Hz, 2H), 5.86 (d, J = 4.62 Hz, 
1H), 5.07 (d, J = 4.63Hz, 1H), 3.09-3.02 (m, 1H), 2.93-2.78 (m, 5H), 2.72-2.60 (m, 2H), 
1.86-1.81 (m, 2H), 1.73-1.67 (m, 1H), 1.58-1.53 (m, 1H), 1.00 (t, J = 7.36 Hz, 3H). 13C 
NMR (CD3OD, 100 MHz): δ = 171.04, 162.39, 149.95, 130.47, 129.19, 123.83, 76.88, 
58.91, 29.05, 26.40, 26.23, 25.90, 24.81, 9.78. 
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 (3c): 97% Yield. 1H NMR (CDCl3, 400 MHz): δ = 8.07 (d, 
J = 8.04 Hz, 2H), 7.67 (d, J = 8.08 Hz, 2H), 5.20 (s, 1H), 3.49(br.s, 1H), 3.19-3.13 (m, 
1H), 3.03-2.97 (m, 1H), 2.87-2.82 (m, 4H), 2.71-2.63 (m, 2H), 2.13-2.10 (m, 1H), 1.86-
1.67 (m, 2H), 1.53-1.50 (m, 2H), 1.13-1.06 (m, 1H), 0.82 (t, J = 7.16 Hz, 3H). 1H NMR 
(CD3OD, 400 MHz): δ = 8.02 (d, J = 8.30 Hz, 2H), 7.72 (d, J = 8.36 Hz, 2H), 5.85 (d, J 
= 4.53 Hz, 1H), 5.09 (d, J = 4.52 Hz, 1H), 3.11-3.06 (m, 1H), 2.97-2.80 (m, 5H), 2.78-
2.65 (m, 2H), 1.87-1.70 (m, 3H), 1.52-1.41 (m, 3H), 0.81 (t, J = 7.35 Hz, 3H); 13C NMR 
(CD3OD, 100 MHz): δ = 171.04, 162.39, 149.93, 130.44, 129.21, 123.83, 76.88, 58.32, 
38.48, 26.57, 26.23, 26.12, 26.06, 24.84, 18.14, 15.03. 
 (3d): 93% Yield. 1H NMR (CDCl3, 400 MHz): δ = 8.06 (d, 
J = 8.20 Hz, 2H), 7.66 (d, J = 8.20 Hz, 2H), 5.19 (s, 1H), 3.49 (br. s, 1H), 3.19-3.12 (m, 
1H), 3.02-2.96 (m, 1H), 2.86-2.81 (m, 4H), 2.71-2.62 (m, 2H), 2.13-2.09 (m, 1H), 1.85-
1.70 (m, 2H), 1.52-1.47 (m, 2H), 1.22-1.08 (m, 3H), 0.84 (t, J = 7.16 Hz, 3H); 1H NMR 
(CD3OD, 400 MHz): δ = 8.03 (d, J = 8.23 Hz, 2H), 7.72 (d, J = 8.38 Hz, 2H), 5.85 (d, J 
= 4.57 Hz, 1H), 5.09 (d, J = 4.60 Hz, 1H), 3.11-3.05 (m, 1H), 2.95-2.78 (m, 5H), 2.68-
2.60 (m, 2H), 1.88-1.67 (m, 3H), 1.50-1.41 (m, 3H), 1.23-1.17 (m, 2H), 0.84 (t, J =  7.30 
Hz, 3H); 13C NMR (CD3OD, 100 MHz): δ = 171.04, 162.39, 149.95, 130.45, 129.19, 
123.83, 76.91, 58.29, 36.00, 26.94, 26.58, 26.23, 26.06, 24.85, 23.28, 14.65. 
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4. Preparation of sugar-based compounds (5 and 6): 
To a mixture of 4-aminobutyric acid (1.70 mmol) and 1-({4-[2-alkyl-1,3-dithian-
2-yl)(hydroxyl)methyl]benzoyl}oxy)pyrollidine-2,5-dione (1.13 mmol) in DMF (15 mL) 
was added triethylamine (2 mL) and a catalytic amount of DMAP. The resulting solution 
was stirred at 100ºC for 12 h. This mixture was poured onto crushed ice and acidified 
with 5% HCl solution. This mixture was extracted with ethyl acetate (100 mL) and the 
organic layer was washed with water, dried over Na2SO4 and the solvent was evaporated 
to get the desired compound. 
 (5b): 91% Yield. 1H NMR (CDCl3, 400 MHz): δ = 7.70 
(d, J = 8.44 Hz, 2H), 7.55 (d, J = 8.26 Hz, 2H), 6.80 (brt, J = 5.71 Hz, 1H), 5.17 (s, 1H), 
3.51 (q, J = 12.60, 6.46 Hz, Hz, 2H), 3.18-3.11 (m, 1H), 3.03-2.96 (m, 1H), 2.73-2.64 (m, 
2H), 2.46 (t, J = 6.85 Hz, 2H), 2.12-2.09 (m, 1H), 1.96-1.79 (m, 4H), 1.32-1.23 (m, 2H), 
1.03 (t, J = 7.43 Hz , 3H). 1H NMR (CD3OD, 400 MHz): δ = 7.75 (d, J = 8.40 Hz, 2H), 
7.62 (d, J = 8.27 Hz, 2H), 5.12 (s, 1H), 3.43 (t, J = 6.94 Hz, 2H), 3.06-3.02 (m, 1H), 
2.90-2.85 (m, 1H), 2.69-2.60 (m, 2H), 2.40 (t, J = 7.35 Hz, 2H), 1.95-1.87 (m, 4H), 1.79-
1.75 (m, 1H), 1.54-1.49 (m, 1H), 1.05 (t, J = 7.40 Hz, 3H). 13C NMR (CD3OD, 100 
MHz): δ = 175.88, 169.04, 143.98, 133.58, 129.03, 125.81, 76.08, 58.55, 39.29, 31.26, 
28.70, 26.26, 25.45, 24.70, 24.42, 8.37. 
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 (5c): 95% Yield. 1H NMR (CDCl3, 400 MHz): δ = 7.70 
(d, J = 8.14 Hz, 2H), 7.49 (d, J = 8.16 Hz, 2H), 7.15 (br. t, J = 5.25 Hz, 1H), 5.11 (s, 
1H), 3.40 (q, J = 12.04, 5.95 Hz, 2H), 3.13-3.06 (m, 1H), 2.96-2.90 (m, 1H), 2.66-2.53 
(m, 2H), 2.38 (t, J = 6.79 Hz, 2H), 2.10-1.97 (m, 1H), 1.86-1.67 (m, 4H), 1.54-1.39 (m, 
2H), 1.22-1.13 (m, 2H), 0.85 (t, J = 7.23 Hz , 3H). 1H NMR (CD3OD, 400 MHz): δ = 
7.75 (d, J = 8.39 Hz, 2H), 7.62 (d, J = 8.28 Hz, 2H), 5.13 (s, 1H), 3.43 (t, J = 6.94 Hz, 
2H), 3.12-3.05 (m, 1H), 2.95-2.89 (m, 1H), 2.67-2.59 (m, 2H), 2.40 (t, J = 7.35 Hz, 2H), 
2.00-1.76 (m, 5H), 1.62-1.53 (m, 2H), 1.42-1.34 (m, 1H), 1.27 (t, J = 7.31 Hz, 3H). 13C 
NMR (CD3OD, 100 MHz): δ = 175.89, 169.07, 143.97, 133.62, 129.01, 125.82, 76.08, 
57.90, 39.28, 38.27, 31.26, 26.41, 25.60, 24.70, 24.45, 17.67, 13.70. 
 (5d): 97% Yield. 1H NMR (CDCl3, 400 MHz): δ = 7.76 
(d, J = 8.20 Hz, 2H), 7.55 (d, J = 8.26 Hz, 2H), 7.10 (br. t, J = 5.42 Hz, 1H), 5.12 (s, 
1H), 3.42 (q, J = 12.50, 5.90 Hz, 2H), 3.13-3.04 (m, 1H), 2.97-2.91 (m, 1H), 2.67-2.56 
(m, 2H), 2.39 (t, J = 6.76 Hz, 2H), 2.07-1.98 (m, 1H), 1.86-1.66 (m, 4H), 1.54-1.38 (m, 
2H), 1.28-1.08 (m, 4H), 0.82 (t, J = 7.21 Hz , 3H). 1H NMR (CD3OD, 400 MHz): δ = 
7.75 (d, J = 8.41 Hz, 2H), 7.62 (d, J = 8.35 Hz, 2H), 5.14 (s, 1H), 3.43 (t, J = 6.96 Hz, 
2H), 3.12-3.05 (m, 1H), 2.96-2.89 (m, 1H), 2.68-2.58 (m, 2H), 2.40 (t, J = 7.36 Hz, 2H), 
1.98-1.75 (m, 5H), 1.61-1.48 (m, 2H), 1.45-1.37 (m, 1H), 1.27-1.18 (m, 2H), 0.88 (t, J = 
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7.34Hz, 3H). 13C NMR (CD3OD, 100 MHz): δ = 175.87, 169.04, 143.96, 133.60, 129.02, 
125.82, 76.05, 57.91, 39.29, 35.74, 31.26, 26.53, 26.44, 25.62, 24.70, 24.48, 23.10, 13.29. 
To a mixture of 5a (190 mg, 0.49 mmol), HBTU (206 mg, 0.54 mmol), and HOBt 
(73 mg, 0.54 mmol) in DMF (10 mL) was added DIPEA (0.2 mL, 1.08 mmol). The 
reaction mixture was then stirred for 5 min at ambient temperature. D-glucosamine 
hydrochloride (117 mg, 0.54 mmol) was dissolved in 1 mL DMSO, added to the above 
solution and stirred at room temperature for 12 h. The reaction mixture was poured into 
cold ether and allowed to settle down. The ether layer was decanted off and the brownish 
yellow material was washed with cold ether several times before drying. The product was 
purified by column chromatography using an eluent of 5% methanol in methylene 
chloride to give the desired compound. 
 (6b): 65% Yield. 1H NMR (CD3OD, 400 
MHz): δ = 7.77 (d, J = 8.46 Hz, 2H), 7.64 (d, J = 8.36 Hz, 2H), 5.12 (s, 1H), 5.10 (d, J = 
3.45 Hz, α-anomer), 4.61 (d, J = 8.4 Hz, β-anomer), 3.89-3.65 (m, 5H), 3.47-3.32 (m, 
3H), 3.11-3.04 (m, 1H), 2.94-2.87 (m, 1H), 2.71-2.61 (m, 2H), 2.36-2.32 (m, 2H), 2.00-
1.87 (m, 4H), 1.83-1.74 (m, 1H), 1.58-1.49 (m, 1H), 1.39-1.27 (m, 1H), 1.06 (t, J = 7.41 
Hz, 3H). 13C NMR (CD3OD, 100 MHz): δ = 174.85, 169.00, 144.09, 133.42, 129.03, 
125.87, 91.42, 76.07, 71.92, 71.53, 71.26, 61.59, 58.53, 54.67, 39.18, 33.06, 28.68, 26.25, 
25.56, 25.45, 24.42, 8.35. 
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 (6c): 62% Yield. 1H NMR (CD3OD, 400 
MHz): δ = 7.78 (d, J = 8.40 Hz, 2H), 7.63 (d, J = 8.32 Hz, 2H), 5.14 (s, 1H), 5.11 (d, J = 
3.40 Hz, α-anomer), 4.62 (d, J = 8.36 Hz, β-anomer), 3.86-3.63 (m, 5H), 3.48-3.32 (m, 
3H), 3.14-3.07 (m, 1H), 2.97-2.90 (m, 1H), 2.70-2.60 (m, 2H), 2.37-2.33 (m, 2H), 2.00-
1.88 (m, 3H), 1.85-1.78 (m, 2H), 1.64-1.51 (m, 2H), 1.38-1.32 (m, 2H), 0.86 (t, J = 7.32 
Hz, 3H). 13C NMR (CD3OD, 100 MHz): δ = 169.06, 144.08, 133.50, 128.98, 125.83, 
125.81, 91.40, 76.12, 71.91, 71.50, 71.28, 61.60, 57.83, 54.68, 39.11, 38.30, 33.03, 28.69, 
26.38, 25.57, 24.45, 17.62, 13.62. 
 (6d): 56% Yield. 1H NMR (CD3OD, 400 
MHz): δ = 7.77 (d, J = 8.45 Hz, 2H), 7.63 (d, J = 8.30 Hz, 2H), 5.14 (s, 1H), 5.11 (d, J = 
3.41 Hz, α-anomer), 4.61 (d, J = 8.31 Hz, β-anomer), 3.84-3.61 (m, 5H), 3.45-3.35 (m, 
3H), 3.14-3.05 (m, 1H), 2.97-2.90 (m, 1H), 2.69-2.58 (m, 2H), 2.36-2.32 (m, 2H), 2.00-
1.88 (m, 5H), 1.59-1.48 (m, 2H), 1.38-1.34 (m, 2H), 1.29-1.18 (m, 2H), 0.89 (t, J = 7.33 
Hz, 3H). 13C NMR (CD3OD, 100 MHz): δ = 174.74, 169.04, 144.04, 133.57, 128.98, 
125.79, 91.40, 76.13, 71.92, 71.46, 71.31, 61.63, 57.83, 54.71, 51.51, 39.12, 35.78, 33.13, 
26.49, 26.39, 25.59, 24.46, 23.06, 17.58, 13.18. 
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5. Preparation of thio-ortho-esters (14): 
 
n-BuLi (8.96 mL, 14.3 mmol, 1.6 M solution in THF) was added at 20ºC to a 
mixture of 2-alkyl-1,3-dithiane (14-17 mmol) in 50 mL of dry THF. The resulting 
solution was stirred at this temperature for 15 min. Monomethylterephthalate (516 mg, 
2.86 mmol) in THF (30 mL) was added to the generated dithiane anion and the solution 
was stirred overnight. Aqueous work-up included quenching with saturated NH4Cl (20 
mL) followed by extraction with ethyl acetate (3x50 mL). The organic layer was dried 
over Na2SO4 and the solvent was removed under vacuum. The crude product was purified 
by chromatography on a slurry-packed silica gel column using 10% EtOAc-hexane as 
eluent. 
 (14a): 85% Yield. 1H NMR (DMSO-d6, 400 MHz): δ = 8.52 (d, 
J = 8.58 Hz, 1H), 7.80 (s, 2H), 7.74 (d, J = 8.49 Hz, 1H), 5.29 (br. s, 1H), 2.84-2.77 (m, 
2H), 2.68-2.63 (m, 2H), 2.59-2.53 (m, 2H), 2.26-2.20 (m, 2H), 2.04 (s, 6H), 1.79-1.72 
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(m, 2H), 1.59-1.49 (m, 2H). 13C NMR (DMSO-d6, 100 MHz): δ = 168.10, 146.65, 
131.26, 130.62, 129.92, 127.47, 126.46, 86.95, 63.29, 28.85, 27.97, 26.48, 24.51. 
 (14b): 82% Yield. 1H NMR (CDCl3, 400 MHz): 
δ = 8.21 (d, J = 8.58 Hz, 2H), 8.62 (d, J = 8.62 Hz, 2H), 4.05 (t, J = 7.30 Hz, 1H), 3.28-
3.20 (m, 2H), 2.63-2.57 (m, 3H), 2.51-2.44 (m, 3H), 2.13-2.05 (m, 2H), 1.99-1.90 (m, 
3H), 1.82-1.73 (m, 3H), 1.11 (t, J = 7.38 Hz, 3H), 1.06 (t, J = 7.33 Hz, 3H). 13C NMR 
(CDCl3, 100 MHz): δ = 194.85, 170.59, 140.58, 132.97, 130.66, 128.74, 63.58, 49.35, 
36.07, 31.87, 28.89, 28.19, 27.53, 25.29, 23.34, 14.60, 12.24, 9.07. 
 (14d): 86% Yield. 1H NMR (CDCl3, 400 MHz): 
δ = 8.20 (d, J = 8.68 Hz, 2H), 8.08 (d, J = 8.75 Hz, 2H), 4.12 (t, J = 7.38 Hz, 1H), 3.29-
3.21 (m, 2H), 2.64-2.42 (m, 6H), 2.12-2.04 (m, 2H), 1.94-1.90 (m, 2H), 1.85-1.75 (m, 
4H), 1.63-1.55 (m, 2H), 1.40-1.29 (m, 6H), 0.93-0.89 (m, 6H). 13C NMR (CDCl3, 100 
MHz): δ = 194.83, 171.45, 140.48, 133.17, 130.63, 128.72, 62.82, 47.47, 42.91, 31.97, 
29.86, 29.82, 28.87, 28.25, 27.58, 26.47, 25.29, 22.92, 22.76, 14.21, 14.20, 14.15. 
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 (14e): 85% Yield. 1H NMR (CDCl3, 400 MHz): 
δ = 8.21 (d, J = 8.67 Hz, 2H), 8.08 (d, J = 8.70 Hz, 2H), 4.12 (t, J = 7.33 Hz, 1H), 3.29-
3.20 (m, 2H), 2.60-2.42 (m, 6H), 2.10-2.04 (m, 2H), 1.93-1.75 (m, 6H), 1.64-1.57 (m, 
2H), 1.38-1.21 (m, 10H), 0.90 (t, J = 7.07 Hz, 6H). 13C NMR (CDCl3, 100 MHz): δ = 
194.83, 171.57, 140.57, 133.00, 130.66, 128.73, 62.87, 47.52, 43.15, 31.98, 31.95, 31.81, 
30.11, 28.90, 28.27, 27.60, 27.59, 27.35, 25.29, 24.02, 22.72, 22.69, 14.26, 14.25. 
6. Preparation of N-hydroxysuccinimide thio-ortho-esters (15): 
A mixture of 14a (900 mg, 2.16 mmol), N-hydroxysuccinimide (398 mg, 3.46 
mmol) and EDC (539 mg, 2.81 mmol) was dissolved in DMF (30 mL) and stirred for 24 
h at room temperature. The solution was poured onto crushed ice and the solid was 
obtained by vacuum filtration, washed with water and dried to give pure 15a. 
 (15a): 96% Yield. 1H NMR (CDCl3, 400 MHz): δ = 8.36 
(dd, J = 8.53, 1.90 Hz, 1H), 8.12 (dq, J = 8.44, 1.94 Hz, 2H), 8.04 (dd, J = 8.52, 1.94 Hz, 
1H), 4.50 (s, 1H), 2.90-2.80 (m, 8H), 2.75-2.70 (m, 4H), 2.16 (s, 6H), 1.96-1.78 (m, 4H). 
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13C NMR (CDCl3, 100 MHz): δ = 169.53, 161.92, 147.43, 130.52, 130.08, 129.46, 
127.94, 124.45, 86.41, 63.41, 28.75, 27.94, 27.77, 25.92, 24.02. 
A mixture 14b (2.95 mmol), N-hydroxysuccinimide (4.72 mmol) and EDC (3.83 
mmol) was dissolved in CH2Cl2 (30 mL) and stirred for 24 h at room temperature. The 
solution was washed with 20 mL water, 20 mL of saturated NaHCO3, followed by 10 mL 
of brine. Then the solution was dried over anhydrous Na2SO4 and the solvent was 
evaporated in vacuum to give the desired compound. 
 (15b): 92% Yield. 1H NMR (CDCl3, 400 
MHz): δ = 8.23 (d, J = 8.74 Hz, 2H), 8.11 (d, J = 8.44 Hz, 2H), 4.02 (t, J = 7.36 Hz, 1H), 
3.27-3.19 (m, 2H), 2.92 (br. s, 4H), 2.62-2.38 (m, 6H), 2.12-2.05 (m, 2H), 2.00-1.74 (m, 
6H), 1.12 (t, J = 7.38 Hz, 3H), 1.06 (t, J = 7.33 Hz, 3H). 
 (15d): 93% Yield. 1H NMR (CDCl3, 400 
MHz): δ = 8.22 (d, J = 8.74 Hz, 2H), 8.10 (d, J = 8.77 Hz, 2H), 4.09 (t, J = 7.35 Hz, 1H), 
3.28-3.19 (m, 2H), 2.92 (br. s, 4H), 2.61-2.44 (m, 6H), 2.10-2.02 (m, 2H), 1.95-1.87 (m, 
2H), 1.85-1.72 (m, 4H), 1.62-1.54 (m, 2H), 1.38-1.24 (m, 6H), 0.92-0.88 (m, 6H). 13C 
NMR (CDCl3, 100 MHz): δ = 194.36, 169.25, 161.35, 141.34, 130.98, 128.95, 128.74, 
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62.88, 47.61, 42.93, 31.97, 29.77, 29.74, 28.87, 28.23, 27.60, 26.47, 25.91, 25.27, 22.91, 
22.73, 14.19. 
 (15e): 97% Yield. 1H NMR (CDCl3, 400 
MHz): δ = 8.23 (d, J = 8.33 Hz, 2H), 8.10 (d, J = 8.36 Hz, 2H), 4.09 (t, J = 7.37 Hz, 1H), 
3.28-3.20 (m, 2H), 2.92 (br. s, 4H), 2.60-2.45 (m, 6H), 2.11-2.01 (m, 2H), 1.94-1.90 (m, 
2H), 1.86-1.73 (m, 4H), 1.65-1.56 (m, 2H), 1.38-1.22 (m, 10H), 0.90 (t, J = 7.05 Hz, 
6H). 13C NMR (CDCl3, 100 MHz): δ = 194.39, 169.30, 161.36, 141.36, 130.97, 128.95, 
128.73, 62.87, 47.65, 43.14, 31.97, 31.92, 31.77, 29.98, 28.90, 28.24, 27.58, 27.28, 25.91, 
25.26, 24.01, 22.69, 22.66, 14.25, 14.23. 
7. Preparation of sugar-based thio-ortho-esters (17 and 18): 
To a mixture of 4-aminobutyric acid (0.63 mmol) and 15b (0.57 mmol) in DMF 
(15 mL) was added triethylamine (2 mL) and a catalytic amount of DMAP. The resulting 
solution was stirred at 100ºC for 12 h, poured onto crushed ice and acidified with 5% HCl 
solution. The solid obtained was filtered, washed with water and dried to give pure 17b. 
 (17b): 92% Yield. 1H NMR (CDCl3, 400 
MHz): δ = 8.03 (d, J = 8.31 Hz, 2H), 7.87 (d, J = 8.29 Hz, 2H), 6.85 (br. t, J = 5.55 Hz, 
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1H), 4.04 (t, J = 7.34 Hz, 1H), 3.57 (q, J = 12.40, 6.35 Hz, 2H), 3.27-3.19 (m, 2H), 2.61-
2.40 (m, 8H), 2.09-1.71 (m, 10H), 1.10 (t, J = 7.38 Hz, 3H), 1.04 (t, J = 7.32 Hz, 3H). 
 (17d): 87% Yield. 1H NMR (CDCl3, 400 
MHz): δ = 8.04 (d, J = 8.38 Hz, 2H), 7.87 (d, J = 8.40 Hz, 2H), 6.75 (br. t, J = 5.54 Hz, 
1H), 4.11 (t, J = 7.40 Hz, 1H), 3.58 (q, J = 12.42, 6.10 Hz, 2H), 3.30-3.21 (m, 2H), 2.60-
2.47 (m, 8H), 2.01-1.90 (m, 10H), 1.62-1.54 (m, 2H), 1.38-1.31 (m, 6H), 0.92 (t, J = 7.28 
Hz, 6H). 
 (17e): 90% Yield. 1H NMR (CDCl3, 400 
MHz): δ = 8.04 (d, J = 8.51 Hz, 2H), 7.87 (d, J = 8.52 Hz, 2H), 6.72 (br. t, J = 5.55 Hz, 
1H), 4.11 (t, J = 7.32 Hz, 1H), 3.58 (q, J = 12.38, 6.05 Hz, Hz, 2H), 3.28-3.20 (m, 2H), 
2.61-2.43 (m, 8H), 2.10-1.84 (m, 10H), 1.64-1.58 (m, 2H), 1.50-1.45 (m, 1H), 1.34-1.25 
(m, 9H), 0.90 (t, J = 7.07 Hz, 6H). 
To a mixture of 17b (0.26 mmol), HBTU (0.29 mmol), and HOBt (0.29 mmol) in 
DMF (10 mL) was added DIPEA (0.58 mmol) and the reaction mixture was stirred for 5 
min at ambient temperature. D-glucosamine hydrochloride (0.29 mmol) was dissolved in 
1 mL of DMSO and added to the above reaction mixture and stirred at room temperature 
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for 12 h. The solution was poured into cold ether and allowed to settle. The ether layer 
was decanted off and the brownish-yellow material was washed with cold ether several 
times and poured onto crushed ice, the obtained solid was filtered and washed with water, 
hexane to get the pure 18b. 
 (18b): 65% Yield. 1H NMR 
(CD3OD, 400 MHz): δ = 8.11 (d, J = 8.69 Hz, 2H), 7.94 (d, J = 8.67 Hz, 2H), 5.11 (d, J 
= 3.47 Hz, α-anomer), 4.61 (d, J = 8.32 Hz, β-anomer), 4.30 (t, J = 7.32 Hz, 1H), 3.88-
3.61 (m, 4H), 3.48-3.34 (m, 4H), 3.23-3.14 (m, 2H), 2.61-2.54 (m, 3H), 2.49-2.43 (m, 
3H), 2.37-2.32 (m, 2H), 2.09-2.01 (m, 2H), 1.96-1.81 (m, 6H), 1.78-1.65 (m, 3H), 1.06 
(m, 6H). 13C NMR (CD3OD, 100 MHz): δ = 195.79, 174.68, 167.95, 138.81, 138.34, 
128.60, 127.47, 91.41, 71.94, 71.47, 71.30, 63.15, 61.64, 54.70, 48.79, 39.32, 35.73, 
33.18, 31.33, 28.73, 28.01, 27.11, 27.10, 25.51, 25.08, 23.24, 11.02, 8.08. 
 (18d): 64% Yield. 1H NMR 
(CD3OD, 400 MHz): δ = 8.10 (d, J = 8.44 Hz, 2H), 7.94 (d, J = 8.30 Hz, 2H), 5.11 (d, J 
= 3.58 Hz, α-anomer), 4.61 (d, J = 8.34 Hz, β-anomer), 4.35 (t, J = 7.32 Hz, 1H), 3.89-
3.68 (m, 4H), 3.48-3.34 (m, 4H), 3.24-3.15 (m, 2H), 2.64-2.44 (m, 6H), 2.37-2.31 (m, 
2H), 2.07-1.77 (m, 11H), 1.60-1.47 (m, 3H), 1.41-1.26 (m, 5H), 0.94-0.88 (m, 6H). 13C 
NMR (CD3OD, 100 MHz): δ = 195.70, 174.66, 167.94, 138.80, 138.36, 128.58, 127.47, 
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91.40, 71.93, 71.46, 71.31, 62.36, 61.63, 54.70, 46.99, 42.66, 39.30, 33.47, 33.16, 31.43, 
29.88, 29.47, 28.70, 28.05, 27.15, 26.28, 25.50, 25.09, 22.58, 22.49, 13.20. 
 (18e): 62% Yield. 1H NMR 
(CD3OD, 400 MHz): δ = 8.10 (d, J = 8.50 Hz, 2H), 7.98 (d, J = 8.30 Hz, 2H), 5.25 (d, J 
= 3.49 Hz, α-anomer), 4.77 (d, J = 8.34 Hz, β-anomer), 4.36 (t, J = 7.35 Hz, 1H), 3.92-
3.71 (m, 4H), 3.46-3.34 (m, 4H), 3.25-3.15 (m, 2H), 2.68-2.44 (m, 7H), 2.10-1.98 (m, 
2H), 1.92-1.81 (m, 7H), 1.63-1.52 (m, 4H), 1.39-1.24 (m, 11H), 0.91-0.88 (m, 6H). 13C 
NMR (CD3OD, 100 MHz): δ = 195.72, 174.67, 167.92, 138.80, 138.34, 128.58, 127.49, 
91.40, 71.93, 71.45, 71.30, 62.42, 61.63, 54.65, 42.88, 42.63, 31.70, 31.45, 30.14, 28.73, 
28.07, 27.16, 26.94, 25.10, 23.75, 22.45, 22.40, 17.56, 16.12, 13.23, 12.04. 
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Chapter Seven: Epilogue 
A. Summary and conclusions. 
The central focus in our research was to develop an efficient methodology leading 
to unique scaffolds with an emphasis on structural and functional diversity. 
An experimentally straightforward, high-yielding photoinduced transformation of 
highly strained polycyclic oxetanes has been developed. The two step sequence, 
involving the Diels-Alder addition of heterocyclic chalcones to a variety of dienes, 
followed by the Paternò-Büchi photocycloaddition, was described in our group and 
referred to as an alkene-carbonyl oxametathesis [30 and Appendix E, reference C]. We 
further demonstrated that the Diels-Alder adducts of chromones are capable of 
photoinduced alkene-arene [2+2] cycloaddition producing dienes, which can either 
dimerize or be introduced into a double-tandem [4π+2π]◦[2π+2π]◦[4π+2π]◦[2π+2π] synthetic 
sequence, followed by an acid-catalyzed oxametathesis [35 and Appendix E, reference 
B]. This methodology offers a rapid growth in molecular complexity over a few simple 
steps. Interestingly, conformationally unconstrained aliphatic compounds, resulting from 
the Diels-Alder addition of cyclohexadiene or cyclopentadiene to methyl vinyl ketone 
and followed by the Paternò-Büchi reaction, underwent an acid-catalysed oxametathesis 
as well. This observation proved the generality of the new approach. 
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 In addition, we prepared polycyclic oxetanes resulting from the Diels-Alder 
adducts of cyclic ketones. This not only gave us access to remarkably strained oxetane 
systems, but also the mechanism for their protolytic ring fragmentation provided a great 
deal of insight to how the strain affects the reactivity [Appendix E, reference A]. 
We found that the Sulfa-Diels-Alder products did not produce Paternò-Büchi 
adducts upon irradiation. Nonetheless, both exo- and endo-3-benzoyl-2-
thiabicyclo[2.2.1]hept-5-enes were photochemically active and assorted products with 
defined stereochemistry were produced during photolysis.  
To demonstrate diverse utilization of light in combinatorial chemistry, we have 
developed an approach to the encoding and screening of solution phase libraries based on 
the photorelease of externally sensitized photolabile tags. The encoding tags can be 
released into solution only when a binding event occurs between the ligand and the 
receptor (biotin-avidin system), equipped with an electron transfer sensitizer. The 
released tags are analyzed in solution revealing the identity of the lead ligand [50 or 
Appendix E, reference J]. 
It should be mentioned that in our group we have developed other research 
projects which were not included in this dissertation (Appendix E, references D-I, K). 
The list of all publications, relevant to my work, can also be found in Appendix E. 
B. Future development.  
Since alkene-carbonyl oxametathesis discussed in this dissertation (Scheme 47A) 
showed such a tremendous potential for the diversity oriented synthesis, several projects 
related to this methodology are ongoing in our research group at this time.  
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We hypothesized that adducts containing endo-phenacyl group (type B1, Scheme 
47B) would have been capable to produce δ-oxetanes. An extra methylene group between 
the bicyclic core and aromatic carbonyl (B1) might provide enough freedom for the 
oxygen atom to reach the farthest end of the double bond (δ-atom) during the Paternò-
Büchi addition to form oxetane δ-B2. Subsequent protolytic oxametathesis would lead to 
the formation of potentially useful pentalene-like aldehydes δ-B3 (Scheme 47B):  
 
Scheme 47. (A) Oxametathesis in the aromatic and chromone-based series (γ-
aldehydes); (B) Oxametathesis leading to the formation of δ- and γ-aldehydes; (C) 
Oxametathesis leading to the formation of δ-aldehydes. 
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However, we do not completely rule out the possibility of forming γ-oxetanes (γ-
B3), similar to the observations described previously (Scheme 47A, Chapter Two, Three 
and Four). Only in this case the resulting aldehyde would contain a [3.n.1]-bycyclic core 
(as opposed to [2.n.1]).  
It is logical to assume that two methylene groups separating the bicyclic core 
from the aroyl group (C1) would encourage the formation of solely δ-aldehydes (Scheme 
47C).  
This hypothesis is currently under extensive investigation in our group. Up to this 
point we have been able to obtain several adducts 3 (B1 in Scheme 47, 3 in Scheme 48) 
containing endo-benzoyl group. The synthesis is based on the Michael addition of enolate 
1 to the D.-A. adduct 2 (Scheme 48): 
 
Scheme 48. Preliminary results of photofragmentation of adducts 3.  
It is interesting that Michael adducts 3 (X = H) based on acetophenone underwent 
oxametathesis yielding γ-aldehyde 4 (Scheme 48). However, in the case of 
propiophenone adduct 3 (X = CH3) did not produce an oxetane (even a trace amount) but 
rather rearranged forming alcohol 5 (Scheme 48). The mechanism for this transformation 
is under investigation.  
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Appendix A 
4,7-Diphenyl-3-oxatetracyclo[4.2.2.02,5.04,8]decane (2e): This crystal structure 
has been deposited at the Cambridge Crystallographic Data Center and allocated the 
deposition number CCDC 727386. 
Ph
PhO
 
11-Benzoyl-4-phenyl-3-oxapentacyclo[4.3.2.02,5. 04,10.07,9]undecane (2r): 
This crystal structure has been deposited at the Cambridge Crystallographic Data Center 
and allocated the deposition number CCDC 727711. 
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1-(2-Furanyl)-8-(4-pyridyl)-2-oxatricyclo[4.2.1.04,9]decan-3-ol (4h): This 
crystal structure has been deposited at the Cambridge Crystallographic Data Center and 
allocated the deposition number CCDC 727710. 
    
 syn-10-Benzoyl-9-phenyltertracyclo[5.2.1.0.2,903,6]dec-4-ene-2-
carboxaldehyde (5t): This crystal structure has been deposited at the Cambridge 
Crystallographic Data Center and allocated the deposition number CCDC 727709. 
  
Ph
O
Ph
H
O
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Appendix B 
1a_endo.cif cif file of compound 1a (endo-isomer): 
 
2a.cif cif file of compound 2a: 
 
3a.cif cif file of compound 3a: 
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3b.cif cif file of compound 3b: 
 
4a.cif cif file of compound 4a: 
 
4b.cif cif file of compound 4b: 
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4c.cif cif file of compound 4c: 
 
6a.cif cif file of compound 6a: 
O
O
O
Ph
NC
 
6b.cif cif file of compound 6b: 
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7a.cif cif file of compound 7a: 
 
7a-1.cif cif file of compound 7a-1: 
 
7b-1.cif cif file of compound 7b-1: 
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8a.cif cif file of compound 8a: 
 
9a.cif cif file of compound 9a: 
 
9c.cif cif file of compound 9c: 
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Appendix C 
3b.cif cif file of compound 3b: 
 
4b.cif cif file of compound 4b: 
                    
5c.cif cif file of compound 5c: 
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5e-1.cif cif file of compound 5e-1: 
 
5f.cif cif file of compound 5f: 
 
6b-1.cif cif file of compound 6b-1: 
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6b-2.cif cif file of compound 6b-2: 
 
 
6b-3.cif cif file of compound 6b-3: 
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Appendix D 
Part I: 
3a-1.cif cif file of compound 3a-1: 
 
 
3b.cif cif file of compound 3b: 
 
3c-1.cif cif file of compound 3c-1: 
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3d-1.cif cif file of compound 3d-1: 
 
3h.cif cif file of compound 3h: 
N
N
O
O Ph
Ts
*
 
3i.cif cif file of compound 3i: 
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Part II: 
exo-2a.cif cif file of compound exo-2a: 
 
exo-3a.cif cif file of compound exo-3a: 
 
exo-3b.cif cif file of compound exo-3b: 
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5a-2.cif cif file of compound 5a-2: 
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Appendix E 
(Papers published at the University of Denver, 2006-2010) 
A. Strained to the Limit: When a Cyclobutyl Moiety Becomes a Thermodynamic Sink 
in a Protolytic Ring Opening of Photogenerated Oxetanes. Valiulin, R. A.; 
Arisco, T. M.; Kutateladze, A. G. Org. Lett. 2010, in press. 
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